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ABSTRACT
ROLE OF T LYMPHOCYTE TRAFFICKING IN DIABETIC CARDIOMYOPATHY
CHOWDHURY SAYEF ABDULLAH
2016
Diabetic cardiomyopathy is a distinct pathological condition characterized by
myocardial fibrosis and cardiac dysfunction in diabetic patients. The resolution of
myocardial fibrosis to improve cardiac function in diabetes is an active area of research.
Notably, increased T lymphocyte infiltration into myocardium has been attributed to
increased cardiac fibrosis and dysfunction in diabetes. However, the experimental data on
the role of T lymphocyte modulation in diabetic myocardial fibrosis is scarce. To this
end, sphingosine 1-phosphate receptor 1 (S1P1) regulates the egress of mature T
lymphocytes from lymphoid organs to blood and peripheral organs. Thus, the inhibition
of T cells trafficking through S1P1 receptor modulation is a potential translational
approach to protect the heart in diabetes. We hypothesized that inhibition of T
lymphocyte trafficking by modulating S1P1 receptor protects diabetic heart and
ameliorates fibrosis. To accomplish this overarching objective, we conducted three
related studies: (1) assess the effects of fingolimod (S1P1 receptor modulator) treatment
in diabetes-induced myocardial fibrosis in mice; (2) study cardiac fibrosis and
dysfunction in diabetes using conditional T-cell S1P1 knockout (TS1P1KO) mice; (3)
evaluate the effects of CD4+ T cells transfer to TS1P1KO mice in diabetes-induced
myocardial fibrosis and dysfunction.

xix

We have demonstrated that FTY720 treatment induces sustained CD4+ and CD8+
T cells deficiency in the blood with reduced CD3+ T cells infiltration into myocardium of
diabetic wild-type (WT) mice. Notably, FTY720 treatment reduced cardiac fibrosis area
and improved cardiac contractility in diabetic WT mice. Our results in Rag1 knock-out
(KO) mice lacking mature lymphocytes, further, confirmed that systemic T lymphocytes
depletion is associated with cardioprotection. However, FTY720 treatment exacerbated
fibrosis and attenuated contractility in diabetic KO mice. Therefore, we utilized Cre-loxP
genetic approach to generate conditional T cell specific S1P1 receptor knock-out
(TS1P1KO) mice to study S1P1 receptor mediated T cells trafficking effects in diabetesinduced cardiac fibrogenesis.
One of the unique findings of our study is reduced cardiac fibrosis area in
TS1P1KO mice in chronic diabetes. TS1P1KO mice showed profound CD4+ and CD8+ T
cells deficiency in circulation and reduced CD3+ T cells infiltration into myocardium in
diabetes. We also found that diabetic TS1P1KO mice myocardium had reduced
profibrotic molecular and cellular milieu. However, normoglycemic TS1P1KO buffer
treated mice exhibited increased fibrosis area and reduced cardiac contractility. This
result indicates the potential role of different types of lymphocytes, and lymphocyte ratio
in the blood in maintaining cardiac collagen homeostasis. Although TS1P1KO mice have
reduced T lymphocytes in the blood, the mice had higher circulatory B lymphocytes,
which also has been implicated in myocardial fibrosis. Thus, to establish the involvement
of S1P1 mediated T lymphocytes trafficking in cardiac fibrosis, we conducted adoptive
transfer of littermate T cells to TS1P1KO mice.

xx

Among CD4+ and CD8+ T cells, all four subsets of CD4+ T cells have been shown
to be involved in cardiac fibrosis. Therefore, our aim was to investigate the effects of
littermate CD4+ T cells transfer on cardiac fibrosis and myocardial contractile force in
TS1P1KO mice in both normoglycemic and hyperglycemic conditions. Our flow
cytometry analysis revealed increased CD4+ and CD4+Foxp3+ T cells in the blood of
TS1P1KO mice after CD4+ T cells transfer. Strikingly, we found that CD4+ T cells
transfer reversed cardioprotection in hyperglycemic TS1P1KO mice, while it protected
normoglycemic TS1P1KO mice heart. In both conditions, TS1P1KO mice showed
increased CD3+ T cells infiltration after CD4+ T cell transfer. These results underpin S1P1
mediated T cells trafficking in maintaining cardiac collagen homeostasis in both
normoglycemic and hyperglycemic conditions.
Overall, through pharmacological and genetic approaches we have demonstrated
that S1P1 mediated T cells trafficking is involved in cardiac fibrogensis in chronic
diabetes. Our studies provide strong evidence of T lymphocytes S1P1 receptor signaling
as a translational target to protect diabetic heart and ameliorate fibrosis.
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CHAPTER 1: INTRODUCTION
1.1. Diabetes and cardiovascular diseases
Diabetes mellitus is characterized by hyperglycemia (increased glucose in plasma)
due to defects in insulin secretion, insulin action or both.1 There are two major prevalent
form of diabetes, namely, type 1 and type 2 diabetes.2,3 Type 1 diabetes is characterized
by early onset due to autoimmune destruction of the insulin producing pancreatic beta
cells.2,3 Thus, type 1 diabetic patients require exogenous insulin administration to
maintain their blood glucose level.3 Etiological risk factors of Type 2 diabetes include
obesity, aging, high calorie intake, lack of exercise and sedentary lifestyle.2,3 Due to these
risk factors, the tissues and cells exhibit reduced insulin sensitivity (insulin resistance)
and glucose uptake in type 2 diabetes leading to increased glucose level in the blood.2,3
According to the American Diabetes Association guidelines, normal fasting blood
glucose level is below 100 mg/dl, while a fasting blood glucose level ≥126 mg/dl is
indicative of diabetes.1 According to the current estimates from World Health
Organization (WHO), there are more than 300 million people affected by diabetes and is
estimated to increase to more than 347 million people worldwide by 2030.4,5 In the
United States, 29.1 million Americans are affected by diabetes with 1.4 million newly
diagnosed diabetes each year.6 Type 1 diabetes accounts for approximately 5% of all
diagnosed diabetes, while type 2 diabetes accounts for the other 90-95% of diagnosed
diabetes cases.6,7 Although there are many oral drugs available to maintain blood glucose
level in diabetic patients, half of the type 2 diabetic patients ultimately rely on insulin
administration to maintain the normal blood glucose level.3 Thus, chronic hyperglycemia
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is a hallmark of both type of diabetes and is a pivotal factor in the development of
diabetic complications in patients.3
Hyperglycemia causes injury, dysfunction and failure in vital organs including heart,
kidney, eye, nerves and blood vessels in diabetic patients.1,3 WHO reports nearly 50% of
diabetic patient’s death occurs from cardiovascular disease, such as heart failure and
atherosclerosis.8 Epidemiological studies have reported strong association between
diabetes and heart failure.7,8,9 Framingham heart study conducted by the National Heart,
Lung and Blood Institute of US to identify cardiovascular disease (CVD) risk factors
reported two-fold and five-fold higher heart failure risk in diabetic men and women,
respectively, than age matched non-diabetic control subjects.10 Chronic hyperglycemia
has been shown to affect cardiac function independent of other diabetes-associated CVD
risk factors, such as atherosclerosis, cerebrovascular disease and hypertension.3,9,10 The
distinct pathologic alterations in the myocardium induced by diabetes are defined as
“diabetic cardiomyopathy”.9 Diabetic cardiomyopathy can occur in the absence of other
CVD risk factors and can contribute to heart failure development in diabetic patients.3,9
Different pathological mechanisms have been shown to be involved in the development
of diabetic cardiomyopathy. Nonetheless, different cellular effectors and their
mechanisms of involvement in diabetic cardiomyopathy need further investigation.
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1.2. Diabetic cardiomyopathy
The European Society of Cardiology defines cardiomyopathy as a myocardial
disorder characterized by abnormal heart muscle structure and function, in absence of
coronary artery disease, hypertension, congenital heart disease and heart valve disease.11
Based on etiology, cardiomyopathy can be divided into two types, primary
cardiomyopathy and secondary cardiomyopathy.11 Primary cardiomyopathy occurs from
disease of the heart muscle cells due to genetic mutation including hypertrophic
cardiomyopathy and dilated cardiomyopathy.11 Secondary cardiomyopathy occurs due to
systemic syndromes such as diabetes, myocarditis and alcohol overuse that negatively
affect cardiac function.11 Thus, diabetic cardiomyopathy is a secondary cardiomyopathy
that occurs in diabetes associated chronic hyperglycemia leading to the development of
the heart failure in diabetic patients.12,13
Rubler et al. first described diabetic cardiomyopathy as a distinct clinical
pathophysiology prevalent in diabetic patients.9 In this study, the authors reported left
ventricular hypertrophy with myocardial fibrosis in diabetic patient hearts who deceased
from heart failure without having coronary artery disease, hypertension or other
etiological conditions underlying for observed heart failure.9 Regan et al. confirmed these
findings in a later study.14 In line with these observations, recent larger population based
studies revealed a 1.5-fold higher risk of heart failure in patients with diabetes after
adjusting for multiple variables including age, sex, obesity, antihypertensive medications,
atrial fibrillation, smoking habit, alcohol use, plasma cholesterol, educational level and
physical activity.15 Therefore, epidemiological studies further confirmed that diabetes can
by itself cause development of cardiomyopathy, termed as diabetic cardiomyopathy.
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Diabetic cardiomyopathy is considered as an important contributing factor for increased
prevalence of heart failure in diabetic patients.12,13
The pathophysiology of diabetic cardiomyopathy development involves various
pathological changes in heart under diabetes including endothelial dysfunction, myocyte
apoptosis, interstitial inflammation, myocardial fibrosis and diastolic dysfunction
followed by systolic dysfunction, if unresolved.13,16-18 Myocardial fibrosis is a pivotal
etiological factor in diabetic cardiomyopathy that underlies diastolic dysfunction
development in diabetes patient heart.19-23 Hyperglycemia activates and affects a diverse
set of molecular and cellular pathways present in mammalian heart that ultimately leads
to increased myocardial fibrosis in diabetes.24 During the early stages of diabetes, the
heart exhibits reduced antioxidant capacity and increased generation of reactive oxygen
species (ROS) resulting in oxidative stress.25 Increased ROS accumulation occurs
through different metabolic pathways including increased flux of glucose into electron
transport chain promoting superoxide generation by electron transfer to molecular oxygen
in mitochondria, increased formation of non-enzymatic advanced glycation end products
(AGEs) and activation of their receptors. Further, activation of other signaling pathways
including activation of protein kinase C isoforms, and reduction of intracellular
antioxidants including nicotinamide adenine dinucleotide phosphate (NADPH) and
glutathione (GSH) induce overproduction of superoxide radicals.25,26 Intracellular ROS,
in turn, can activate redox sensitive transcription factor NF-κB, which is the central
modulator of transcription of numerous genes including proinflammatory cytokines and
adhesion molecules in the diabetic myocardium.27,28 Thus, oxidative stress leads to an
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ongoing inflammation in diabetic heart that is further potentiated by activation of
proinflammatory pathways.
Presence of inflammation in diabetic myocardium is manifested as enhanced
expression of proinflammatory cytokines including tumor necrosis factor-α (TNF-α),
interleukin-6 (IL-6), interleukin-1β (IL-1β) and profibrotic growth factors, such as
transforming growth factor-β1 (TGF-β1). Inflammation further enhances chemokines
expression, such as chemokine C-C motif ligand-2 and 5 (CCL2, CCL5) and adhesion
molecules expression including intercellular adhesion molecule-1 (ICAM-1), vascular
adhesion molecule-1 (VCAM-1) and monocyte chemoattractant protein-1 (MCP-1).3,28-35
Increased expression of adhesion molecules under chronic inflammation further enhances
recruitment of blood derived immunocompetent cells including lymphocytes, monocytes,
macrophages, reparative mesenchymal cells and fibrocytes into the diabetic
myocardium.36,37 The recruited immune cells, in turn, secrete cytokines and growth
factors which potentiate, the profibrotic microenvironment development in the
myocardium. Proinflammatory and profibrotic microenvironments, in turn, activate
resident and recruited collagen producing fibroblasts and fibroblast progenitor cells that
results in increased collagen synthesis by these cells. Increased collagen deposition in
myocardium ultimately leads to fibrosis development in diabetes (Table 1-1).16,38
Increased cardiac fibrosis in diabetic myocardium underlies diastolic and systolic
dysfunction in diabetes patients (Table 1-1).13,17 Enhanced fibrosis reduces myocardial
ventricular wall compliance and stiffens the ventricular walls that impair cardiac
ventricles relaxation during diastole. Impaired cardiac ventricular relaxation, in turn,
leads to diastolic dysfunction. Diastolic dysfunction further, if unresolved, leads to
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systolic dysfunction underlying development of heart failure.13,17-19,39-42 Prevalence of
diastolic dysfunction is estimated to be as high as 40% to 60% patients with type 1 and
type 2 diabetes without overt coronary artery disease.21-23 Other epidemiological studies
also show association between enhanced myocardial fibrosis with impaired ventricular
function in diabetic patients.17 Increased myocardial collagen content has been detected
in insulin dependent diabetic normotensive patients as compared to age- and sex-matched
control subjects, assessed by ultrasound echoreflectivity.18 Similar results with increased
myocardial collagen in diabetic patients have been confirmed in larger studies by Fang et
al.19 Thus, epidemiological studies confirmed the presence of myocardial fibrosis with
cardiac dysfunction in diabetic patients. To this end, resolution of myocardial fibrosis to
improve cardiac function in diabetes is an active area of research. As discussed above, the
recruited effector immune cells facilitate and potentiate myocardial fibrosis. Thus, the
modulation of immune cells function is a potential approach to ameliorate myocardial
fibrosis in diabetes.
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Table 1-1: Summary of diabetic cardiomyopathy associated notable pathophysiological,
structural and functional changes in myocardium.
Diabetic Cardiomyopathy
Pathophysiological Changes


Increased ROS

Structural Changes


generation


Increased AGEs



Decreased antioxidants



Oxidative stress



Increased inflammation



Activation of immune

Maladaptive cardiac

Functional Changes


remodeling


Increased LV wall
thickness



Impaired
diastolic function



Impaired systolic
function

Increased LV mass

system


Increased cell death



Myocardial fibrosis

ROS: reactive oxygen species, AGEs: advanced glycation end products, LV: left
ventricle.
1.3. Myocardial fibrosis in diabetic cardiomyopathy
As discussed earlier (see section 1.2.), myocardial fibrosis is one of the hallmark
pathological features in diabetic patient heart as detected by echocardiography and
autopsy studies.9,11,18-23 The mechanism of fibrosis induced cardiac dysfunction involves
impairment of heart diastolic relaxation. Human heart works through consecutive systole
(contraction) and diastole (relaxation) phases. During systole, the heart pumps the blood
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throughout the body, whereas during diastole heart ventricles relax to fill blood that is
pumped at the next systole. Increased cardiac fibrosis reduces ventricular wall
compliance and increases stiffness that impairs normal relaxation of ventricles during
diastole leading to diastolic dysfunction.42-44 Excess collagen deposition in myocardium,
further impedes proper contraction of the heart as electrical impulse conduction gets
impaired due to collagen deposition in between cardiomyocytes.42-46 Thus, enhanced
myocardial fibrosis underlies the development of diastolic dysfunction preceding systolic
dysfunction in diabetic patient that ultimately leads to heart failure development.47,48
Myocardial fibrosis is a complex, multifactorial process that occurs at the site of
tissue injury and inflammation.36,40,46 It is a natural tissue repair process that results from
increased deposition of non-contractile collagen in cardiac interstitium leading to cardiac
functional impairment.46 Two types of cardiac fibrosis has been described reparative
(replacement) fibrosis and reactive fibrosis.46 Reparative fibrosis occurs after sudden cell
death of a large number of cardiomyocytes resulting from myocardial infarction upon
coronary artery block. On the other hand, reactive fibrosis develops in chronic
inflammatory conditions, such as diabetes and hypertension. Reactive fibrosis, if
unresolved, can turn into reparative fibrosis (Figure 1-1).44-46 The increased synthesis of
collagen during fibrogenesis involves molecular stimuli to cellular functions as discussed
below.
Myocardial fibrosis is characterized by increased collagen deposition in the heart
tissue.40 The extracellular matrix protein (ECM) components provide support for cellular
function in the heart including distribution of mechanical forces, signal transduction as
well as play important role in maintaining functional cardiac shape and size.41
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Myocardial ECM components consist of fibril collagen, proteoglycans and
glycosaminoglycans.42 The most abundant fibrillary collagen in the heart is collagen type
I and type III including less abundant types of IV, V, and VI, elastin and laminin.41-43 In
diabetic heart, as was discussed earlier (see section 1.2), increased ROS, inflammation
and growth factor stimuli result in enhanced synthesis of the ECM proteins leading to the
development of cardiac fibrosis.43,44 During cardiac fibrogeneis, cardiomyocytes and noncardiomyocytes including resident cardiac fibroblasts, immune cells, vascular endothelial
cells and the immunocompetent cells, closely interact with each other in fibrotic
remodeling of the heart (Figure 1-1).46 The fibroblasts upon stimulation by inflammatory
signals produce and secrete collagen matrix proteins in excess, while other cells, such as
macrophages, mast cells, lymphocytes, cardiomyocytes and vascular cells secrete
profibrogenic cytokines that stimulate fibroblasts’ collagen synthesizing activity.36,49
Diabetes associated hyperglycemic conditions can activate, among others, fibrogenic
transforming growth factor beta-1 (TGF-β1) signaling.50,51 TGF-β1 is a well reported
mediator in cardiac fibrosis and the most predominant isoform present in cardiovascular
system among three isoforms.52-54 TGF-β1 mediates its effects by directly inducing
matrix protein synthesis by stimulating collagen producing cells, decreasing production
of matrix degrading proteolytic enzymes, and modulating the expression of integrins,
which increases cellular adhesions to the matrix.55,56 TGF-β1 is present in both
cardiomyocytes and cardiac fibroblasts and has been found to take part in cardiomyocyte
growth, fibrosis and re-expression of fetal isoforms of myofibrillar protein genes, that are
salient characteristics of pathological cardiac remodeling.57-60 Further, the recruited
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blood derived immune cells also participate in fibrosis by secreting cytokines, growth
factors, and can transdifferentiate in collagen synthesizing fibroblasts.36,48,61

Reactive Fibrosis

Reparative Fibrosis

Figure 1-1: Cellular composition of myocardium and fibrosis type. Cardiac interstitium
comprises of cardiomyocytes and non-cardiomyocytes including macrophages,
lymphocytes, mast cells, myofibroblasts, endothelial cells (upper panel). Under chronic
inflammation (diabetes, hypertension) or due to sudden loss of cardiomyocytes
(myocardial infarction) non-contractile collagen deposited in cardiac interstitium as a
natural tissue repair process results in reactive and replacement fibrosis, respectively. All
cellular components in cardiac tissue participate in cardiac fibrogenesis. Adapted and
modified from Mewton et al.46
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Among other recruited cell types, fibrocytes are mesenchymal origin monocyte
precursor cells that are recruited at the site of injury. Fibrocytes have both inflammatory
properties like innate immune cells (i.e., macrophages) and tissue remodeling properties
(i.e., fibroblasts).62,63 Chronic inflammatory conditions promote accumulation,
differentiation and trafficking of fibrocytes to the inflamed tissue. Cluster of
differentiation antigen 34 (CD34) is one of the biomarkers to distinguish fibrocytes from
other cells in tissues.64,65 These cells are spindle shaped, adherent cells in cell culture
studies. Chronic proinflammatory conditions and profibrotic microenvironment can
stimulate fibrocytes to secrete collagen. Fibrocytes can also transdifferentiate into
collagen synthesizing fibroblasts.61-63 Altogether, fibrocytes have been reported to be
important components in fibrosis generation under chronic inflammatory conditions,
although a therapeutic intervention strategy to modulate fibrocytes function is yet to be
established.
No specific treatment strategy to ameliorate myocardial fibrosis in diabetes has been
yet determined. Inhibition of renin-angiotensin-aldosterone system by angiotensin
converting enzyme (ACE) inhibitors and aldosterone antagonists have shown beneficial
effect in hypertensive diabetic patient heart in the context of cardiac remodeling.66,67
However, cardiac remodeling has also been observed in normotensive diabetic patients.20
This indicates that further research is required to understand the mechanism of cardiac
fibrosis generation to devise effective therapeutic approach to ameliorate maladaptive
cardiac remodeling under diabetes.
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1.4. T lymphocytes involvement in myocardial fibrosis
T lymphocytes are lymphoid lineage adaptive immune cells. T lymphocytes can
be divided mainly into two types, helper T cells (CD4+, TH) and cytotoxic T cells (CD8+,
TC).68 Based on their cytokine expression pattern and functions, CD4+ T cells can be
further divided into TH1, TH2, TH17 and regulatory T cells (Tregs). TH1 cells secrete
mainly interferon-γ (IFN-γ), TH2 cells secrete interleukin-4 (IL-4), TH17 cells secret IL17 and Treg cells secrete TGF-β.68 In C57BL/6 mice, induction of TH1 lymphocytes
through TCR-Vβ peptide increases collagen content and cross-linking of collagen fibers
with reduced collagen degrading MMP enzyme activity.69 In the same report, TH2
induction resulted in decreased collagen content with increased collagen degrading
matrix metalloproteinase (MMP) enzyme activity.69 Co-culture experiments with
untreated fibroblasts revealed that both TH1 and TH2 lymphocytes can affect fibroblast
function, whereas TH1 decreases MMP-9 gene expression and TH2 increases MMP-9
activity.69 In another study, overexpression of TH1 lymphocytes increased left ventricular
interstitial fibrosis with diastolic dysfunction as detected by transthoracic
echocardiography in mice.70 TH1 cytokine IFN-γ has been shown to induce interferon
regulatory factor 1 (IRF1) which is a positive regulatory factor of collagen cross-linking
enzyme lysyl oxidase (LOX).71 Notably, chronic hypertensive BALB/c mice with
predominant TH2 cytokine expression exhibited increased ventricular collagen and crosslinking.72 Thus, depending on the physiological conditions both TH1 and TH2 cytokines
can participate in cardiac fibrogenesis, whereas TH1 cytokines play a role in initiation
phase of fibrosis and TH2 cytokines potentiate fibrosis in chronic conditions.72,73
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More recently, in experimental heart failure model including left coronary artery
occlusion induced myocardial infarction model and chronic pressure overload transverse
aortic constriction model, T lymphocytes proliferation has been detected in heart draining
secondary lymphoid organs i.e., lymph nodes (LNs) by flow cytometry analysis of
proliferation marker Ki67 expression in T cells.74-76 Increased proliferation of T cells in
heart draining lymph nodes corresponds to an increased presence of lymphocytes in the
heart tissue in these models.74-76 Thus, it is proposed that after myocardial injury,
activation of antigen presenting cells (APCs) by cardiac derived neoantigens occurs.77
Activated APCs, in turn, activate T lymphocytes in heart draining lymph nodes (Figure 12). Activated effector T cells then migrate to injured myocardium and participate in
fibrogenesis.77 Increased T lymphocytes infiltration and presence in cardiac tissue has
been shown to increase in collagen content and fibrosis in heart.75,76 Thus, T lymphocytes
has been detected as an important participant in myocardial fibrosis after cardiac injury
(Figure 1-2).74-77 To this end, it is intriguing to note that the modulation of T cells
trafficking from lymphoid organs to blood/heart could be a potential therapeutic approach
to protect heart under cardiac injury/inflammation.
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Figure 1-2: Proposed role of T lymphocytes trafficking to heart in steady state and postmyocardial infarction. In steady state, tolerogenic antigen presenting cells (APCs)
prevent T cell activation, whereas after myocardial injury activation of APCs result in
activation of T lymphocytes in heart draining lymph nodes. Adapted and modified from
Hofmann et al.77
Proinflammatory cytokines have been shown to negatively affect cardiac
contractility leading to heart failure.78-80 Several epidemiological studies have reported
that expansion of proinflammatory T lymphocytes expressing TH1 cytokine IFN-γ in
diabetic patients positively correlated with cardiac diseases including acute coronary
syndrome and coronary atherosclerotic heart disease.81,82 Thus, the modulation of T
lymphocytes to attenuate cardiac fibrosis is a potential therapeutic avenue that needs to
be further investigated.
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1.5. Role of Sphingosine 1-phosphate receptor 1 in T lymphocytes trafficking
T lymphocytes upon maturation increase cell surface expression of sphingosine 1phosphate receptor 1 (S1P1) in thymus.83 Sphingosine 1-phosphate receptor 1 (S1P1) is a
G-protein coupled receptor that signals through Gαi/o subunit.84,85 Upon activation, Gαi/o
activates phosphatidylinositol 3-kinase (PI3K) effector pathway that activates Rac
pathway.84,85 Rac pathway controls cell polarization, lamellipodium formation and
expansion and organization of focal complexes at the frontal edge of the cell and
adhesion. The endogenous natural ligand for S1P1 is the bioactive lipid molecule
sphingosine 1-phosphate (S1P).86,87 S1P is synthesized by phosphorylation from
membrane lipid sphingosine. Two isoforms of sphingosine kinase enzyme catalyzed the
conversion of sphingosine to sphingosine 1-phosphate. Notably, S1P is degraded by S1P
lyase enzyme in tissues due to the high expression of this enzyme. Thus, S1P
concentration in tissues (e.g. thymus, lymph nodes) is low (5-20 nM) as compared to high
concentration in plasma (200-900 nM).85,88 This creates a concentration gradient of S1P
from lymphoid tissues to systemic circulation. Thus, the increased expression of S1P1
receptor on cell surface enables T lymphocytes to sense the increased chemotactic
gradient of S1P in systemic circulation leading to egress from the lymphoid organs to the
blood (Figure 1-3C).83-89
Under normal physiological conditions, T lymphocytes continually recirculate
between secondary lymphoid organs and blood, which increases the likelihood of T cell
interaction with antigen presenting cells (APCs) e.g. macrophages, dendritic cells, B
lymphocytes.90 T cells encounter antigen bearing APCs in secondary lymphoid organs,
such as lymph nodes and spleen. Presentation of foreign antigen to T cells by APCs
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activate the T cells followed by proliferation in respective secondary lymphoid organs.
Activated effector T cells then migrate to target tissue to generate appropriate immune
response by secreting cytokines, activating B cells through cell-cell contact (CD4+ T
cells) or direct cell killing (CD8+ T cells).77,90
T lymphocytes trafficking through S1P-S1P1 signaling axis has been utilized for
therapeutic purposes. Fingolimod (FTY720) is a novel immunomodulatory drug that acts
on S1P1 receptor (Figure 1-3A and 1-3B).91,92 It is a structural analogue of sphingosine
and phosphorylated by sphingosine kinase 2 enzyme in vivo.93 Phosphorylated FTY720
binds to S1P1 as an agonist that later induces β-arrestin mediated internalization from cell
surface. S1P1-FTY720 complex in cell cytosol stays longer due to metabolic stability of
FTY720 against S1P lyase and promotes proteasomal degradation of the receptor.94 Thus,
FTY720 reduces mature single positive CD4+ and CD8+ T cells in blood (Figure 1-3C).95
FTY720 administration in murine experimental autoimmune encephalomyelitis (EAE)
model and in multiple sclerosis patients reduces autoimmune TH17 cells in blood and
CNS that protects the central nervous system from autoimmune T cell mediated
destruction of neural tissues.88-89,92
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A

C

B

Figure 1-3: Sphingosine 1-phosphate receptor 1 in T lymphocytes trafficking. (A)
Chemical structure of sphingosine 1-phosphate and phosphorylated (S)-FTY720. (B)
Biosynthesis of sphingosine 1-phosphate from sphingomyelin. (C) Simplified
representation of S1P-S1P1 mediated egress of T lymphocytes from lymph nodes and
inhibition of their egress by FTY720 to systemic circulation. Images are adapted and
modified from Brinkmann et al.92 (Figure 1-3A and 1-3B) and Camm et al. (Figure 13C).88
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As discussed earlier, T lymphocytes are involved in myocardial fibrosis and
dysfunction; however, therapeutic strategies to modulate T cell function in the setting of
cardiac disease need to be further explored. Experimental data of modulation of T cells’
role in diabetic cardiomyopathy are also lacking. Thus, in current dissertation work, we
studied T cell trafficking modulation effect in myocardial fibrosis and contractility in a
murine diabetic cardiomyopathy model.
1.6. Streptozotocin induced type 1 diabetic cardiomyopathy model
Streptozotocin (STZ) is a glucosamine-nitorosourea that is structurally similar to
glucose and is taken up by insulin producing beta cells of islets of Langerhans through
cell membrane glucose transporter 2 (GLUT2) (Figure 1-4A and 1-4B).96 STZ is a DNA
alkylating agent that methylates guanine at O6 position. This transfer of methyl group
from STZ to DNA molecule results in DNA fragmentation that increases the activation of
DNA repair enzyme poly (ADP-ribose) polymerase (PARP)97. Overactivation of PARP
results in diminished cellular NAD+ and ATP stores. The cellular energy store depletion
results in beta cell necrosis.97,98 Thus, STZ induced DNA methylation of pancreatic beta
cells ultimately ensues destruction of insulin producing beta cells (Figure 1-4B).96-99
Streptozotocin induced mice model is a widely used type 1 diabetic mice model
as these mice lack insulin producing beta cells upon STZ treatment.100 STZ recipient
mice promptly develop hyperglycemia (450 to 540 mg/dl) within 7 to 14 days after the
first administration with marked reduction in plasma insulin levels (<20 pmol/L).14,15,100
Both high dose (single dose of up to 200 mg/kg) and low dose with consecutive regimens
have been reported in the literature to induce diabetes in rodents.100 Animal Models of
Diabetic Complications Consortium (AMDCC) recommends low dose protocol with five
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consecutive injections of 50 mg/kg STZ to induce type 1 diabetes in rodents.100 In the
present dissertation work, a similar protocol was used to induce type 1 diabetes in mice
according to AMDCC guidelines.

B

A

Selective pancreatic beta cell uptake
through the
GLUT2 transporter
Streptozotocin

Beta cell toxicity through DNA
alkylation

Beta cell death through necrosis

Insulin-dependent diabetes mellitus
(chronic hyperglycemia)

Figure 1-4: Mechanism of action of streptozotocin-induced type 1 diabetes. (A)
Chemical structure of streptozotocin. (B) Simplified schematic diagram of mechanism of
action of streptozotocin to induce type 1 diabetes in mice. Adapted and modified from
Lenzen.96
Streptozotocin (STZ) induced type 1 diabetic mouse model represents salient
cellular and functional features of diabetic cardiomyopathy under hyperglycemia that
makes it suitable to study molecular mechanisms and effects of therapeutic
interventions.13 STZ induced mice myocardium show reduced contractile protein α-actin
and myosin ATPase activity, altered calcium handling, impaired diastolic function and
progressive systolic dysfunction corresponding to the magnitude and duration of
hyperglycemia progression.12,13 STZ murine myocardium has been reported to show
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increased cellular ROS levels with enhanced superoxide production, increased NADPH
oxidase expression and decreased GSSG/GSH ratio indicating presence of oxidative
stress.12,13,32,33 Increased expression of adhesion molecules, such as ICAM-1, VCAM-1
and MCP-1 in STZ rodent myocardium has been detected.32,33 Impaired calcium
homeostasis by myocytes has been also observed in STZ murine hearts, including
attenuated expression and activity of sarcoendoplasmic reticulum Ca2+-ATPase 2a
enzyme with impaired calcium release and reuptake.100 These molecular consequences
coupled with structural abnormalities in STZ murine hearts including increased cardiac
fibrosis with decline in cardiac function.13,100,101
In the present dissertation, we assessed T lymphocytes trafficking modulation
effect on the extent of myocardial fibrosis and contractility by utilizing validated STZinduced murine diabetic cardiomyopathy model.
1.7. Cre-loxP recombination approach to generate T cell specific S1P1
receptor knock out mice
Sphingosine 1-phsophate receptor 1 (S1P1) is a widely distributed G proteincoupled receptor in central nervous system, cardiovascular system, endothelial cells,
hepatocytes and kidney tubular cells in human and rodents.85 S1P1 expression and
activation in vascular endothelial cells are essential for new blood vessel formation and
endothelial junction integrity maintenance.84,88 Global knockout of S1P1 receptor is lethal
as mice die at early embryonic stage from hemorrhage due to leaky blood vessel
formation.84,102 Lack of S1P1 receptor results in deformity in endothelial junction
formation leading to hemorrhage.84,102 Thus, cell- and tissue- specific S1P1 receptor gene
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knock out approach has been utilized for experimental studies. In this regard, Cre-loxP
site specific genetic recombination approach is one of the successful approach.
Cre-loxP recombination system is a conditional gene inactivation approach that
allows investigators to study single gene function in tissue- or cell-specific manner. It is a
binary genetic system includes complementary activator and responder cassettes bearing
two separate lines of transgenic mice.103,104 Activator and responder cassette containing
mice are then crossed to generate progeny containing both activator and responder
cassettes.104 The activator cassette contains Cre recombinase gene under the control of
tissue specific promoter gene. The responder cassette contains flanked gene of interest by
loxP sequences, usually coding region of a protein. After crossing activator and responder
cassettes containing mouse strains, tissue specific Cre recombinase expression in
offspring mice leads to excision of the flanked gene by loxP sites as Cre recombination
action is specific at loxP sites (Figure 1-5).105,106
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P

Cre

X

mouse with target gene A
flanked by loxP sites

transgenic mouse with Cre genes
linked to a tissue-specific promoter, P

C
P
Cre

loxP

A

X
loxP
loxP

offspring with floxed
target with Cre transgene

tissue- or cell-specific Cre mediated
deletion of A at target locus

Figure 1-5: Simplified scheme of conditional gene knock-out approach by using CreloxP site specific recombination system. Mouse (A) bearing flanked specific genomic
DNA sequence ‘A’ by two loxP sites is responder cassette containing mouse line. Mouse
(B) bearing Cre transgene with a tissue-or cell-specific promoter ‘P’ is activator cassette
containing mouse line. Cre mediated recombination under the tissue promoter ‘ P’ occurs
at two loxP sites of the particular cells of the tissue, resulting in deletion of gene ‘A’
specifically of the tissue- or cells- targeted offspring mice (C) . Adapted and modified
from Strachan et al.106
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In our investigation, we generated conditional T cell specific S1P1 knock out mice
by crossing S1P1loxP/loxP mice containing flanked exon 2 of S1P1 gene with lymphocyte
tyrosine kinase (Lck)-Cre promoter containing mice.83 Offspring mice from the crossing
that contain both a floxed target sequence and a Cre transgene were identified by
genotyping PCR. T cell specific S1P1 knock out mice were utilized to study effects of
S1P1 genetic depletion of T lymphocytes in myocardial fibrosis in STZ-induced type 1
diabetic cardiomyopathy model.
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1.8. Rationale and objectives
As we discussed in previous sections (see section 1.4. and 1.5.), T lymphocytes
are involved in myocardial fibrosis in cardiac diseases including hypertension, chronic
heart failure and myocardial infarction. However, the experimental data in modulating T
lymphocytes role in long term hyperglycemic condition to ameliorate cardiac fibrosis and
improve cardiac contractility is scarce. In addition, the effects of T lymphocytes
inhibition in fibrotic microenvironment have not been investigated in chronic diabetes.
To this end, we hypothesized that modulation of T lymphocytic S1P1 receptor protects
diabetic myocardium by reducing profibrotic milieu in chronic diabetic conditions. Our
studies encompass broadly three areas including diabetes, immune system and
cardiovascular diseases (Figure 1-6). More specifically, we studied the effects of T
lymphocytes trafficking modulation in diabetic cardiomyopathy associated myocardial
fibrosis (Figure 1-6).

Three areas of study (broadly)

Specific areas studied

Figure 1-6: Simplistic representation of physiological fields of study in this dissertation.
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The objectives of this dissertation are as follows:
I.

To determine the effects of pharmacological inhibition of T lymphocytes trafficking
in myocardial fibrogenesis in chronic streptozotocin (STZ)-induced type 1 diabetes in
mice (chapter 2).
a. to assess the effects of S1P1 modulator-fingolimod (FTY720) administration
in T lymphocytes number in the blood and extent of cardiac fibrosis in wildtype (WT) C57BL/6 mice in chronic diabetes;
b. to assess myocardial fibrosis and cardiac function in recombination activating
gene 1 knock-out (Rag1 KO) mice as complementary to WT C57Bl/6 mice
under chronic diabetes;
c. to determine the effects of T lymphocytes trafficking modulation in
profibrotic cellular and molecular milieu in diabetic myocardium of WT and
KO mice.

II.

To investigate the effects of T cell specific S1P1 receptor genetic depletion in T
lymphocytes trafficking in the blood and cardiac fibrosis in STZ-induced diabetic
cardiomyopathy model (chapter 3).
a. to generate T cell specific S1P1 receptor knockout (TS1P1KO) mice and study
T lymphocytes number in the blood and secondary lymphoid organs of
TS1P1KO mice;
b. to study fibrotic remodeling in TS1P1KO mice under STZ-induced diabetic
cardiomyopathy model;
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c. to assess profibrotic cellular and molecular expression in TS1P1KO mice
myocardium under chronic diabetes;
III.

To evaluate the effects of CD4+ T cells transfer to TS1P1KO mice in myocardial
fibrosis under chronic diabetes (chapter 4).
a. to isolate CD4+ T cells from littermate mice spleen and adoptive transfer of
isolated CD4+ T cells to TS1P1KO mice;
b. to study the effects of CD4+ T cells transfer in T cells number in the blood and
myocardium in TS1P1KO mice;
c. to assess myocardial fibrosis in TS1P1KO mice after CD4+ T cells transfer in
STZ-induced diabetic cardiomyopathy model.
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CHAPTER 2: EFFECTS OF S1P RECEPTOR 1 MODULATOR FINGOLIMOD ON
CARDIAC FIBROSIS IN DIABETIC CARDIOMYOPATHY

2.1. Introduction
As discussed in chapter 1, cardiovascular dysfunction resulting in heart failure is a
prevalent cause of morbidity and mortality in diabetic patients.2,10 Diabetic
cardiomyopathy, first reported by Rubler et al., refers to structural and functional
abnormalities in diabetic heart as characterized by myocyte apoptosis, interstitial
inflammation, myocardial fibrosis and ventricular dysfunction independent of other
cardiovascular disease risk factors e.g., age, gender, hypertension, coronary artery
disease, congenital heart disease and valvular heart disease.9,15,16,24,31,32,107,108 Myocardial
fibrosis, one of the cardinal features of diabetic cardiomyopathy, contributes to increased
ventricular stiffness which leads to contractile dysfunction in failing diabetic hearts.46,109
Epidemiological studies have shown increased proinflammatory T cell subsets expansion
in diabetic patient blood that correlates with adverse cardiac events including acute
coronary syndrome.79,110 Recent investigations in murine pressure-overload-induced heart
failure model have shown the presence of T lymphocytes in injured cardiac tissue
associated with exacerbated fibrosis.76 Increased T lymphocytes infiltration in diabetic
myocardium has been detected that correlates with enhanced collagen deposition in
myocardium with increased ventricular stiffness.111 T lymphocytes secrete
proinflammatory cytokines, growth factors that activate profibrotic cells.73 Stimulated
profibrotic cells, such as fibroblasts and fibrocytes, secrete excess collagen that facilitates
fibrosis development in heart.73,163 Although different approaches including antibodyinduced neutralization or genetic knockout of signaling protein of T cells have
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demonstrated reduced fibrosis in murine heart failure models, therapeutic interventions to
protect hearts in T cell mediated injury need to be explored. Modulation of T cell
trafficking and its effect in long term diabetic fibrogenesis are not known yet. Further, the
crosstalk between T cells and other cellular components in myocardial fibrosis is not
completely understood. Therefore, we hypothesized that the modulation of T cell
trafficking could protect heart from diabetes-associated fibrosis and cardiac dysfunction.
In this chapter, we investigated T cell trafficking modulation by using novel
immunomodulator drug fingolimod (FTY720) in wild-type C57BL/6 mice through
streptozotocin-induced type 1 diabetic cardiomyopathy model. Rag1 knock-out mice that
lacks mature lymphocytes were used as a complementary genetic approach of wild-type
C57BL/6 mice.113
Sphingosine 1-phosphate receptor 1 (S1P1) is a cell membrane resident G proteincoupled receptor. Sphingosine 1-phosphate (S1P) is the endogenous ligand for S1P
receptor 1. Mature T lymphocytes upregulate the expression of sphingosine 1-phosphate
receptor for egress from lymphoid organs to circulation.114 Interaction of S1P and S1P1 is
crucial for egress of mature T lymphocytes from lymphoid organs to circulation. FTY720
is a S1P analogue which binds to S1P1 as an agonist. The binding of FTY720 to S1P1
down-modulates cell surface S1P1 receptor on T cells and disables the T cells to sense the
chemotactic gradient of endogenous ligand S1P in circulation. Thus, FTY720 induces
lymphopenia by sequestering lymphocytes in secondary lymphoid organs.91,95,115
Additionally, S1P and S1P1 signaling have been implicated in inflammation mediation in
myocardial injury.116 Notably, S1P1 expression status in diabetic myocardium has not yet
been reported. Thus, chronic FTY720 administration effects in long term experimental
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diabetes settings in the context of myocardial fibrotic remodeling and cardiac function
needs to be explored.
In this dissertation, we evaluated the effects of chronic administration of FTY720
on cardiac fibrosis and cardiac function in streptozotocin-induced diabetic wild-type and
Rag1 knockout mice at the end of 11-week experimental period. In this study, we
assessed outcomes of FTY720 treatment in murine diabetic cardiomyopathy model. We
determined T lymphocytes number in heart and circulation by flow cytometry analysis.
We conducted immunohistological studies to detect CD34 expressing fibrocytes
localization, profibrotic TGF-β1 and S1P1 expression in myocardium after long term
diabetes. We studied heart histology and measured fibrosis area in heart sections at the
end of experimental period. We, further, evaluated the cardiac function of the mouse
heart using ex vivo Langendorff’s heart perfusion system.
2.2. Materials and Methods
2.2.1. Animals
This investigation was carried out in accordance with the Guide for the Care and
Use of Laboratory Animals set forth by U.S. National Research Council (Eighth Edition,
2011). All experimental procedures involving research animals were approved by the
Institutional Animal Care and Use Committee (IACUC) at South Dakota State University
(SDSU). Eight-week old male wild-type (WT) C57BL/6 mice weighing 22-25 g were
purchased from the Charles River Laboratories (Wilmington, MA, USA) and two
breeding pairs of Rag1 knockout (KO) mice weighing ~20 g lacking mature lymphocytes
were obtained from The Jackson Laboratory (Bar Harbor, ME, USA). Rag1 KO mice
were bred in the Animal Research Wing (ARW) at SDSU. All the mice were housed in
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the ARW facility at SDSU and given ad libitum standard rodent chow food (5001;
LabDiet, St. Louis, MO, USA) and water. Rag1 KO mice were kept in a specific
pathogen free room and had free access to autoclaved food (5010; LabDiet) and water.
2.2.2. Type 1 diabetes induction and physiological assessment
Streptozotocin (STZ) is a glucosamine-nitrosourea antibiotic that destroys insulin
secreting pancreatic beta cells rendering recipient animal diabetic.125 In present study, we
used multiple low doses of STZ to induce type 1 diabetes in mice. Briefly, streptozotocin
(STZ) (S0103; Sigma-Aldrich, MO, USA) was administered through intraperitoneal (i.p.)
injection at a dose of 50 mg/kg body weight in 0.1 M sodium citrate buffer (pH 4.5) for 5
consecutive day to induce Type 1 diabetes while the control group received only buffer
(i.p). Body weights (g) were measured by an electric balance twice each week (OHAUS®
Scout-Pro™, OHAUS, NJ, USA). Blood glucose levels (mg/dl) were measured in blood
samples from tail veins at the beginning, 4- and 11-week post STZ injection by using a
blood glucose meter (CONTOUR®, Bayer Healthcare LLC, IN, USA). STZ recipient
mice with fasting blood glucose level over 200 mg/dl were considered as diabetic.
2.2.3. Experimental protocol
Age-matched WT and KO mice were divided into three groups: control, untreated
diabetic (STZ), diabetic treated with FTY720 (FTY720+STZ). All mice went through 11week study period as described earlier.117 FTY720 (10006292; Cayman Chemical, MI,
USA) was administered by i.p. injection at 0.3 mg/kg body weight every day for first four
weeks. After that, there was an interim three week no treatment period, and then FTY720
administration was resumed for another four week till the end of 11-weeks (Figure 2-1).
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Serum insulin levels were measured after 11-week by using an ultrasensitive mouse
insulin ELISA kit according to manufacturer’s instructions (90080; Crystal Chem Inc.,
IL, USA).

FTY720 (0.3 mg/kg/day i.p.)
for 4-week

3-week pause

FTY720 (0.3 mg/kg/day i.p.)
resumed for next 4-week



5-day STZ (50 mg/kg i.p.) to STZ and FTY720+STZ mice
or buffer only i.p. to control mice





Flow cytometry analysis
Heart contractile force
development measurement
in ex-vivo Langendorff Heart
perfusion system
Histology study
Fibrosis area assessment
Immunohistochemistry

Figure 2-1: Schematic diagram of 11-week long streptozotocin (STZ)-induced type 1
diabetes mice model and treatment protocol.
2.2.4. Flow cytometry analysis
CD4+ and CD8+ T lymphocytes were measured in blood by two-color flow
cytometry analysis at the end of 11-weeks. The blood samples were collected into
heparinized blood collection tubes (367884, BD Biosciences, NJ) and mixed well to
achieve anti-coagulation. The anti-mouse fluorescein isothiocyanate (FITC) conjugated
CD4 (561828; IgG2b; BD Pharmingen, CA) and anti-mouse phycoerythrin (PE)-CD8a
(561095; IgG2a; BD Pharmingen) antibodies were added into the freshly prepared 100
µL of heparinized blood. Respective isotype controls for both FITC- (553988; IgG2b; BD
Pharmingen) and PE-conjugated antibodies (551799; IgG2a; BD Pharmingen) were used
to set detector compensation at the instrument during analysis. The tubes were then
incubated for 30 min(s) at room temperature in the dark for antibody staining. Red blood
cells lysis and cell fixation were done by adding 2 mL of 1x 1-step fix/lyse solution (00-
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5333; eBioscience, San Diego, CA, USA) and incubated for 15 min(s) at room
temperature in the dark. After incubation, cells were washed by centrifugation
(Eppendorf 5810R, Hauppauge, NY) at 500 x g for 5 min(s) at room temperature with 2
mL of flow cytometry staining buffer (00-4222; eBioscience) twice. The supernatants
were discarded. The remaining cell pellets were re-suspended with 200 µL of flow
cytometry staining buffer and proceeded to flow cytometry analysis. Positively stained
CD4+ and CD8+ cell populations were counted on a BD FACSCalibur flow cytometry
system (BD Biosciences, San Jose, CA, USA). Data acquisition and analysis were done
by BD CellQuest Pro Software (BD Biosciences).
2.2.5. Hemodynamics Study
At the end of 11-week experimental period, mice were weighed, heparin (500 U
kg-1) was injected i.p. and then anesthetized with phenobarbital (120 mg kg-1, i.p.).
Surgical anesthesia was assessed by the absence of toe pinch reflex in anesthetized mice
before starting the operation. Hearts were then rapidly excised and washed in ice-cold
arresting solution (NaCl 120 mmol L-1, KCl 30 mmol L-1), and cannulated via the aorta
with a 20 gauge stainless steel blunt needle. Heart perfusions were carried out at 70
mmHg pressure on a modified Langendorff apparatus using Krebs–Henseleit solution
(NaCl 118.5 mmol L-1, NaHCO3 25.0 mmol L-1, KCl 4.75 mmol L-1, KH2PO4 1.18 mmol
L-1, MgSO4 1.19 mmol L-1, D-glucose 11.0 mmol L-1, CaCl2 1.41 mmol L-1)
supplemented with 95% O2 and 5% CO2 at 37°C.118 Cardiac contractility was measured
by a force displacement transducer (Model T03; Grass, Warwick, RI, USA) attached to
the apex of the heart with a thin thread and a metal hook. The cardiac contractility was
recorded with Biopac MP 100 data system (Goleta, CA, USA).
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2.2.6. Hematoxylin and eosin (H&E) and Masson’s trichrome staining of heart
sections
After cardiac contractile force measurement, hearts were perfused and fixed with
freshly prepared 4% paraformaldehyde in 0.1 M phosphate buffered saline, pH 7.4 for 10
minutes. Hearts were removed after perfusion and placed in 4% paraformaldehyde
overnight at 4⁰C. Paraffin-embedded (5 µm) heart sections were prepared. Hematoxylin
& Eosin and Masson’s trichrome staining were done according to standard procedures.
Heart histology was examined in H&E stained slides using Zeiss Axio Imager A1 upright
microscope. Each heart section was graded based on the presence of eosinophilic
interstitial collagen fibers, interstitial cellular infiltration, myocardial cell necrosis and
myofiber striation and organization on a five-point scale for each characteristic from 0 to
4.120,121 The composite scores were expressed from 0 to 16 for each group. Trichrome
stained whole heart sections images were taken using Leica EZ4 HD stereomicroscope
(Leica Microsystems, Buffalo Grove, IL, USA). The percent of fibrosis area in whole
heart sections was quantified by using NIH Image J software (Bethesda, MA, USA).117
2.2.7. Immunohistochemistry of heart sections
Immunohistochemical detection of CD3, S1P1, TGF-β1 and CD34 expression was
conducted with CD3 (10 µg/mL, sc-20047; Santa Cruz Biotechnology, Inc., CA), S1P1
(15 µg/mL, MAB7089; R&D Systems, Inc., Minneapolis, MN), TGF-β1 (15 µg/mL,
MAB240; R&D Systems, Inc.) and CD34 (10 µg/mL, MA5-17825; Pierce
Biotechnology, Rockford, IL, USA) primary antibodies in 5 µm thick paraffin-embedded
heart tissue sections. We used R&D systems mouse/rat cell and tissue staining HRP-DAB
kit (CTS002/CTS017; R&D Systems) according to primary antibodies host species to
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amplify and visualize primary antibody staining localization in heart tissue sections.
Briefly, heart sections were first deparaffinized and hydrated through consecutive washes
with xylene and graded alcohol series. Antigen unmasking was done through heatinduced epitope retrieval (HIER) procedure by heating the slides at 95 ºC with 10 mM
sodium citrate buffer (pH 6.0) for 40 minutes. Slides were cooled to room temperature
and were washed with 1x Tris-buffered saline containing 0.01% v/v Tween 20 (1x TBST,
pH 7.4). Endogenous peroxidase activity was quenched by incubating with peroxidase
blocking reagent (R&D Systems) for 5 minutes. Sections were washed and blocked with
blocking solution composed of 1% w/v bovine serum albumin, 1% v/v normal goat
serum, 1% v/v donkey serum, 0.3% v/v Triton X-100 and 0.05% v/v Tween 20 in 1x
phosphate buffered saline for 1 hour at room temperature. Avidin and biotin were
blocked according to the manufacturer’s instructions (R&D Systems). Sections were then
incubated with respective primary antibodies diluted in blocking solution overnight at 4
ºC in sealed humid boxes. After overnight incubation, sections were washed with 1x
TBST and incubated with secondary biotinylated antibody for 30 minutes at room
temperature. Sections were then washed with 1x TBST and incubated with high
sensitivity streptavidin conjugated to horseradish peroxidase (HSS-HRP) (Part 865006;
R&D systems) for 30 minutes at room temperature. After incubation, sections were
washed and incubated with 3, 3´ diaminobenzidine (DAB) for 2 minutes. DAB is a
chromogenic substrate for HRP, and enzymatic conversion of DAB by peroxidase
enzyme yields brown color precipitation at antigen localization site. Sections were gently
washed under running tap water for 5 minutes and counterstained with Mayer’s
hematoxylin (MHS16; Sigma-Aldrich, St. Louis, MO, USA) for nuclear staining. Finally,
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sections were mounted with histological mounting medium Permount® (SP15; Fisher
Scientific, Fair Lawn, NJ, USA). All experiments were done in triplicate. In all
experiments, the slides incubated only with blocking solution was used as negative
control to ensure specificity of IHC detection. To count immunopositive CD3+ cells, 3o
fields for each stained slide were pictured at bright-field under high magnification (400x)
in Zeiss Axio Imager.A1 upright microscope equipped with Zeiss Achroplan objective
lens (Carl Zeiss). Myocardium infiltrating cells number was calculated by counting the
cells in imaged 400x fields and was expressed as cells/field.75 TGF-β1, S1P1 and CD34
positive staining percent area were quantified in ten images and averaged.122 Stained
sections were examined under Zeiss Axio microscope and imaged with Axiocam MRc 5
digital camera. Images were used to quantify positively stained regions in heart section.
2.2.8. Plasma S1P quantification by LC/MS/MS
At the end of 11-weeks, blood samples were collected from mice in EDTA blood
collection tubes (367856, BD Biosciences, NJ) and mixed well to achieve anticoagulation. The tubes were centrifuged immediately at 1300 x g at room temperature
and plasma samples were collected from the top. The mice plasma samples were stored at
-80 ºC until further analysis. Sphingosine 1-phosphate (S1P) levels in plasma were
measured using liquid chromatography-tandem mass spectrometry method
(LC/MS/MS).123,124 Briefly, S1P was extracted from 10 µL of plasma by methanol
extraction. After dilution with methanol, final concentration was 10% plasma, 90%
methanol, and 30 ng/ml of internal standard D-erhythro-sphingosine-1-phosphate (C17
base) (860641; Avanti Polar Lipids, Alabaster, AL, USA). Sample tubes were then
vortexed and centrifuged at 14,000 rpm for 10 minutes at 4 ºC. Supernatants were
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collected and analyzed by LC/MS/MS. S1P and internal standard were eluted with
isocratic mobile phase consisting of 70% acetonitrile/30% water/0.1% formic acid mobile
phase at a flow rate of 0.25 ml/min through Waters XBridge™ Phenyl Column (150 cm
length x 2 mm internal diameter; i.d., 5 µm particle size) with a C18 guard column (4 mm
length x 2 mm i.d.) (Waters Corporation, Milford, MA, USA). The runtime for each
injection was 4 min(s). The retention time for S1P and internal standard were about 1.87
and 1.75, respectively. All the components of mobile phase were LC/MS grade reagents
(Optima; Fisher Scientific, Fair Lawn, NJ, USA). Separation and LC/MS/MS analysis
was carried out using Agilent 1100 series HPLC system (Agilent Technologies,
Waldbronn, Germany) coupled with Finnigan TSQ Quantum Ultra triple quadrupole
mass spectrometer (Thermo Electron Corporation, San Jose, CA, USA) operating in
positive ion mode. S1P and internal standard were monitored by Multiple Reaction
Monitoring (MRM) at 380.31 -> 264.31 m/z and 366.26 -> 250.27 m/z, respectively. S1P
peak area was divided by the percent recovery of the internal standard in each sample to
reconcile the loss. The concentration of S1P was calculated from loss-adjusted S1P peak
area using a loss-adjusted standard curve of S1P (860492; Avanti Polar Lipids). The
linearity of standard curve to calculate S1P concentration was determined by R2 value of
0.99.
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2.2.9. Data analyses
Data was expressed as mean ± SEM. One-way ANOVA was used for statistical
analysis followed by Tukey’s post hoc test for multiple comparisons of group means.
Two-tailed unpaired student’s t-test was done, where applicable. Data were analyzed in
GraphPad Prism Software (v5.01, 2007). A P value of less than 0.05 was considered
statistically significant and indicated with an asterisk (*) or a number (#) sign.
2.3. Results
2.3.1. Assessment of metabolic and physiological parameters in diabetic mice
In WT mice, both untreated (STZ, n=9) and FTY720 treated (FTY720+STZ, n=9)
STZ recipient mice demonstrated lower body weight gain compared to only buffer
recipient (Control, n=8) mice throughout the 11-week treatment period (Figure 2-2).
There was no statistically significant difference in body weight between groups at the
beginning. After 11-week, control mice gained 8.67 % higher body weight than STZ and
14.63% higher body weight than FTY720+STZ mice (Table 2-1, Figure 2-2).
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Figure 2-2: Body weight (g) changes in wild-type (WT) C57BL/6 mice during 11-week
experimental period. Streptozotocin recipient both STZ and FTY720+STZ mouse groups
exhibited less body weight gain during treatment period. Sample size, n=8-9 mice in
each group, *P < 0.05 as compared to control mice at the end of 11-weeks. The data is
expressed as mean ± SEM.
Blood glucose level was higher both in STZ (466.7±22.4 mg/dl vs. 159.3±8.21
mg/dl, **P < 0.01, after 4-week) and FTY720+STZ (563.4±10.92 mg/dl vs. 159.3±8.21
mg/dl, **P < 0.01, after 4-week) mice than control mice post STZ induction, although at
the beginning there was no statistically significant difference in blood glucose levels
between these groups (Table 2-1, Figure 2-3). After 11-week, STZ and FTY720+STZ
mice remained hyperglycemic compared with control mice (Table 2-1, Figure 2-3).
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Figure 2-3: Blood glucose levels (mg/dl) in WT C57BL/6 mice at the beginning, after 4week and after 11-week of STZ induction. Sample size, n = 8-9 mice per each group, **P
< 0.01 as compared to control mice after 4-weeks and after 11-weeks of post STZinduction. The data is expressed as mean ± SEM.

Hyperglycemic STZ (0.41±0.02 ng/ml vs. 0.66±0.08 ng/ml, *P < 0.05) and
FTY720+STZ (0.38±0.03 ng/ml vs. 0.66±0.08 ng/ml, *P < 0.05) mice had lower serum
insulin level compared to control mice at the end of the treatment period (Figure 2-4). In
sum, FTY720 treatment did not improve body weight, blood glucose and serum insulin
levels in diabetic WT mice compared to untreated diabetic mice.
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Figure 2-4: Serum insulin levels (ng/mL) in WT C57BL/6 mice after 11-week of STZ
induction. Sample size, n = 8-9 mice per each group, *P < 0.05 between control and STZ
& FTY720+STZ mice after 11-week of post STZ-induction. The data is expressed as
mean ± SEM.

Table 2-1: Summary of metabolic and physiological parameters in WT C57BL/6 mice after 11-week experimental period.
Control

STZ

FTY720+STZ

Body wt. (g)

22.1±0.53

22.2±0.47

20.86±0.23

Blood glucose level (mg/dl)

162.38±3.59

152.33±9.05

131.67±8.68

Body wt. (g)

23.33±0.60

22.4±0.75

19.50±0.15

Blood glucose level (mg/dl)

159.29±8.21

466.67±22.41**

563.44±10.92**

Body wt. (g)

26.83±0.51

24.5±0.65*

22.9±0.34*

Blood glucose level (mg/dl)

151.29±15.39

504.00±20.29**

466.56±17.38**

Serum insulin level (ng/ml)

0.66±0.08

0.41±0.02*

0.38±0.03*

At the beginning
(before STZ induction)

After 4-week of STZ induction

After 11-week of STZ
induction

The data is expressed as mean ± SEM. Sample size, n = 8-9 mice in each group. *P < 0.05 and **P < 0.01 as compared to control
group. STZ, streptozotocin; FTY720, fingolimod.
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In Rag1 KO mice, both untreated (STZ) and FTY720 treated diabetic
(FTY720+STZ) mice showed lower body weight gain during study period similar to WT
C57BL/6 mice. Rag1 STZ and FT720+STZ mice had 13.90% and 10.20% lower body
weight than age-matched non-diabetic control mice, respectively, at the end of 11-week
after STZ administration (23.97±1.09 g vs. 27.84±0.62 g and 25±0.51 g vs. 27.84±0.62 g,
P < 0.05; n=4-6 mice in each group) (Figure 2-5).
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Figure 2-5: Body weight (g) changes in Rag1 KO mice throughout 11-week
experimental period. Sample size n =4-6 mice in each group, #P < 0.05 as compared to
control mice. The data is expressed as mean ± SEM.

43

There was no significant difference in blood glucose levels between Rag1 KO
mouse groups at the beginning (Figure 2-6, Table 2-2). After STZ induction, STZ
(374.8±37.05 mg/dl vs. 155.7±6.06 mg/dl, ##P < 0.01) and FTY720+STZ (443.75±72.42
mg/dl vs. 155.7±6.06 mg/dl, ##P < 0.01) mice exhibited higher blood glucose level as
measured after 4-weeks. Both STZ and FTY720+STZ groups remained hyperglycemic at
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Figure 2-6: Blood glucose levels (mg/dl) at the beginning, after 4-week and after 11week of STZ administration in Rag1 KO mouse groups. Sample size, n =4-6 mice in each
group, ##P < 0.01 as compared to control mice. The data is expressed as mean ± SEM.
Along with hyperglycemia, diabetic KO mice had lower serum insulin level than
control mice (0.78±0.12 ng/ml vs. 0.43±0.02 ng/ml, #P < 0.05) (Figure 2-7, Table 2-2). In
summary, FTY720 treatment in Rag1 KO diabetic mice, did not exhibit significant
improvement in body weight, and remained hyperglycemic as compared to control mice.

Serum insulin level
(ng ml -1)

44

1.0
0.8
0.6

#

0.4
0.2
0.0
Control

STZ

Figure 2-7: Serum insulin levels (ng/ml) after 11-week of post STZ induction in Rag1
KO mouse groups. Sample size, n =5 mice in each group, #P < 0.05 as compared to
control mice. The data is expressed as mean ± SEM.

Table 2-2: Summary of metabolic and physiological parameters in Rag1 KO mice after 11-week of experimental period.
Control

STZ

FTY720+STZ

Body wt. (g)

24.95±0.58

22.23±1.02

25.43±0.40

Blood glucose level (mg/dl)

162.50±10.00

153.29±4.48

129.75±6.05

Body wt. (g)

26.06±0.47

22.82±1.19

24.73±0.52

Blood glucose level (mg/dl)

155.67±6.06

374.83±37.05##

443.75±72.42##

Body wt. (g)

27.84±0.61

23.97±1.09#

25.00±0.51#

Blood glucose level (mg/dl)

150.80±10.27

394.00±47.86##

379.00±74.88##

Serum insulin level (ng/ml)

0.66±0.08

0.41±0.02#

At the beginning
(before STZ induction)

After 4-week of STZ induction

After 11-week of STZ
induction

The data is expressed as mean ± SEM. Sample size, n = 4-6 mice in each group. #P<0.05 and ##P < 0.01 as compared to control group.
STZ, streptozotocin; FTY720, fingolimod.
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2.3.2. Effects of FTY720 treatment in CD4+ and CD8+ T cells number in the blood
Sphingosine 1-phosphate (S1P) is an endogenous-bioactive lipid molecule that
acts on five G-protein coupled receptors, S1P1-5. The concentration of S1P in plasma and
lymph is 200 to 900 nM. Due to metabolic degradation of S1P in tissues, its
concentration is 5 to 20 nM in tissues. This difference in concentrations of S1P between
systemic circulation and tissues creates a concentration gradient of S1P.85,88 Single
positive CD4+ and CD8+ T lymphocytes upregulate S1P1 receptor expression on their cell
membrane upon maturation in lymphoid organs.114 The upregulation of S1P1 enables T
lymphocytes to egress from lymphoid organs to blood and lymph through chemotactic
response towards higher concentration of S1P present in systemic circulation. FTY720
(Fingolimod) acts as ‘functional antagonist’ to S1P1 (EC50 0.2 nM).88 Fingolimod binds
to S1P1 and causes its internalization following subsequent degradation of the receptor in
T lymphocytes.92 Thus, T lymphocytes chemotactic movement to blood is inhibited by
FTY720 that causes sequestration of T cells in lymphoid organs. In our present study, we
counted both CD4+ helper T cells and CD8+ cytotoxic T cells in blood by flow cytometry
(Table 2-3, Figure 2-8 and Figure 2-9). FTY720 treatment in WT diabetic mice,
significantly reduced both CD4+ (control, n=3, 12.02±1.06 %, STZ, n=4, 12.79±1.42 %,
FTY720+STZ, n=4, 0.19±0.03 %; **P < 0.01 when FTY720+STZ compared with
control and STZ group, data after 4-week) and CD8+ T cells in blood (control, n=3,
7.97±0.68 %, STZ, n=4, 7.89±1.07 %, FTY720+STZ, n=4, 0.32±0.04 %; **P < 0.01
when FTY720+STZ compared with control and STZ group, data after 4-week). The
observed lymphopenia in FTY720 treated group sustained after 11-week (CD4 T cells:
control, n=6, 9.10±1.44 %, STZ, n=8, 8.87±0.81%, FTY720+STZ, n=7, 0.24±0.07%;
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**P < 0.01 when FTY720+STZ compared with control and STZ group, data after 11week; CD8+ T cells: control, n=6, 6.89±1.40 %, STZ, n=8, 5.80±0.78 %, FTY720+STZ,
n=7, 0.75±0.21 %; **P < 0.01 when FTY720+STZ compared with control and STZ
group, data after 11-week) (Table 2-3, Figure 2-8 and Figure 2-9).
Control
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FTY720+STZ

CD8+

CD4+
CD4+

CD8+

Figure 2-8: Flow cytometry analysis of CD4+ and CD8+ T lymphocytes in peripheral
blood of WT C57BL/6 mice after 11-week experimental period. Representative dot plot
(upper panel) and histogram plot (lower two panel) of flow cytometry analysis of CD4+
and CD8+ T lymphocytes in WT C57BL/6 mice blood. FTY720 treatment noticeably
depleted both CD4+ and CD8+ T cells in peripheral blood compartment as observed in
lower right (CD4+ stained cells) and upper left (CD8+ stained cells) quadrants in dot plot
and in M1 gate in histogram.
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Figure 2-9: Quantification of CD4+ and CD8+ T cells percent numbers in WT C57BL/6
mice blood after 11-week of experimental period. **P < 0.01 as compared to control and
STZ groups, n = 6-8 mice per group. The data is expressed as mean ± SEM.

Table 2-3: Summary of CD4+ and CD8+ T cells percent numbers in peripheral blood of WT C57BL/6 mice after 11-weeks.
Control

STZ

FTY720+STZ

12.02±1.06 (n=3)

12.79±1.42 (n=4)

0.19±0.03** (n=4)

7.97±0.68 (n=3)

7.89±1.07 (n=4)

0.32±0.04** (n=4)

9.1±1.44 (n=6)

8.87±0.81 (n=8)

0.24±0.07** (n=7)

6.89±1.40 (n=6)

5.80±0.78 (n=8)

0.75±0.21** (n=7)

After 4-week of
STZ induction
CD4+ (relative % of total cell
populations)
CD8+ (relative % of total cell
populations)
After 11-week of
STZ induction
CD4+ (relative % of total cell
populations)
CD8+ (relative % of total cell
populations)

The data is expressed as mean ± SEM. The value of ‘n’ represents number of mice in each group. **P<0.01 as compared with control
and STZ mice. STZ, streptozotocin; FTY720, fingolimod.
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Recombination activating gene 1 (Rag1) encodes recombinase enzyme Rag1
which along with Rag2 mediate recombination in development process of both B and T
cells receptor repertoire. In Rag1 deficient mice, recombination does not occur which
thwart lymphocytes development at early stage. Thus, Rag1 deficient mice does not have
any mature B or T lymphocytes.113 In our present study, flow cytometry analysis of Rag1
KO mice blood did not yield any detectable CD4+ and CD8+ T cells (Figure 2-10).
CD8+

CD8+

CD4+

CD4+
Figure 2-10: Representative flow cytometry analysis dot plot and histogram plot of CD4+
and CD8+ T cells in Rag1 KO mice peripheral blood. There was no detectable CD4+ and
CD8+ T cells in Rag1 KO mice blood. Experiments are representative of triplicate
samples.
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2.3.3. Effects of FTY720 treatment on heart histology

After 11-week diabetic period, heart sections from all the groups were prepared
and H&E staining was done to evaluate heart histology. H&E stained sections were
observed under microscope and graded on histological parameters. WT diabetic mice
heart exhibited noticeable cardiomyocyte loss, large interstitial space indicating edema,
focal and diffuse increased cellularity and myofiber disorganization in myocardium in
comparison to control group. In contrast, FTY720 treatment in WT diabetic mice
protected heart histology with improved myocytes organization and structure (Figure 211). FTY720 treated WT diabetic mice heart had reduced cumulative histology score
compared to WT STZ mice (control [n=5] 2.2±0.80; STZ [n=6], 9.67±0.49;
FTY720+STZ [n=5], 3.4±0.75, #P < 0.05 when FTY720+STZ compared with STZ)
(Figure 2-13).
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Control

STZ

FTY720+STZ

Figure 2-11: Representative images of Hematoxylin and Eosin (H&E) stained heart
tissue sections of WT C57BL/6 mice after 11-week of experimental period. Untreated
WT diabetic mice heart sections exhibited altered cardiac architecture and
disorganization of myocytes as compared to control group. FTY720 treatment preserved
cardiac histology under diabetes. Upper panel magnification is 100x, lower panel
magnification is 400x. Images are representative of n=5-6 mice heart tissue sections in
each group.
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Diabetic Rag1 KO mice (STZ, n=5) heart exhibited protected heart histology
under hyperglycemic conditions. KO STZ mice heart histology score had no significant
difference compared with control group (n=6) (control, 3.33±0.42; STZ, 3.00±0.45; P >
0.05) (Figure 2-12). Notably, treatment with FTY720 exacerbated heart histology with
marked myocytes breakage and disorganization in KO diabetic mice (FTY720+STZ,
n=3; 10.33±0.33) (Figure 2-12 and Figure 2-13).

Control

STZ

FTY720+STZ

Figure 2-12: Representative images of Hematoxylin and Eosin (H&E) stained heart
tissue sections of Rag1 KO mice after 11-week of experimental period. Rag1 KO diabetic
mice heart showed no significant difference in heart histology than control mice.
Noticeably, FTY720 treatment in diabetic Rag1 KO mice exhibited altered cardiac
histology with marked myocytes disarray. Upper panel magnification is 100x, lower
panel magnification is 400x. Images are representative of n=3-6 mice heart tissue
sections in each group.

54

Cumulative
histological scores
(0-16)

15

10

*

*

Control
STZ
FTY720+STZ

5

#

ns

0
WT C57BL/6

Rag1 KO

Figure 2-13: Quantification of heart histology scores in WT C57BL/6 and Rag1 KO
mice heart tissue sections. In WT mice, Control vs. STZ, *P < 0.05 and FTY720+STZ vs.
STZ, #P < 0.05. In KO mice, control vs. STZ (P = ns) and STZ vs. FTY720+STZ, *P <
0.05. Sample size, n = 3-6 mice in each group. The data is expressed as mean ± SEM.
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2.3.4. Effects of FTY720 treatment on myocardial fibrosis

Fibrosis area was measured in paraffin-embedded whole heart sections stained
with Masson’s Trichrome staining. Blue color represents collagen deposition in heart
sections (Figure 2-14 and 2-15). After 11-weeks, WT diabetic mice had increased
collagen deposition in myocardium and perivascular area compared to control group
(38.09±4.35 % vs. 7.40±1.23 %, *P < 0.05) (Figure 2-14 and 2-16). FTY720 treatment in
WT diabetic mice significantly reduced interstitial and perivascular fibrosis compared to
untreated diabetic mice (9.40±2.23 % vs. 38.09±4.35%, #P < 0.05) (Figure 2-14 and 216).

Rag1 KO control and STZ mice do not have any significant difference in total
fibrosis percent area (7.20±1.72 % vs. 10.60±0.91 %, P= ns) (Figure 2-15 and 2-16).
FTY720 treatment in Rag1 KO diabetic mice markedly increased interstitial fibrosis area
compared to untreated KO diabetic mice (42.16±4.30 % vs. 10.60±0.91 %, *P < 0.05).
(Figure 2-15 and 2-16).
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Control

STZ

FTY720+STZ

Figure 2-14: Representative images of Masson’s Trichrome stained heart tissue sections
of WT C57BL/6 mice after 11-week experimental period. Arrows indicate collagen
staining as blue color. Diabetic WT mice myocardium exhibited increased interstitial and
perivascular fibrosis. FTY720 treatment reduced markedly fibrosis development in
diabetic WT mice heart sections. Upper panel magnification is 16x, lower panel
magnification is 400x. Images are representative of n=5-7 mice heart tissue sections in
each group.
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Control
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Figure 2-15: Representative images of Masson’s Trichrome stained heart tissue sections
of Rag1 KO mice after 11-week experimental period. Untreated Rag1 KO diabetic mice
heart did not exhibit increased fibrosis compared with control mice, while FTY720
treatment in this mice strain developed increased fibrosis. Arrow indicates collagen
deposition. Upper panel magnification is 16x, lower panel magnification is 400x. Images
are representative of n=3-6 mice heart tissue sections in each group.
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Figure 2-16: Quantification of percent fibrosis area in WT C57BL/6 and Rag1 KO mice
heart after 11-weeks. In WT mice, control (n=6) vs. STZ (n=7), *P < 0.05; control (n=6)
vs. FTY720+STZ (n=5), #P < 0.05. In Rag1 KO mice, control (n=6) vs. STZ (n=5), P = ns,
STZ vs. FTY720+STZ (n=3), *P < 0.05. The data is reported as mean ± SEM.
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2.3.5. Effects of FTY720 treatment on cardiac contractility

We determined the force of contraction development in an ex-vivo Langendorff’s
heart perfusion system after 11-weeks. The data is expressed as fold change in contractile
force development compared to control. Cardiac dysfunction was observed in STZinduced diabetic WT C57BL/6 mice. There was no alternation in myocardial contractility
between STZ-induced diabetic Rag1 KO mice and control Rag1 KO mice (Figure 217B). Chronic treatment with FTY720 improved cardiac contractile force in diabetic WT
C57BL/6 mice but reduced contractile force in diabetic Rag1 KO mice (Figure 2-17A
and 2-17B).
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Figure 2-17: Effect of FTY720 on cardiac contractile force in diabetic WT C57BL/6 and
(A) and Rag1 knockout mice (B) hearts. Chronic Treatment with FTY720 preserved the
cardiac function of diabetic WT hearts but attenuated contractile force of diabetic Rag1
KO mice. The contractile force was expressed as fold change relative to control. Sample
size, n = 4-9 mice in each group. The data is expressed as mean ± SEM. *P < 0.05, control
vs. STZ; #P < 0.05, STZ vs. FTY720+STZ.
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2.3.6. FTY720 reduces CD3+ T cells infiltration into the myocardium

Although normal heart does not exhibit appreciable amount of CD3+ T
lymphocytes, under pathological conditions T cells can infiltrate the heart.76 To detect
CD3+ T lymphocytes in diabetic myocardium, we carried out immunostaining with
mouse monoclonal CD3 IgG antibody. CD3+ T cells were barely detected in WT control
hearts. On the other hand, we observed increased CD3+ T cells presence in interstitial
space with close proximity to cardiomyocytes in diabetic WT mice, indicating T cells
direct involvement in cardiac injury under diabetes (Figure 2-18A). FTY720 treatment
reduced detectable CD3+ T cells in WT diabetic mice myocardium (STZ, 0.97±0.03
cells/field vs. FTY720+STZ, 0.28±0.05 cells/field; #P<0.05) (Figure 2-18B). Rag1 KO
heart sections exhibited no CD3+ T cell staining.
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Figure 2-18: Immunohistochemical detection of CD3+ T cells in heart tissue section of
WT C57BL/6 mice after 11-week experimental period. (A) Increased infiltration of CD3+
T cells in diabetic WT C57BL/6 mice myocardium were observed. FTY720 treatment
reduced CD3+ T cells number in diabetic WT mice myocardium. Black arrows indicate
detected CD3+ T cells in mice myocardium. Images are representative of three
independent experiments. The magnification is 400x. (B) Results are from three
independent experiments. The data is expressed as mean ± SEM. Control vs. STZ; *P <
0.05; STZ vs. FTY720+STZ; #P < 0.05.
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2.3.7. FTY720 reduces TGF-β1 expression in diabetic WT myocardium

Transforming growth factor beta 1 (TGF-β1) is a profibrotic cytokine that can
activate fibrotic pathway in heart that induces fibrosis.126 To measure total TGF-β1
expression in cardiac tissue, we conducted immunohistochemistry and quantified the
intensity and staining area. TGF-β1 expression was increased in diabetic WT mice
myocardium after 11-week diabetic period compared to control mice (8.09±0.19 %
staining area vs. 3.69±0.17 % staining area, *P<0.05) (Figure 2-19A and 2-20). FTY720
treatment significantly reduces TGF-β1 expression in diabetic heart compared to
untreated diabetic mice (3.80±0.12 % staining area vs. 8.09±0.19 % staining area,
#

P<0.05) (Figure 2-19A and 2-20).

In contrast, diabetic Rag1 KO mice heart sections exhibited statistically no
significant difference in TGF-β1 expression than control mice (3.48±0.26 % staining area
vs. 3.35±0.38 % staining area, P=ns). FTY720 treatment in Rag1 KO hyperglycemic
mice increased TGF-β1 expression in myocardium compared to untreated diabetic mice
(6.61±0.51% vs. 3.35±0.38%, *P<0.05) (Figure 2-19B and 2-20).
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A WT C57BL/6
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B Rag1 KO
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Figure 2-19: FTY720 treatment effect in TGF-β1 expression in heart tissue sections of
WT C57BL/6 and Rag1 KO mice after 11-week treatment period. (A) Representative
immunohistochemical images show reduced TGF-β1 expression in WT FTY720 treated
diabetic mice compared to untreated diabetic mice. (B) TGF-β1 expression was reduced in
diabetic Rag1 KO mice, while FTY720 treatment increased TGF-β1 expression in Rag1
KO mice heart sections. Black arrows indicate TGF-β1 expression localization in
myocardium. Images are representative of three independent experiments. The
magnification is 400x.
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Figure 2-20: Quantification of TGF-β1 percent staining area in WT C57BL/6 and Rag1
KO mice myocardium. Results are from three independent experiments. The data is
expressed as mean ± SEM. In WT mice, Control vs. STZ, *P < 0.05, STZ vs.
FTY720+STZ, #P < 0.05. In Rag1 KO mice, control vs. STZ, P = ns, Control, STZ vs
FTY720+STZ, *P < 0.05.
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2.3.8. Effects of FTY720 treatment on CD34 fibrocyte expression in the myocardium

Fibrocytes are circulatory, sphindle shaped, monocyte-derived profibrotic cells
that augment fibrotic conditions. Chronic injury invokes fibrocytes recruitment at the site
of inflammation.62 CD34 surface expression can be considered as a biomarker for
fibrocytes.62,63 We detected CD34 expression pattern and quantified expression level by
immunostaining in mice heart sections. In WT control mice, CD34 expressing cells
predominantly appeared in perivascular region, while in diabetic WT mice, CD34
expressing cells appeared in interstitial space of myocardium and closely adherent to
myocytes (Figure 2-21A). The total expression of CD34 in myocardium was increased in
untreated diabetic mice heart tissue compared with control mice (6.59±0.20% vs.
2.97±0.44%, *P<0.05) (Figure 2-22). Fingolimod treatment markedly reduced CD34
expressing cells presence in diabetic myocardium compared to untreated diabetic mice
(3.11±0.21% vs. 6.59±0.20%, #P<0.05) (Figure 2-21A and 2-22).

Rag1 KO control and diabetic mice heart sections exhibited minimal expression
of CD34 cells in myocardium (2.35±0.05% vs. 2.27±0.20%, P=ns) (Figure 2-21B and 222). FTY720 treatment increased CD34 cells expression in interstitial space of diabetic
Rag1 KO mice heart compared to untreated KO diabetic mice (4.45±0.12% vs.
2.27±0.20%, *P<0.05) (Figure 2-21B and 2-22).
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A WT C57BL/6
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B Rag1 KO
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Figure 2-21: Representative immunostaining images of CD34 bearing fibrocytes in heart
tissue sections of WT C57BL/6 and Rag1 KO mice after 11-weeks. (A) In WT control
mice, CD34 fibrocytes are localized in perivascular area, while in WT diabetic mice heart
CD34 cells are found increasingly adjacent to myocardium. FTY720 treatment reduced
CD34 cells in myocardium of WT diabetic mice. (B) Rag1 KO control and diabetic mice
myocardium have minimal CD34 expressing cells. FTY720 treatment in Rag1 KO
diabetic mice significantly increased CD34 cells expression in the mouse heart sections.
Black arrows indicate CD34 cells detected by immunostaining. Images are from three
independent experiments. The magnification is 400x.
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Figure 2-22: Quantification of percent area staining of CD34 expression in heart tissue
sections of WT C57BL/6 and Rag1 KO mice after 11-weeks. Results are from three
independent experiments. The data is expressed as mean ± SEM. Control vs. STZ; *P <
0.05 and STZ vs. FTY720+STZ; #P < 0.05 in WT mice. Control vs. STZ, P = ns, STZ vs.
FTY720+STZ; *P < 0.05 in Rag1 KO mice.
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2.3.9. Increased plasma S1P levels and S1P1 expression in myocardium in diabetic
mice

Chronic inflammatory conditions in mice, such as colitis-associated cancer and
myocardial infarction, lead to increased S1P synthesis at the site of tissue
injury/inflammation.116,130 In addition, S1P1 receptor expression has been detected to
increase at the site of tissue injury/inflammation. This phenomenon indicates presence of
a positive feedback loop of S1P-S1P1 signaling in inflamed tissue.116,130 To this end, it is
noteworthy that long term diabetes is associated with chronic systemic and local
inflammation. Thus, in the present study we measured mice plasma S1P level by using
LC/MS/MS technique and also detected S1P1 expression in the myocardium.

Hyperglycemia increased plasma S1P level in both WT and KO mice (Figure 223A, 2-23B and 2-24A, 2-24B, *P<0.05, as compared with control mice). In WT mice,
plasma S1P level was increased in diabetic mice compared to control mice (0.61±0.02 µM
vs. 0.42±0.05 µM, *P < 0.05) (Figure 2-24A). FTY720 treatment reduced plasma S1P level
about 1.20 –fold, but yielded no statistical significant difference with diabetic mice S1P
level (0.51±0.05 µM vs. 0.61±0.02 µM, P > 0.05) (Figure 2-24A). Similarly, Rag1 KO
diabetic mice have increased S1P levels compared to control mice (0.70±0.02 µM vs.
0.50±0.04 µM, *P < 0.05) (Figure 2-24B).
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B

Figure 2-23: Measurement of sphingosine 1-phosphate (S1P) level in the plasma samples
of WT C57BL/6 and Rag1 KO mice by LC/MS/MS. (A) Representative full-scan product
ion mass spectra of [M+H]+ for S1P (upper panel) and internal standard (IS) C17-S1P
(lower panel). (B) Representative SRM chromatograms of S1P (upper panel) and IS
(lower panel).
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Figure 2-24: Quantification of plasma S1P level in the plasma samples of WT C57BL/6
and Rag1 KO mice after 11-week experimental period. (A) In WT mice, Control (n=7)
vs. STZ (n=9), *P < 0.05, STZ (n=9) vs. FTY720+STZ (n=8), P > 0.05. (B) In Rag1 KO
mice, control (n=3) vs. STZ (n=4), *P < 0.05. The data is expressed as mean ± SEM.
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We further detected sphingosine 1-phosphate receptor 1 (S1P1) expression in
heart tissue sections by immunohistochemistry and quantified the expression level. S1P1
expression was detected in cardiomyocytes, cells in interstitial spaces and in endothelial
cells in control mouse heart tissue (Figure 2-25A). Hyperglycemia increased S1P1
expression in cardiomyocytes in WT STZ mice compared to control mice (6.13±0.27%
vs. 3.13±0.18%, *P<0.05) (Figure 2-25A and 2-26). Fingolimod treatment markedly
reduced S1P1 expression in cardiomyocytes and limits the expression mainly on the
endothelial cells compared to untreated diabetic mice (3.15±0.08% vs. 6.13±0.27%,
#

P<0.05) (Figure 2-25A and 2-26).

Similar S1P1 expression profile was observed in Rag1 KO heart sections.
Untreated Rag1 KO diabetic mice heart sections exhibited increased S1P1 expression
(5.30±0.18 % [STZ] vs. 3.29±0.25 % [control], *P < 0.05), while FTY720 treatment
reduces S1P1 expression (3.10±0.36 % [FTY720+STZ] vs. 5.30±0.18 % [STZ], #P <
0.05) (Figure 2-25B and 2-26).
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Figure 2-25: Representative immunohistochemistry images of S1P1 expression in WT
C57BL/6 and Rag1 KO mice myocardium after 11-weeks. Both WT C57BL/6 (A) and
Rag1 KO (B) diabetic mice heart sections exhibited increased S1P1 expression. FTY720
treatment limits cardiomyocyte expression of S1P1 in both WT (A) and KO (B) mice
myocardium. Images are representative of triplicate experiments for each group. The
magnification is 400x.
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Figure 2-26: Quantification of S1P1 expression in WT C57BL/6 and Rag1 KO mice
heart tissue sections after 11-weeks. Results are from three independent experiments. The
data is expressed as mean ± SEM. Control vs. STZ, *P < 0.05, STZ vs. FTY720+STZ, #P
< 0.05 in WT and KO mice.
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2.4. Discussion
Recent studies have reported that the T lymphocytes infiltration is an important
component in myocardial fibrogenesis in murine myocardial infarction model and
pressure overload transverse aortic constriction models.74,76 In the present study, we for
the first time report the chronic administration of FTY720 treatment reduced cardiac
fibrosis area and improved contractility under chronic hyperglycemic condition compared
to untreated diabetic mice in wild-type (WT) C57BL/6 mice. FTY720 treatment induced
sustained reduction of CD4+ and CD8+ T lymphocytes in the blood and was associated
with reduced CD3+ T cells infiltration into heart tissue of diabetic WT mice compared to
untreated WT diabetic mice. Cardiac protection and anti-fibrosis were also observed in
diabetic Rag1 knock-out (KO) mice without any mature lymphocytes. Remarkably,
FTY720 caused heart injury in diabetic Rag1 KO mice.
FTY720, also known as fingolimod, is an orally active immunomodulator drug
approved by FDA for relapsing multiple sclerosis.92 FTY720 is a synthetic structural
analogue of endogenous sphingosine, becomes activated in vivo upon phosphorylation by
sphingosine kinase 2 and then acts on all five S1P receptors (S1P1-5).92,93,128 FTY720
binds with S1P1 receptor with high affinity (0.3 nM); causes ligand induced
internalization and degradation of the receptor (functional antagonism).88,89 Mature T
cells express higher S1P1 receptor on their cell surface that enables these cells to sense
the increased concentration gradient of endogenous ligand sphingosine 1-phosphate
(S1P) in blood and lymph than in lymphoid tissues.85,89 Thus, S1P-S1P1 driven
chemotaxis enables T cells exit from lymphoid organs to periphery. Fingolimod
downmodulates mature T lymphocytes cell surface S1P1 receptor and sequesters the T
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cells in lymphoid organs. Thus, FTY720 inhibits the recirculation of T cells between
lymphoid organs and blood.95 In experimental autoimmune encephalomyelitis, FTY720
alters lymphocytes trafficking directed towards central nervous system and thus provides
protection from immune assault mediated by T lymphocytes.92,95 Similarly, we found that
FTY720 causes both CD4+ and CD8+ T cells sustained depletion in blood as shown in
this study, and maintained the pronounced lymphopenia at the end of 11-week study
period. To correlate circulatory T cells deficiency effect with heart T cells infiltration, we
conducted immunostaining to detect myocardium infiltrating CD3+ T cells. WT diabetic
mice myocardium increased CD3+ T cells presence in interstitial space that was reduced
in FTY720 treatment WT diabetic mice. FTY720 protected diabetic WT mouse hearts
against hyperglycemia-induced injury. Trichrome staining showed less fibrosis area in
heart sections of FTY720 treatment diabetic WT mice compared to untreated diabetic
mice. These cardiac protective effects are consistent with the study in diabetic Rag1 KO
mice that lacks mature lymphocytes.
After 11-weeks, diabetic Rag1 KO mouse hearts showed integrated cardiac
structure with less fibrosis and preserved contractile force. Fibrosis development involves
complex network of cellular and molecular milieu. We further investigated CD34 bearing
fibrocytes localization in cardiac tissue. Diabetic mice myocardium exhibited increased
myocytes adherent CD34 fibrocytes with increased expression of profibrotic mediator
TGF-β1. Diabetic WT mice under FTY720 treatment as well as Rag1 KO diabetic mice
showed significantly less fibrocytes presence in interstitial space of myocytes with
reduced TGF-β1 expression. Elevated sphingosine 1-phosphate receptor 1 (S1P1)
signaling has been implicated in potentiating inflammation in murine myocardium after
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left anterior coronary artery ligation induced myocardial infarction within 4-weeks.116
Similarly, both WT and KO mice under long term hyperglycemia in present study
exhibited increased S1P1 expression in heart tissue after 11-weeks. This increment is
reversed in both mice strain under FTY720 treatment. Paradoxically, FTY720
administration in KO diabetic mice attenuates cardioprotection as observed in untreated
diabetic KO mice: FTY720 treatment increases fibrotic area, worsens cardiac histology
and reduces contractile force in KO diabetic mice. Increased CD34 infiltration with
increased TGF-β1 expression has been observed in these mouse hearts. These findings
indicate that FTY720 can modulate myocardial fibrosis through different mechanisms
depending on the presence of T lymphocytes discussed later.
Diabetic heart generates increased reactive oxygen species (ROS) due to
metabolic perturbations in presence of hyperglycemia.3,26 Increased ROS induces
proinflammatory signaling that activates endothelial cells.3 Activated endothelial cells as
well as inflamed myocardium express increased adhesion molecules expression (e.g.
vascular cell adhesion molecule 1; intercellular adhesion molecule 1) as observed in STZinduced diabetic rodent myocardium.129 Increased adhesion molecules expression recruits
inflammatory mononuclear cells in heart that participate in inflammation potentiation and
fibrosis generation. Increased infiltration of CD3+ T cells into heart tissue, as early as 2week, has been reported in a STZ-induced diabetic rodent model that is associated with
increased collagen deposition into myocardium with declined left ventricular
contractility.111 Increased endothelial cell adhesion molecule ICAM-1 and increased T
cells recruitment into heart tissue were detected in pressure overload TAC heart.76 T cells
as an adaptive immune system cell continually recirculate between secondary lymphoid
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organs e.g. spleen and lymph nodes as well as periphery that maximizes their interaction
with antigen bearing antigen-presenting cells e.g. macrophages, B cells, dendritic cells.
The continuous recirculation of T cells is necessary for activation, proliferation and
subsequent generation of immune response in target organ. This concept has been
implicated in recent report where T cells proliferation have been detected in heart
draining lymph nodes of mice underwent MI and TAC surgery induced injury after
activation through heart derived neoantigens e.g. myocytes debris encountering.77 In
these models, increased T cells recruitment into heart was associated with increased
fibrosis. From our lab, we have also reported earlier that the inhibition of PKC-θ, a
selectively T cell expressed protein kinase C family protein necessary for T cell
activation, by a cell permeable peptide inhibitor in STZ-induced diabetic cardiomyopathy
model reduces T cells presence into cardiac tissue associated with antifibrotic effect.117
Despite these findings, the effect of T cells trafficking modulation in long term diabetes
associated fibrogenesis is still not known. In our present chapter work, we for the first
time report that FTY720 induced T cells reduction in blood is associated with reduced
myocardial fibrosis under long term 11-week diabetic period.
Fibrocytes are circulating monocyte-derived CD34 expressing cells that appear in
injured tissue and can secrete extracellular matrix (ECM) protein as well as under chronic
profibrotic milieu e.g. TGF-β1, apoptotic debris etc. and can differentiate in to ECM
protein synthesizing fibroblasts.62 To determine fibrocytes localization in diabetic heart
tissue, we used CD34 as a biomarker for immunostaining of fibrocytes. One of the unique
findings of our current work is that FTY720 treatment reduced interstitial appearance of
CD34 expressing fibrocytes in diabetic myocardium. Similarly, diabetic KO mice without
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FTY720 treatment exhibited minimal expression of CD34 cells in their heart tissue. In
addition, profibrotic mediator TGF-β1 expression is markedly reduced in FTY720
treatment diabetic WT mice heart. Rag1 KO diabetic mice heart sections showed similar
expression profile of TGF-β1. Altogether, our findings for the first time demonstrate that
simultaneous high magnitude presence of T cells and fibrocytes in diabetic myocardium
results in profibrotic microenvironment as manifested by increased TGF-β1 expression
and increased myocardial fibrosis. Fingolimod causes reduction of T lymphocytes in
circulation and heart tissue that is associated with attenuation in TGF-β1 expression and
CD34 fibrocytes in diabetic cardiac tissue.
S1P-S1P1 signaling has been reported as a proinflammatory mediator in colitisassociated cancer127 and more recently, in the long term myocardial infarction murine
model.116 In this paradigm, increased S1P level under inflammatory condition increases
S1P1 expression that causes persistent activation of transcription factor STAT3 which
further potentiates proinflammatory molecules gene expression. Thus, we measured S1P
level by LC/MS/MS in plasma and quantified S1P1 expression in heart tissue by
immunohistochemistry. Increased plasma S1P levels were observed in both diabetic WT
and KO mice. Although FTY720 treatment reduced about 1.20-fold S1P level in diabetic
mice, the statistical test did not show any significant difference between untreated and
treated diabetic mice blood. This result is consistent with earlier reports as in heart injury
model FTY720 treatment did not reduce serum S1P level.116,127 Further, diabetic
myocardium showed increased expression of S1P1 receptor suggesting activation of S1PS1P1 inflammatory loop in present long term diabetic model. Here, we for the first time
demonstrate increased S1P1 expression in diabetic myocardium. Notably, FTY720
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reduces increased S1P1 expression in cardiomyocytes in both WT and KO mice.
Recently, Zhang et al. reported FTY720 reduces S1P1 expression in mouse heart tissue
after myocardial infarction and protects the heart from inflammation, dysfunction and
cardiac remodeling.116
Surprisingly, FTY720 treatment in diabetic Rag1 KO mice exacerbated fibrosis,
worsened cardiac histology and decreased cardiac force of contraction with discernible
disarray and loss of myofibers compared with untreated diabetic KO mice. There could
be two possible explanations to describe this paradoxical result. First, fate of cell
membrane S1P1 receptor in presence of sustained FTY720 in extracellular space, and
second, FTY720 actions on other S1P receptors. S1P1 receptor is widely distributed in
different tissues/cells and involved in many important physiological functions including
maintenance of vascular tone and maturation and endothelial cell barrier regulation.85
Cell surface residing receptor internalization and re-insertion to cell membrane is a way
of G protein-coupled receptors regulation that maintains receptor responsiveness in case
of sustained ligand presence in extracellular space. FTY720 binds to S1P1 and
internalizes the receptor and causes ubiquitinylation and proteasomal degradation unlike
natural ligand S1P induced S1P1 internalization, in which case receptor surface
expression recycled back shortly.84,94 FTY720 induced downregulation and degradation
of S1P1 receptor can be a possible cause of contradicting results in reported studies. In
lipopolysaccharide-induced murine inflammatory lung injury model, treatment with
single dose of FTY720 (0.1 mg kg-1 body weight, i.p.) after 1 hour of lipopolysaccharide
administration, prevented pulmonary vascular leakage by endothelial barrier
enhancement as examined after 24 hours.130 In another study, FTY720 (0.5 mg kg-1 body
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weight, i.p.) administration before and after 24 hour lipopolysaccharide induction; at 48
hour examination of bronchoalveolar lavage showed increased total protein
concentration, suggesting increased pulmonary vascular leak.131 In the same study,
authors reported in bleomycin induced lung injury model (fibrosis independent of T
cells), FTY720 (0.5 mg kg-1 body weight, i.p.) three times for 2 weeks increased collagen
deposition and fibrosis compared with control mice. Notably, in later investigation higher
dose and chronic administration of FTY720 opposes pulmonary vascular protection as
seen in single dose FTY720. As lungs are more susceptible to endothelial barrier
disruption due to presence of extensive microvascular network associated with alveolar
air spaces might be the reason for observed effect. In contrast, cardiac microvascular
endothelial cells in STZ-induced diabetic rats have reduced S1P1 expression and
increased membrane translocation of S1P3.132 The opposing roles of S1P1 and S1P3 in
endothelial cells have been reported in STZ-induced rodent model.132 Activation of S1P1
has been implicated in promoting angiogenesis whereas S1P3 stimulation leads to
impaired barrier function.132 We have observed similar S1P1 expression pattern in
diabetic mouse heart section in present work. Although FTY720 reduces total S1P1
expression in diabetic myocardium, but maintained its expression on endothelial cells in
WT diabetic mice (Figure 2-25). This discrepancy in FTY720 effects on S1P1 receptor on
T cells and cardiac microvascular endothelial cells might be due to the differential
association of the receptor with specific molecules in lipid rafts, cellular niche where G
protein-coupled receptor specific signaling and internalization/recycling tasks occur, in
different cell types.84 In another paradigm, FTY720 (1 mg kg-1 body weight, immediately
before) protects WT mice brain in transient middle cerebral artery occlusion, but
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abolishes protection in Rag1 KO mice.133 This implies that FTY720- mediated protection
in acute transient cerebral ischemia and reperfusion results from not by direct
neuroprotection rather its effect on neurovasculature and its interaction with immune
cells. In our present study, although Rag1 KO mice heart does not have any T cells but
FTY720 treatment causes increased TGF-β1, CD34 expression with increased collagen
deposition in heart. These results indicate FTY720 in absence of T cells may activate
different fibrotic pathway, while in presence of T cells by inhibiting T cells infiltration
and profibrotic milieu into the heart it exerts cardioprotection in diabetes. In this regard,
both pharmacokinetic and pharmacodynamic characteristics of FTY720 should be taken
into consideration. FTY720 is a lipophilic drug molecule with large volume of
distribution (VD is 1116-1737 L) and long elimination half-life (t1/2 is 4.5 days).134,135
Thus, in our present study continuous systemic administration of FTY720 might create a
sustained drug pool in the blood to act on its target receptors. Keller et al. reported that
FTY720 in dose dependent manner (0.1-1 µM) can activate S1P3 receptor on fibroblasts
that causes differentiation into collagen producing myofibroblasts.136 In summary,
FTY720 treatment induced increased fibrosis area in Rag1 KO diabetic mice indicates
that the drug might activate other fibrotic pathways in absence of lymphocytes either by
affecting S1P1 receptor functions in heart or by acting on other S1P receptors.

84

2.5. Conclusions
In summary, the important findings of the present study are: (1) diabetic
myocardium exhibited profibrotic milieu manifested by increased T cells infiltration with
increased TGF-β1 and CD34 expressing fibrocytes into myocardium, (2) fingolimod
(FTY720) reduced T lymphocytes infiltration into the myocardium, inhibited profibrotic
milieu in myocardium and attenuated fibrotic remodeling with improved cardiac
contractility in WT diabetic mice, (3) FTY720 induced cardiac fibrosis in Rag1 KO mice
indicates the potential role of FTY720 in activating fibrotic remodeling in absence of
lymphocytes under diabetes.
Nonetheless, FTY720 is a non-specific S1P1 receptor agonist, and S1P1 receptor
expression not exclusive to T lymphocytes only. Therefore, for the next set of
experiments, we utilized conditional T cell specific S1P1 receptor knock out (TS1P1KO)
mice through Cre-loxP approach. These studies are discussed in the next chapter.
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CHAPTER 3: EFFECTS OF GENTIC DEPLETION OF T CELL S1P1 RECEPTOR ON
CARDIAC FIBROSIS IN DIABETIC CARDIOMYOPATHY
3.1. Introduction

In chapter 2, we discussed that chronic administration of sphingosine 1-phosphate
receptor 1 (S1P1) modulator, FTY720, profoundly reduced circulatory CD4+ and CD8+ T
cells number in wild-type (WT) C57BL/6 diabetic mice. FTY720 treatment reduced
CD3+ T cells infiltration in diabetic WT mice myocardium compared to untreated
diabetic mice. Further, FTY720 treated diabetic WT mice myocardium showed
attenuated profibrotic TGF-β1 and CD34 expressing cells expression compared to
untreated diabetic mice heart. Rag1 knock out mice, lacking mature B and T
lymphocytes, exhibited less fibrosis and preserved contractility under diabetic conditions.
Interestingly, FTY720 treatment in Rag1 KO diabetic mice increased fibrosis area and
attenuated contractility. These contrary results indicate that FTY720 may target different
mechanistic pathways in the absence of lymphocytes to induce cardiac fibrosis. Notably,
FTY720 is not only selective to S1P1 receptor among five S1P receptors, but can also act
on other S1P receptors (S1P2,3,4,5).88,92,128,136 FTY720 can induce transdifferentiation of
fibroblasts to myofibroblasts similar to TGF-β at concentrations of 0.1 to 1 µM by acting
through S1P3 receptor.136 In another recent report, FTY720 was shown to cause
contraction of fibroblasts by targeting S1P2 receptor.128 Thus, FTY720 may induce
fibrosis by activating other fibrotic pathways that override lymphocytes depletion
associated cardioprotection in Rag1 knock out mice under diabetes.
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In this chapter of the dissertation, we have reported the use of Cre-loxP mediated
genetic recombination approach to generate conditional T cell specific S1P1 receptor
knock out mice (TS1P1KO). Use of this genetic tool enables us to deplete S1P1 receptor
gene specifically on T lymphocytes. To this end, our goal is to demonstrate that the
modulation of S1P1 mediated T lymphocytes trafficking protects heart under diabetic
conditions. Littermate and TS1P1KO mice undergone chronic STZ-induced type 1
diabetic cardiomyopathy model. At the end point of experimental period (11-weeks), we
studied heart histology, assessed fibrosis area, and measured cardiac contractility in exvivo Langendorff perfusion system. CD3+ T cells number, profibrotic molecular and
cellular milieu were assessed through evaluation of TGF-β1 and CD34 expression by
immunohistochemistry in heart tissue.
3.2. Materials and Methods
3.2.1. T cell specific S1P receptor 1 knock out mice generation
To achieve conditional T cell specific sphingosine 1-phosphate receptor 1 (S1P1)
depletion we used reported Cre-LoxP approach.83,137 Specific depletion of S1P1 on T cell
was achieved by crossing S1P1loxP/loxP mice (The Jackson Laboratory, Bar Harbor, ME),
carrying modified S1P1 gene with two loxP sequences flanking exon 2 (coding region of
S1P1), with lymphocyte tyrosine kinase (Lck) promoter bearing Cre mice (Taconic,
Hudson, NY).83 The offspring mice were genotyped to detect TS1P1KO mice bearing
S1P1loxp/loxP allele with the Lck-Cre gene and littermate control mice with S1P1WT allele
with Cre by genotyping polymerase chain reaction. Briefly, genomic DNA was extracted
from ear punch tissues by using sodium hydroxide and Tris-HCl buffer.138 Presence of
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Cre transgene and S1P1 alleles in extracted genomic DNA from offspring mice, primers
and PCR conditions were used as described in table 3-1.
Table 3-1: Genotyping PCR primers and reaction conditions for Cre and S1P1 genes.
Genes
Cre

Primers

PCR Reaction Conditions

Forward (5’-->3’): CCTGGAAAATGCTTCTGTCCGTTTG

Initial denaturation: 95 ºC for 5 minutes

Reverse (5’-->3’): ACGAACCTGGTCGAAATCAGTGCG

30 cycles of
Denaturation: 95 ºC for 1 minute
Annealing: 56 ºC for 1 minute 30 seconds
Extension: 72 ºC for 2 minutes; followed by
Final extension: 72 ºC for 8 minutes

S1P1

Forward (5’-->3’): GAGCGGAGGAAGTTAAAAGTG

Initial denaturation: 94 ºC for 3 minutes

Reverse (5’-->3’): CCTCCTAAGAGATTGCAGCAA

35 cycles of
Denaturation: 94 ºC for 30 seconds
Annealing: 55 ºC for 30 seconds
Extension: 72 ºC for 30 seconds; followed by
Final extension: 72 ºC for 2 minutes

In both cases, primer sequences and PCR conditions were followed according to
the manufacturers’ instruction (S1P1: The Jackson Laboratory; Cre: Taconic). All primer
pairs were acquired from Eurofins MWG Operon (Huntsville, AL). PCR reactions were
carried out by using KAPA LongRange HotStart kit (KK3501, Kapa Biosystems Inc.
Wilmington, MA) in a thermal cycler (MasterCycler Personal, Eppendorf). After PCR
amplification, DNA bands were detected in 3% w/v agarose gel electrophoresis
containing 0.02 % v/v ethidium bromide and imaged at ChemiDoc™ XRS+ system
coupled with Image Lab software (Bio-Rad, Hercules, CA). Mutant S1P1loxP allele
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amplified at 250-bp and wild-type S1P1 allele at 200-bp (The Jackson Laboratory). Mice
carrying mutant S1P1loxP allele with Cre transgene were TS1P1KO mice. Blood samples
from all the mouse used in the present study were analyzed by flow cytometry to confirm
appropriate use of mouse type. All mice were housed in specific pathogen free room in
Animal Research Wing (ARW) facility at South Dakota State University (SDSU) and
given free access to autoclaved food (5010, LabDiet) and water. Mice used in the present
investigation were handled and cared for according to the Guide for the Care and Use of
Laboratory Animals by U.S. National Research Council (Eighth Edition, 2011). All the
experimental procedures were approved by Institutional Animal Care and Use Committee
at SDSU.
3.2.2. Induction of Type 1 diabetes
We used repeated low doses of streptozotocin (STZ) to induce type 1 diabetes in
mice as described in chapter 2. Briefly, streptozotocin (S0103, Sigma-Aldrich, MO) at a
dose of 50 mg/kg body weight in 0.1 M sodium citrate buffer (pH 4.5) was administered
intraperitoneally for five day at the beginning. Both littermate control and TS1P1KO mice
were divided into vehicle and STZ treated (diabetic) groups. Vehicle group received 0.1
M sodium citrate buffer (pH 4.5) only. All mice then underwent 11-week long study
period. Body weights (g) were measured twice each week in an electric balance machine
(OHAUS® Scout-Pro™, OHAUS, NJ, USA). Blood glucose levels (mg/dl) were
measured in the blood samples from tail vein of mice in a glucose meter (CONTOUR®,
Bayer Healthcare LLC, IN) at three time points: at the beginning, 4- and 11-week post
STZ induction. STZ recipient mice with blood glucose levels above 200 mg/dl were
considered hyperglycemic.
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3.2.3. Flow cytometry analysis of CD4+ and CD8+ T cells
We measured helper CD4+ and cytotoxic CD8+ T cells proportions in peripheral
blood of all mice by two color flow cytometry analysis as described in chapter 2 in a BD
FACSCalibur flow cytometer (BD Biosciences, San Jose, CA). Data was acquired and
analyzed by BD CellQuest Pro software (BD Biosciences).
3.2.4. Flow cytometry analysis of regulatory T cells
We measured percentage of CD4+Foxp3+ regulatory T cells (Treg cells) in spleen
and blood after 11-weeks. Single-cell suspension of spleen was prepared from freshly
dissected spleen from anesthetized mice. Spleen was cut into 1 mm3 pieces and passed
through 70 µm nylon cell strainer (352350, Corning Inc. NY) by gentle press with a
rubber plunger. The dissociated cells were collected in isolation buffer containing 0.5%
w/v bovine serum albumin (A2153, Sigma-Aldrich, MO) and 2 mM EDTA in 0.01 M
PBS (P3813, Sigma-Aldrich). The cell suspension was centrifuged at 300 x g for 10
minutes at RT. Supernatant was discarded and incubated at RT for 5 minutes with 5 mL
of 1 x RBC lysis buffer (00-4333, eBioscience) per spleen. Cell suspension was washed
twice in isolation buffer by centrifugation at 500 x g for 10 minutes at RT. The cell pellet
was re-suspended in 10 mL isolation buffer and counted in Cellometer Auto T4
(Nexcelom, MA). One million (1 x 106) cells were taken in 100 µL FCS buffer into each
tube for staining. For staining in blood, 100 µL of heparinized blood was prepared as
described above. Red blood cells were lysed with 2 mL of 1 x RBC lysis buffer by
incubating for 5 minutes at RT. Both splenocytes (1 x 106) and blood (100 µL) were dual
stained with fluorescein isothiocyante (FITC)-conjugated anti-mouse CD4 (11-0041-82,
eBioscience) and phycoerythrin (PE)-conjugated anti-mouse Foxp3 (12-5773,

90

eBioscience) antibodies. Respective isotype controls FITC-IgG2b (11-4732, eBioscience)
and PE-IgG2a were used to set compensations at detectors of flow cytometer. We used
anti-mouse/rat Foxp3 staining set (Catalog# 72-5775, eBioscience) for Foxp3 staining
according to manufacturer’s instructions (eBioscience, CA). Briefly, first staining with
CD4 antibody was carried out at RT for 30 minutes followed by washing with 2 mL of
FCS buffer at 500 x g for 5 minutes twice. The cells were then prepared for intracellular
staining by re-suspending in 1 mL of fixation/permeabilization buffer at 4 ºC for 30
minutes in dark. The cells were then washed with 2 mL of 1 x permeabilization buffer at
500 x g for 5 minutes at RT twice. The cell pellets were re-suspended with 100 µL of 1 x
permeabilization buffer and incubated with Foxp3 antibody for 30 minutes at 4 ºC in
dark. The cells were washed with 2 mL of 1 x permeabilization buffer followed by 2 mL
of FCS buffer at 500 x g at RT. The cell pellets were re-suspended in 200 µL of FCS
buffer. Flow cytometry analysis was carried out in BD FACSCalibur flow cytometer
coupled with CellQuest Pro software (BD Biosciences).
3.2.5. Cardiac contractility measurement
We assessed cardiac contractile force (g) in all mice after 11-week diabetic period
in a modified Langendorrf heart perfusion system ex-vivo, as described in chapter 2.
Developed cardiac contractile force (Fc) and the maximal rate of development of
contractile force (±dFc/dtmax) were recorded and analyzed with Biopac MP 100 data
system (Goleta, CA, USA).
3.2.6. Evaluation of heart histology and fibrosis area
Heart histology was studied in H&E stained, and fibrosis area was determined in
Masson’s trichrome stained heart sections at the end of 11-weeks. H&E stained sections
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were examined under bight field microscope (Carl Zeiss, Germany), and histological
scores were given to each heart sections based on the observed characteristics, such as,
(i) presence of eosinophilic interstitial collagen fibers, (ii) extent of cellularity in
interstitial space of myocardium, (iii) myocardial cell necrosis/loss, (iv) myofiber
striation and myocytes organization on a five-point scale for each characteristic from 0 to
4.120,121 The cumulative scores were expressed from 0 to 16 for each group. Trichrome
stained heart sections images were acquired through a Leica EZ4 HD stereomicroscope
as a whole (Leica Microsystems, Buffalo Grove, IL, USA). The percentage of fibrosis
area relative to whole heart area was quantified by using NIH Image J (Bethesda, MA)
software as described by Zhao et al.117
3.2.7. Immunohistochemical (IHC) analysis of heart sections
CD3+ T cells, TGF-β1 and CD34 bearing cells expression were analyzed in
myocardium by immunohistochemistry in paraffin-embedded 5 µm tissue sections with
CD3 (10 µg/mL, sc-20047; Santa Cruz Biotechnology, Inc., CA), TGF-β1 (15 µg/mL,
MAB240; R&D Systems, Inc., Minneapolis, MN) and CD34 (10 µg/mL, MA5-17825;
Pierce Biotechnology, Rockford, IL, USA) primary antibodies. R&D systems mouse/rat
cell and tissue staining HRP-DAB kit (CTS002/CTS017; R&D Systems) were used to
amplify positive signals and visualize corresponding to mouse/rat primary antibodies.
Detailed procedure was described in chapter 2. To count immunopositive CD3+ cells, 30
fields of stained heart sections were pictured at bright-field under 400x magnification in
an upright microscope (Carl Zeiss, Germany). Myocardium infiltrating cells number
(cells/field) was calculated by counting the cells number in imaged 400x fields.75 TGF-β1
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and CD34 positive staining percent area were quantified and averaged in 10 fields of
400x magnification images by using NIH ImageJ software (Bethesda, MD).119,139
3.2.8. Data analyses
Data was expressed as mean ± SEM. One-way ANOVA was used for statistical
analysis of data followed by Tukey’s post hoc test of group means. Data was analyzed in
GraphPad Prism Software (v5.01, 2007). A P value of less than 0.05 was considered
statistically significant and is indicated with an asterisk (*) or a number (#) or a currency
(¤) sign when comparing between different groups.

3.3. Results

3.3.1. T cell specific S1P receptor 1 knock-out mice showed lymphopenia
All offspring mice from S1P1loxP/loxP and Lck-Cre breeding pair were genotyped
by PCR and immunophenotyped for CD3+ T cells in spleen, CD4+ and CD8+ T cells in
blood by flow cytometry. Lymphocyte tyrosine kinase driven Cre recombinase deletes
coding region of sphingosine 1-phsophate receptor 1 (S1P1) at exon 2 in offspring mutant
mice specifically on T cells (Figure 3-1A). Figure 3-1B demonstrated PCR amplicons
band for S1P1 gene and Cre gene in offspring mice after genomic DNA amplification by
using specific primer sets for mentioned genes. Mice bearing S1P1 mutant allele
amplified at 250-bp with Cre transgene presence were T cell specific S1P receptor 1
knock out (TS1P1KO) mice (Figure 3-1B). Littermate control mice with S1P1 WT allele
amplified at 217-bp with Cre transgene were used.
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Figure 3-1: Generation and detection of conditional T cell specific S1P receptor 1 knock
out mice. (A) Mice carrying flanked S1P1 gene at exon 2 (coding region of S1P1 gene) by
loxP sites are cross-bred with mice carrying Lck promoter driven Cre recombinase,
results in T cell specific S1P1 genetic depletion in progenies. Figure adapted and
modified from Allende et al.83 (B) Left panel: PCR bands for S1P1 gene and right panel:
PCR bands for Cre transgene amplification in genomic DNA extracted from offspring
mice. Left panel: lane ‘a’ represents heterozygote, lane ‘b’ represents wild-type and lane
‘c’ represents mutant band of S1P1 gene. In two panel combination, lane ‘b’ represents
littermate control mice genotype and lane ‘c’ represents TS1P1KO mice genotype. In
both panels, lane ‘d’ represents DNA ladder.

Mature T lymphocytes express S1P1 on their cell surface to exit from thymus and
secondary lymphoid organs to blood and lymph. As TS1P1KO mice T cells lack S1P1 due
to Cre mediated recombination at genomic level, T cells mature in thymus but could not
exit in periphery as reported earlier.83 In our present study, thus, we counted CD3+ T cells
proportions in spleen of littermate control and TS1P1KO mice. TS1P1KO mice exhibited
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near 2.73-fold decrease in CD3+ T cells percent in spleen as compared to littermate
control mice (Figure 3-2A and 3-2B, Table 3-2). Similarly, TS1P1KO mice had about
90% less CD4+ and CD8+ T cells in blood as compared with littermate control mice
(Figure 3-3A and 3-3B, Table 3-2).
A
Littermate Control

TS1P1KO

CD3+

B

CD3+ T cells (%)

40
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Littermate Control
TS1P1 KO
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*
10
0
Littermate Control

TS1P1KO

Figure 3-2: Flow cytometry analysis of CD3+ T cells in spleen of littermate control and
TS1P1KO mice. (A) Representative flow cytometry histogram plot exhibit depleted CD3+
T cells in TS1P1KO mice spleen than littermate mice under M1 gate. (B) Quantification
of CD3+ T cells number in littermate control and TS1P1KO mice spleen. Data are
representative of three independent experiments. *P<0.05 between littermate control and
TS1P1KO mice. The data is expressed as mean ± SEM.
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Figure 3-3: Flow cytometry analysis of CD4+ and CD8+ T cells in littermate control and
TS1P1KO mice blood. (A) Histogram plot show remarkable deficiency of both CD4+ and
CD8+ T cells in TS1P1KO mice blood compared to littermate mice under M1 gate. (B)
Quantification of CD4+ and CD8+ T cells number in littermate and TS1P1KO mice blood.
**P < 0.01 between littermate and TS1P1KO mice, n= 5-6 mice in each group. The data
is expressed as mean ± SEM.
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Table 3-2: Summary of CD3+ T cells in spleen, CD4+ and CD8+ T cells number in blood
of littermate control and TS1P1KO mice.

CD3+ T cells in spleen

Littermate Control

TS1P1KO

30.80±1.75 (n=3)

11.27±3.25* (n=3)

20.94±0.47 (n = 5)

0.91±0.17** (n = 5)

11.86±0.21 (n = 6)

1.37±0.26** (n = 6)

(% of cell populations)
CD4+ T cells in blood
(% of cell populations)
CD8+ T cells in blood
(% of cell populations)

The data is expressed as mean ± SEM. The value of ‘n’ represents number of mice in
each group. *P < 0.05 and **P < 0.01 as compared to littermate control mice.

3.3.2. Physiological characteristics assessment
Streptozotocin (STZ) is a nitrosourea compound that alkylates DNA and is
pancreatic β-cells toxic due to its transport through glucose transporter 2 into these
cells.96,125 Thus, STZ administration in mice destroys insulin producing β-cells rendering
them hyperglycemic.96 STZ-induced type 1 diabetic model exhibits salient pathological
changes in heart corresponding to clinical diabetic cardiomyopathy manifested by
increased oxidative stress and inflammation and increased collagen deposition in cardiac
interstitium with cardiac ventricular dysfunction. In the present work, both littermate
control and TS1P1KO mice were divided into vehicle treated and STZ treated groups.
There was no significant difference in body weight between littermate vehicle and
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littermate STZ mice, and TS1P1KO vehicle and TS1P1KO STZ mice at the beginning
before STZ induction (Figure 3-4, Table 3-3). After STZ administration, through 11week both littermate and KO STZ recipient mice showed less body weight gain trend
compared to only vehicle treated mice (Figure 3-4). After 11-weeks, littermate STZ mice
had 15.29% reduced body weight compared with littermate vehicle mice, and TS1P1KO
STZ mice have 17.75% reduced body weight compared to TS1P1KO vehicle mice
(Figure 3-4, Table 3-3). There was no significant difference between littermate STZ and
TS1P1KO STZ mice body weight at the end of 11-weeks (Figure 3-4, Table 3-3).

Body weight (g)
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*

20
Littermate Vehicle
TS1P1 KO Vehicle

15

Littermate STZ
TS1P1 KO STZ
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80

Days post STZ administration

Figure 3-4: Body weights (g) change in littermate and TS1P1KO mice during 11-week
experimental period. Both littermate and TS1P1KO STZ-recipient mice exhibited lower
body weight gain throughout 11-weeks. Both littermate and TS1P1KO STZ mice had
significantly low body weights (g) at the end of 11-week compared to littermate and
TS1P1KO vehicle mice, respectively. *P<0.05 between vehicle and STZ groups of
littermate and TS1P1KO mice. Sample size n = 6-10 mice in each group. The data is
expressed as mean ± SEM.

Table 3-3: Summary of physiological parameter in littermate and TS1P1KO mice during 11-week experimental period.
Littermate Vehicle

TS1P1KO Vehicle

Littermate STZ

TS1P1KO STZ

(n=6)

(n=6)

(n=10)

(n=8)

20.45±0.78

20.73±0.53

21.58±0.52

21.93±0.35

22.73±0.64

21.72±0.83

20.95±0.49

20.30±0.59

25.30±0.73

23.54±1.15

21.97±0.40*

19.99±1.003*

At the beginning
(before STZ
induction)
Body wt. (g)
After 4-week of STZ
induction
Body wt. (g)
After 11-week of
STZ induction
Body wt. (g)

The data is expressed as mean ± SEM. *P < 0.05 between vehicle and STZ groups of littermate and TS1P1KO mice. The value of ‘n’
represents number of mice in each group.
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There was no significant difference between littermate and TS1P1KO mice blood
glucose levels (mg/dl) at the beginning (Figure 3-5, Table 3-4). STZ administration
rendered both littermate and TS1P1KO mice hyperglycemic as measured in 4-weeks.
Hyperglycemia was sustained in STZ recipient littermate and TS1P1KO mice at the end
of 11-weeks (Figure 3-5, Table 3-4). There was no significant difference between
littermate STZ and TS1P1KO STZ mice blood glucose levels at the end of 11-weeks
(Figure 3-5, Table 3-4).

Blood glucose level
(mg dl -1)
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TS1P1 KO STZ
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At the
beginning

After
4-week

After
11-week

Figure 3-5: Blood glucose levels (mg/dl) during 11-week study period in littermate and
TS1P1KO mice. Bar graph shows blood glucose levels (mg/dl) at the beginning, after 4week and after 11-week. Sample size, n = 6-10 mice in each group. **P < 0.01 between
vehicle and STZ groups of littermate and TS1P1KO mice, respectively. The data is
expressed as mean ± SEM.

Table 3-4: Summary of metabolic parameter in littermate and TS1P1KO mice during 11-week experimental period.
Littermate Vehicle

TS1P1KO Vehicle

Littermate STZ

TS1P1KO STZ

(n=6)

(n=6)

(n=10)

(n=8)

142.67±13.59

139.83±11.33

142.70±7.32

140.63±10.15

128.5±7.61

123.67±13.52

433.50±46.57**

391.63±44.30**

129.67±9.87

129.50±15.96

422.80±44.69**

350.00±32.98**

At the beginning
(before STZ
induction)
Blood glucose level
(mg/dl)
After 4-week of STZ
induction
Blood glucose level
(mg/dl)
After 11- week of
STZ induction
Blood glucose level
(mg/dl)

The data is expressed as mean ± SEM. **P < 0.01 between vehicle and STZ groups of littermate and TS1P1KO mice. The value of ‘n’
represents number of mice in each group.
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3.3.3. Flow cytometry analysis of T lymphocyte subsets
Flow cytometry analysis was used to determine CD4+ and CD8+ T cells in the
blood and CD4+Foxp3+ T cells in spleen and blood after 11-weeks (Figure 3-6 and 3-7).
TS1P1KO vehicle and STZ mice had about 90% reduction of both CD4+ (CD4+ T cells:
littermate vehicle, 12.93±3.98 %, littermate STZ, 12.10±1.75 % vs. TS1P1KO vehicle,
1.37±0.02 %, TS1P1KO STZ, 1.21±0.61 %, n=4-5 mice in each group, **P < 0.01) and
CD8+ (CD8+ T cells: littermate vehicle, 7.73±1.43%, littermate STZ, 7.11±0.80 % vs.
TS1P1KO vehicle, 1.61±0.13 %, TS1P1KO STZ, 1.29±0.44%, n=4-5 mice in each group,
**P < 0.01) T cells in blood after 11-week experimental period (Figure 3-6A and 3-6B,
Table 3-5). This data demonstrates sustained T lymphocytes deficiency in TS1P1KO mice
circulation.
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Figure 3-6: Flow cytometry analysis of CD4+ and CD8+ T cells in blood of littermate and
TS1P1KO mice at the end of 11-weeks. (A) Representative flow cytometry dot plots
showing CD4+ (in lower right quadrant) and CD8+ (in upper left quadrant) T cells in the
blood of littermate and TS1P1KO mice. TS1P1KO mice exhibited noticeable less CD4+
and CD8+ T cells in the blood. (B) Both vehicle and STZ groups of TS1P1KO mice had
significantly reduced CD4+ and CD8+ T cells number than littermate vehicle and STZ
mice, respectively. **P<0.01 between littermate and TS1P1KO mouse groups. Sample
size, n = 3-5 mice in each group. The data is expressed as mean ± SEM.
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Further, we counted CD4+FoxP3+ T cells proportion percent in spleen and blood
by two-color flow cytometry. In littermate diabetic mice, CD4+FoxP3+ T cells were
increased by 1.60-fold in spleen (3.15±0.22 % vs. 1.97±0.27 %, n=3, #P < 0.05) and 1.82fold in blood (1.58±0.19 % vs. 0.87±0.21 %, n=3, #P < 0.05) compared to littermate
vehicle mice after 11-weeks (Figure 3-7A and 3-7B). In contrast, similar to reduced
CD3+ T cells in spleen and CD4+ and CD8+ T cells in blood, TS1P1KO vehicle mice had
2.94-fold (in spleen) and 4.58-fold (in blood) decreased (spleen: 0.67±0.12 % vs.
1.97±0.27 %, n=3, *P < 0.05, blood: 0.19±0.03 % vs. 0.87±0.21 %, n=3, *P < 0.05) and
TS1P1KO STZ mice had 2.28-fold (in spleen) and 3.76-fold (in blood) decreased (spleen:
1.38±0.37 % vs. 3.15±0.22 %, n=3, *P < 0.05, blood: 0.42±0.18 % vs. 1.58±0.19 %, n=3,
*P < 0.05) CD4+Foxp3+ T cells compared to littermate vehicle and STZ mice,
respectively (Figure 3-7A and 3-7B, Table 3-5). There was no statistically significant
difference between TS1P1KO vehicle and STZ mice (spleen: 1.38±0.37 % vs. 0.67±0.12
%, n=3, P value = 0.1407, blood: 0.42±0.18 % vs. 0.19±0.03 %, n=3, P value = 0.2624)
in CD4+Foxp3+ T cells percent in spleen and blood, although about 2-fold increase in
average percent of cells was observed in TS1P1KO diabetic mice (Figure 3-7A and 3-7B,
Table 3-5).
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Figure 3-7: Flow cytometry analysis of CD4+Foxp3+ regulatory T cells in spleen and
blood of littermate and TS1P1KO mice at the end of 11-weeks. (A) Representative flow
cytometry dot plots showing CD4+Foxp3+ T cells staining (in upper right quadrant) in
littermate and TS1P1KO mice spleen after 11 weeks. (B) Diabetic littermate mice had
increased CD4+Foxp3+ T cells number in spleen and blood compared to littermate vehicle
mice. Both vehicle and STZ mice of TS1P1KO had reduced CD4+Foxp3+ T cells in
spleen and blood than littermate vehicle and STZ mice, respectively, at the end of 11weeks. #P<0.05 littermate STZ vs. littermate vehicle, and *P<0.05 between TS1P1KO
vehicle, STZ and littermate vehicle, STZ mice. The data is expressed as mean ± SEM.
Sample size, n = 3 mice in each group.

Table 3-5: Summary of CD4+, CD8+ T cells percent in blood, and CD4+Foxp3+ T cells percent in spleen and blood of littermate and
TS1P1KO mice after 11-weeks.

CD4+ T cells in

Littermate Vehicle

TS1P1KO Vehicle

Littermate STZ

TS1P1KO STZ

12.93±3.98

1.37±0.02**

12.10±1.75

1.21±0.61**

7.73±1.43

1.61±0.13**

7.11±0.80

1.29±0.44**

1.97±0.27

0.67±0.12*

3.15±0.22#

1.38±0.37*

0.87±0.21

0.19±0.03*

1.58±0.19#

0.42±0.17*

blood
CD8+ T cells in
blood
CD4+Foxp3+ T cells
in spleen
CD4+Foxp3+ T cells
in blood

All values represent percent (%) of cell population. The data is expressed as mean ± SEM. n = 3-5 mice in each group. *P < 0.05 and
**P < 0.01 between vehicle and STZ groups of littermate and TS1P1KO mice. #P < 0.05 between vehicle and STZ groups of littermate
mice. Percent of CD4+Foxp3+ T cells, spleen: P = 0.14 between TS1P1KO vehicle and TS1P1KO STZ mice, blood: P = 0.26 between
TS1P1KO vehicle and TS1P1KO STZ mice.
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3.3.4. Assessment of cardiac histology and fibrosis area
Hematoxylin and Eosin (H&E) stained heart sections were prepared after 11weeks. H&E stained sections were examined microscopically at magnification of 400x
and graded based on morphology, organization, presence of cellularity in myocardium,
myocytes loss presence of collagen fiber. Littermate STZ (diabetic) mice exhibited
deteriorated myocardium structure manifested by myocytes loss and increased interstitial
space with presence of increased cellularity compared with littermate vehicle mice
(cumulative histology score; littermate STZ (n=9): 9.56±0.58 vs. littermate vehicle (n=4):
3±0.41, *P < 0.05) (Figure 3-8 and 3-9). TS1P1KO STZ mice (diabetic) heart exhibited
preserved myocardial structural phenotype as compared with littermate diabetic mice
(TS1P1KO STZ (n=7): 3±0.58 vs. littermate STZ (n=9): 3±0.41, #P < 0.05) (Figure 3-8
and 3-9). Notably, TS1P1KO vehicle mice showed altered heart phenotype demonstrated
by loss of interstitial space between myocytes with thickening of vascular smooth muscle
cells and perivascular edema compared with littermate vehicle mice (TS1P1KO vehicle
(n=4): 9.5±0.87 vs. littermate vehicle (n=4): 3±0.41, ¤P < 0.05) (Figure 3-8 and 3-9).
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Figure 3-8: Representative images of Hematoxylin and Eosin (H&E) stained heart tissue
sections of littermate and TS1P1KO mice after 11-weeks. Littermate STZ mice heart
section showed discernible myocytes loss with increased cellularity and disorganization
in myocardium after 11-week experimental period. TS1P1KO mice heart sections
exhibited preserved heart histology under diabetes. Interestingly, TS1P1KO vehicle mice
exhibited altered cardiac phenotype with congested myocytes and thickening of
perivascular smooth muscles. Images are representative of heart sections of 4-9 mice in
each group. The magnification is 200x.
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Figure 3-9: Quantification of heart histological scores in littermate and TS1P1KO mice
after 11-weeks. *P < 0.05 between littermate vehicle and littermate STZ mice, #P < 0.05
between TS1P1KO STZ and littermate STZ mice, ¤P < 0.05 between littermate vehicle
and TS1P1KO vehicle mice. The data is expressed as mean ± SEM, n = 4-9 mice in each
group.
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Collagen deposition was quantified semi-quantitatively in Masson’s Trichrome
stained heart sections of all mice after 11-week experimental period. Diabetic littermate
mice (n=9) showed increased fibrosis area relative to whole heart area compared to
littermate vehicle mice (n=4) (46.48±8.06 % vs. 7.65±0.86 %, *P < 0.05) (Figure 3-10
and 3-11). Diabetes induced increase of collagen deposition in interstitial and
perivascular area in littermate diabetic mice. TS1P1KO vehicle mice (n=4) heart showed
increased fibrosis area as compared with littermate vehicle mice (n=4) (46.03±7.16 % vs.
7.65±0.86 %, ¤P < 0.05) (Figure 3-10 and 3-11). Notably, TS1P1KO diabetic mice (n=7)
heart showed less fibrosis area compared to littermate diabetic mice (6.15±0.62 % vs.
46.48±8.06 %, #P < 0.05) (Figure 3-10 and 3-11).
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Figure 3-10: Representative images of Masson’s Trichrome stained heart tissue sections
in littermate and TS1P1KO mice after 11-weeks. Upper panel shows whole heart sections
(magnification is 16x) and lower panel shows magnified section images (magnification is
200x). Littermate STZ mice had increased perivascular and interstitial fibrosis area
compared with littermate vehicle mice. TS1P1KO STZ mice had noticeable less fibrosis
than littermate STZ. Interestingly, TS1P1KO vehicle mice heart sections exhibited
increased fibrosis than littermate vehicle mice.
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Figure 3-11: Quantification of percent fibrosis area in heart sections of littermate and
TS1P1KO mice after 11-weeks. *P<0.05 in littermate STZ vs. littermate vehicle mice,
#

P<0.05 in TS1P1KO STZ vs. littermate STZ mice and ¤P<0.05 in TS1P1KO vehicle vs.

littermate vehicle mice. Sample size, n = 4-9 mice in each group. The data is expressed as
mean ± SEM.
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3.3.5. TS1P1KO mice exhibits improved cardiac contractility under hyperglycemia

We determined the cardiac force of contraction in an ex-vivo Langendorff’s heart
perfusion system. The data is expressed as a fold change in contractile force development
compared to littermate control mice. Littermate diabetic mice showed 29.37% reduction
in contractility as compared with littermate vehicle mice (P = 0.19) (Figure 3-12).
TS1P1KO mice exhibited 33.07% increase in force of contraction development than
littermate diabetic mice (P=0.06) (Figure 3-12). Interestingly, TS1P1KO vehicle mice
have attenuated contractility compared to littermate vehicle mice (*P < 0.05) (Figure 312).
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Figure 3-12: Cardiac contractility in littermate and TS1P1KO mice after 11-week study
period. Littermate STZ mice (n=8) showed reduction in contractile force compared to
littermate vehicle mice (n=5) (P value is 0.19 between these two groups). TS1P1KO STZ
mice (n=5) showed improved contractile force compared to littermate STZ mice (n=8) (P
= 0.06 between these two groups). TS1P1KO vehicle mice (n=6) have significantly
attenuated force of contraction than littermate vehicle mice (*P < 0.05). The contractile
force is expressed as fold change relative to control. The data is expressed as mean ±
SEM.
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3.3.6. Reduced CD3+ T cells infiltration in diabetic TS1P1KO mice myocardium
We detected CD3+ T cells in myocardium by immunostaining with anti-mouse
CD3 antibody. Increased CD3+ T cells infiltration has been observed in myocardium of
littermate STZ mice (1.75±0.15 cells/field vs. 0.86±0.04 cells/field, n=3 independent
experiments, *P < 0.05) than littermate control mice (Figure 3-13 and 3-14). TS1P1KO
STZ mice myocardium exhibited significantly less CD3+ T cells (0.84±0.09 cells/field vs.
1.75±0.15 cells/field, n=3 independent experiments, #P < 0.05) than littermate STZ mice
(Figure 3-13 and 3-14).
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Figure 3-13: Immunohistochemical detection of CD3+ T cells in littermate and TS1P1KO
mice heart tissue section at the end of 11-weeks. Littermate STZ mice heart section show
increased infiltration of CD3+ T cells into cardiac tissue compared to littermate vehicle
mice. TS1P1KO STZ mice myocardium do not have noticeable CD3+ T cells infiltration
compared to littermate STZ mice. Images are representative of three independent
experiments.
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Figure 3-14: Quantification of infiltrated CD3+ T cells in heart tissue sections of
littermate and TS1P1KO mice after 11-week experimental period. CD3+ T cells number
(cells per 400x magnification field) was significantly higher in littermate STZ mice heart
section than littermate vehicle mice. *P < 0.05 between littermate STZ and littermate
vehicle mice. TS1P1KO STZ mice heart tissue have reduced CD3+ T cells infiltration as
compared to littermate STZ mice. *P < 0.05 between TS1P1KO STZ and littermate STZ
mice. Results are from three independent experiments. The data is presented as mean ±
SEM.
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3.3.7. Reduced TGF-β1 expression in TS1P1KO diabetic mice myocardium

We determined profibrotic cytokine transforming growth factor beta 1 (TGF-β1)
expression in myocardium of all mice group after 11-week diabetic period. TGF-β1
expression was increased in littermate diabetic mice cardiac tissue compared to littermate
vehicle mice (6.79±0.59 % staining area vs. 2.64±0.23 % staining area, *P < 0.05)
(Figure 3-15 and 3-16). TS1P1KO diabetic mice exhibited reduced TGF-β1 expression in
myocardium after 11 weeks as compared with littermate diabetic mice (3.54±0.10 %
staining area vs. 6.79±0.59 % staining area, #P < 0.05) (Figure 3-15 and 3-16). In
contrast, TS1P1KO vehicle mice myocardium exhibited increment of TGF-β1 expression
as compared with littermate vehicle mice (6.78±0.71 % staining area vs. 2.64±0.23 %
staining area, ¤P < 0.05) (Figure 3-15 and 3-16).
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Figure 3-15: Immunohistochemical detection of TGF-β1 expression in littermate and
TS1P1KO mice heart tissue sections after 11-weeks. Representative images of TGF-β1
immuno-staining. Littermate STZ mice myocardium show increased TGF-β1 expression
compared to littermate vehicle mice. TS1P1KO STZ mice myocardium exhibit reduced
TGF-β1 expression than littermate STZ mice. Notably, TS1P1KO vehicle mice
myocardium exhibit increased TGF-β1 expression than littermate vehicle mice. The
magnification for all images is 400x.
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Figure 3-16: Quantification of TGF-β1 expression in heart tissue sections of littermate
and TS1P1KO mice after 11-week experimental period. Results are from three
independent experiments. The data is expressed as mean ± SEM. *P < 0.05 between
littermate vehicle and littermate STZ, #P < 0.05 between littermate STZ and TS1P1KO
STZ and ¤P < 0.05 between littermate vehicle and TS1P1KO vehicle.
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3.3.8. TS1P1KO mice myocardium have less CD34 cells in diabetes

Fibrocytes under chronic inflammation are recruited through chemokine
interactions to the site of injury. Recruited fibrocytes can synthesize extracellular matrix
protein and transdifferentiate into collagen producing myofibroblasts. CD34 is a surface
antigen that is expressed by fibrocytes and can be used as a biomarker to detect these
cells from other cell types. In our present work, we detected CD34 expressing cells in
mice myocardium after 11-week of experimental period. Littermate STZ mice
myocardium exhibited higher CD34 expressing cells than littermate vehicle mice
(6.25±0.28 % staining area vs. 2.74±0.12 % staining area, *P < 0.05) (Figure 3-17 and 318). Notably, diabetic TS1P1KO mice myocardium exhibited less CD34 expressing cells
than littermate diabetic mice (2.97±0.17 % staining area vs. 6.25±0.28 % staining area, #P
< 0.05) (Figure 3-17 and 3-18). In contrast, TS1P1KO vehicle mice myocardium have
increased CD34 expressing cells compared to littermate vehicle mice (6.52±0.47 %
staining area vs. 2.74±0.12 % staining area, ¤P < 0.05) (Figure 3-17 and 3-18).
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Figure 3-17: Immunohistochemical detection of CD34 fibrocytes expression in littermate
and TS1P1KO mice heart tissue sections after 11-weeks. Representative images of CD34
fibrocytes immunostaining. Littermate STZ mice myocardium show increased CD34
expressing cells than littermate vehicle mice. Notably, diabetic TS1P1KO mice
myocardium exhibit reduction of CD34 expression than littermate diabetic mice. In
contrast, TS1P1KO vehicle mice myocardium exhibit increased CD34 expression
compared to littermate vehicle mice. The magnification for all images is 400x.
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Figure 3-18: Quantification of CD34 fibrocytes expression in heart tissue sections of
littermate and TS1P1KO mice after 11-week experimental period. Results are from three
independent experiments. The data is expressed as mean ± SEM. *P < 0.05 between
littermate vehicle and littermate STZ, #P < 0.05 between littermate STZ and TS1P1KO
STZ and ¤P < 0.05 between littermate vehicle and TS1P1KO vehicle.
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3.4. Discussion
In the present study, we for the first time demonstrated that conditional T cell
specific sphingosine 1-phosphate receptor 1 genetic depletion associated T lymphocytes
deficiency in circulation exerts cardioprotection with reduced myocardial fibrosis under
chronic hyperglycemia compared to littermate diabetic mice.
Several lines of investigation demonstrated T lymphocytes involvement in cardiac
injury and cardiac remodeling in experimental cardiac injury settings.77 In chronic
pressure overload murine transverse aortic constriction model, increased
activated/effector CD4+CD44high T cells have been detected in heart tissue with increased
cardiac collagen content and cardiac dysfunction after 6-week of this model.75 In murine
myocardial infarction (MI) model, increased CD4+Ki67+ T cells have been detected in
heart draining mediastinal lymph nodes after 7-day of MI injury.74 Increased CD4+IFN-γ+
T cells have been detected in 7-day post-MI heart tissues. In this report, the authors
demonstrated that presence of CD4+ T cells increases collagen deposition in heart as CD4
knock out mice showed reduction of collagen density after MI injury.74 Becher et al.
demonstrated that diabetic rodent myocardium have augmented infiltration of CD3+ T
lymphocytes within 6-week of diabetes induction by STZ that positively correlated with
increased ventricular stiffness and decreased systolic and diastolic left ventricular
function.111 Increased proinflammatory T cell subsets, such as CD4+IFN-γ+,
CD4+CD28null, in peripheral blood of human diabetic patients associated with adverse
cardiac events.78,79,110 Thus, modulation of T cell function and abundance can be a
potential therapeutic strategy to protect heart under chronic diabetic conditions. To this
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end, the effects of T cells trafficking modulation by means of molecular mechanism to
heart in diabetes has not been precisely determined yet.
In chapter 2, we demonstrated that fingolimod (FTY720), a novel
immunomodulator drug, causes sustained CD4+ and CD8+ T cells deficiency in the blood
of C57BL/6 mice that is associated with reduced fibrosis area and improved cardiac
contractility. FTY720 acts as a functional antagonist on mature T lymphocytic cell
membrane G protein coupled receptor, sphingosine 1-phosphate receptor 1 (S1P1).88,89,92
Binding of phosphorylated FTY720 to S1P1 receptor causes internalization of the
receptor from cell membrane to cytosol and promotes proteasomal degradation there. The
absence of S1P1 receptor on cell membrane disables T lymphocytes to sense the
increased chemotactic gradient of sphingosine 1-phosphate (S1P) present in blood and
lymph that results in sequestration of mature lymphocytes in primary (thymus) and
secondary lymphoid organs, such as spleen, and lymph nodes. Thereby, FTY720 creates
substantial T lymphocytes deficiency in systemic circulation. For this immunomodulatory
function, fingolimod (FTY720) is approved for treatment of relapsing-remitting multiple
sclerosis. FTY720 treatment reduces autoimmune TH17 cells in circulation and reduces
infiltrating autoreactive T lymphocytes in central nervous system. Therefore,
administration of FTY720 protects the central nervous system from autoimmune T cell
mediated destruction in these patients and in experimental autoimmune
encephalomyelitis rodents.91,92 To this point, it is noteworthy that S1P1 receptor is widely
expressed in different type of cells, other than T lymphocytes, including vascular
endothelial cells, cardiomyocytes and both innate and adaptive immune cells.85,140
Although FTY720 reduced myocardial fibrosis in C57BL/6 mice, administration of
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FTY720 exacerbated cardiac histology and increased fibrosis area in Rag1 knockout mice
(lacking mature B and T lymphocytes) under diabetic conditions. FTY720 can act on
other four S1P receptors (S1P2,3,4,5) besides S1P1 (EC50 value is 0.2 nM) in varying
affinity (EC50 value for S1P2 is >10000 nM and for S1P3 is 5 nM).88 Opposite results
between C57BL/6 and Rag1 KO mice of FTY720 treatment indicate that the drug targets
different fibrotic pathway in complete absence of lymphocytes under chronic
hyperglycemia. Notably, FTY720 at higher concentrations (0.1-1 µM) can activate S1P3
receptor in fibroblasts that causes them to differentiate into collagen producing
myofibroblasts.136 In isolated murine S1P3 knock out fibroblasts, FTY720 did not
increase myofibroblast differentiation marker alpha smooth muscle actin (α-SMA),
whereas FTY720 was able to increase α-SMA expression in wild-type mice fibroblasts.
Primary human fibroblasts express mRNAs for different S1P receptors in the following
order: S1P3 >> S1P1 > S1P2 > S1P5 > S1P4. Treatment with S1P1-, S1P3-, S1P4- and
S1P5- antisense oligonucleotide to isolated primary human fibroblasts resulted in
substantial reduction of respective protein levels. Notably, FTY720 mediated
myofibroblast differentiation only abrogated in S1P3 ASO treated fibroblasts. Further, it
has been found that FTY720 activates Smad3 pathway in fibroblasts acting through S1P3
receptor in fibroblasts leading to myofibroblast differentiation.136 In a more recent report,
FTY720 has been shown to activate S1P2 receptor to induce myofibroblast contraction in
vitro.128 Thus, nonselective functions of FTY720 on S1P receptor subtypes make it
obscure to dissect the mechanism through which it increases fibrosis area in Rag1 knock
out mice, devoid of mature B and T lymphocytes. These circumstances set the premise
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for our current study objective to dissect the effects of genetic S1P1 receptor deficiency in
T lymphocytes in murine diabetic cardiomyopathy model.
In the present study through genetic loss-of-function approach we generated T
cell specific S1P1 knockout (TS1P1KO) mice. TS1P1KO mice showed profound
deficiency of CD3+ T cells in spleen and reduced CD4+ and CD8+ T cells in blood than
littermate control mice. Immunohistochemical analysis in cardiac tissue revealed the
presence of fibrotic milieu in littermate mice myocardium under 11-week diabetic period.
Littermate diabetic mice myocardium showed increased presence of CD3+ T cells with
concomitant increase of profibrotic cytokine TGF-β1 expression and fibroblast progenitor
CD34 expressing fibrocytes presence after 11-week of chronic hyperglycemia.
Comparatively, TS1P1KO mice myocardium showed less CD3+ T cells infiltration with
reduced TGF-β1 and CD34 expression in myocardium with improved cardiac contractile
force than littermate diabetic mice after the same length of diabetic period. Additionally,
CD4+Foxp3+ T cells number were increased in spleen and blood of diabetic littermate
mice. CD4+Foxp3+ T cells are considered as regulatory T cells (Treg cells) that maintain
immune tolerance by suppressing excessive immune reaction at periphery. S1P1 mediated
signaling has been shown to negatively regulate Treg cells development in thymus and
periphery through Akt-mTOR pathway activation, whereas it promotes TH1 helper T cells
differentiation.141,142 It is beyond the scope of our present study objectives to elucidate
S1P1 mediated T cells differentiation effect on cardiac fibrosis in diabetes. However, it is
important to note that, Zhen et al. reported increased Treg cells in STZ-induced diabetic
mice spleen and blood with activated/memory phenotype. Notably, Treg cells from STZ
treated mice showed reduced immunosuppressive ability than buffer recipient control
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mice after 4-month diabetic period.143 The authors observations indicate that under
chronic hyperglycemia T cells phenotype changed towards more effector phenotype.
Several epidemiological studies reported increased proinflammatory T cells in periphery
in diabetic patients that correlate with the adverse cardiac outcomes.78,79 To this end,
based on the results of the present study, our conclusion is deficiency of T lymphocytes
in TS1P1KO mice under chronic hyperglycemia ameliorates fibrosis and preserves heart
histology as compared with littermate diabetic mice.
Mature T lymphocytes continually recirculate between secondary lymphoid
organs and systemic circulation. This movement increases the probability of interaction
of T cells with antigen presenting cells (APCs), such as macrophages and dendritic
cells.90 T lymphocytes encounter with antigen bearing APCs activates T cells that results
in proliferation of activated T cells in respective lymph nodes. Effector T cells then can
migrate to inflamed tissue and participate in potentiating the immune response by
secreting cytokines, growth factors, and through direct cell-cell contact. T lymphocytes
trafficking has been found to be involved in murine myocardial injury models.77,144 After
left coronary artery ligation in mouse heart, heart draining lymph nodes have increased
CD4+ T cells proliferation and infiltration into the myocardium.74 Another report
demonstrated that in murine chronic transverse aortic constriction model, increased CD3+
T cells infiltration was associated with increased fibrosis area and cardiac
dysfunction.75,76 In our present study, TS1P1KO mice have reduced CD4+ and CD8+ T
cells in circulation, as T cells in these mice have decreased S1P1 mRNA expression due
to Lck driven Cre-mediated recombination of S1P1 gene at the coding region.83 CD4+ and
CD8+ T cells in these mice sequester in thymus and have reduced in secondary lymphoid
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organs as shown consistent with the literature.83 We observed less CD3+ T lymphocytes
infiltration in diabetic TS1P1KO mice myocardium than littermate diabetic mice.
Altogether, altered T lymphocytes trafficking in TS1P1KO mice is a contributing factor
for the observed cardioprotection under long term hyperglycemia.
Surprisingly, TS1P1KO vehicle mice myocardium exhibited increased collagen
deposition in myocardium with altered heart histology and attenuated cardiac force of
contraction. Although TS1P1KO vehicle mice myocardium did not exhibit increased
presence of T cells compared with littermate vehicle mice, TGF-β1 and CD34 bearing
cells expression were increased in these mouse myocardium. These contrasting results
indicate the complexity of cardiac fibrotic remodeling and important contributions of
different types of immune cells to maintain the collagen homeostasis in heart under both
physiological and pathological conditions. To this point, it is noteworthy that TS1P1KO
mice have increased circulatory B lymphocytes (B220+ lymphocytes) in their blood as
immune compensatory mechanism of reduced circulating T cells.83 Lack of programmed
cell death protein-1 (PD-1-/-) in mice resulted in severe form of dilated cardiomyopathy
with increased interstitial fibrosis, disarrayed and disrupted myofilaments.145 PD-1 acts as
negative regulator of lymphocytes proliferation. Increased IgG autoantibodies against
cardiac proteins were deposited in PD-1-/- murine myocardium. Strikingly, PD1-/- mice
generated in Rag2-/- background (mice lacking mature B and T lymphocytes) did not
develop dilated cardiomyopathy.145 Interestingly, B lymphocytes have been also
implicated in heart failure development by secreting autoantibodies against
cardiomyocytes.146 Similarly, our results presented in chapter 2 and earlier117 demonstrate
that Rag1 knock-out mice lacking mature B and T lymphocytes exhibit resistance against
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diabetes induced fibrosis and cardiac dysfunction as compared to C57BL/6 mice with
normal B and T cells compartment. TS1P1KO mice had significantly lower T cells in
circulation and lymphoid organs due to the lack of S1P1 in T cells that increases B cells
number in circulation.83 Altered B and T cells number in the circulation might contribute
to develop fibrosis in TS1P1KO vehicle mice, as B lymphocytes secreted antibodies have
shown detrimental effects on cardiomyocytes.146
Proinflammatory cytokines, such as TNF-α, IL-1β and IL-6, can cause cardiac
dysfunction by negatively affecting cardiac contractility and cardiac extracellular matrix
compartment remodeling. To this end, the inhibition of proinflammatory cytokine TNF-α
is not proven efficacious in a human clinical trial.147 Thus, a more comprehensive
understanding of molecular and cellular basis of heart failure development should be
investigated in different models of cardiac dysfunction to devise better and effective
therapeutic interventions. In our present study, T cell trafficking modulation by genetic
depletion of T cell S1P receptor 1 protects heart in chronic diabetes. To this end, T cells
S1P1 receptor is a potential therapeutic target to modulate T cells trafficking in chronic
inflammatory conditions, such as diabetes and hypertension, to ameliorate cardiac
fibrosis. In this regard, several newer, more specific S1P1 receptor modulator drug
molecules have shown promising results. For instance, unlike S1P1 receptor non-specific
agonist FTY720, ponesimod (Actelion, Switzerland), a selective S1P1 agonist (EC50
value is 5.7 nM), is now under Phase III clinical trial for depleting T lymphocytes in
circulation.149 Ponesimod has been shown efficacious in preventing T cell mediated tissue
damage in rodent delayed-type hypersensitivity of the skin and adjuvant-induced rodent
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arthritis model.148,149 Thus, specific S1P1 receptor modulator drugs can be used more
effectively to modulate T lymphocytes trafficking in clinical practices.
3.5. Conclusions
In summary, key findings of our present investigation are: (1) presence of T
lymphocytes normal trafficking between lymphoid organs and circulation is an important
determinant of cardiac fibrotic remodeling both under physiological and pathological
conditions; (2) T cell specific genetic S1P receptor 1 deficiency reduces circulatory T
lymphocytes in TS1P1KO mice; (3) TS1P1KO mice myocardium exhibits less CD3+ T
cells with reduced fibrosis area, preserved cardiac histology and improved cardiac
contractility under chronic diabetes.
However, our present study did not assess the role of specific subset of T
lymphocytes in diabetic myocardial fibrogenesis. In the next study, we isolated CD4+ T
cells from wild-type littermate mice, and intravenously transfer the isolated CD4+ T cells
to TS1P1KO mice. We evaluated cardiac fibrotic response in TS1P1KO mice after CD4+
T cells transfer in chronic diabetes. These studies are discussed in the next chapter.
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CHAPTER 4: EFFECTS OF CD4 T CELL TRANSFER TO TS1P1KO MICE ON
CARDIAC FIBROSIS IN DIABETIC CARDIOMYOPATHY

4.1. Background

In chapter 3, we demonstrated that conditional T cell specific sphingosine 1phosphate receptor 1 (S1P1) genetic depletion results in marked reduction of both single
positive CD4+ and CD8+ T lymphocytes in systemic circulation. T-cell specific S1P1
knock-out mice (TS1P1KO) in long term streptozotocin (STZ)-induced type 1 diabetic
cardiomyopathy model exerted less fibrosis and improved cardiac contractility compared
to diabetic littermate mice. We found less CD3+ T cells invasion into diabetic TS1P1KO
mice heart sections compared to diabetic littermate mice. The expression of profibrotic
cytokine TGF-β1 and CD34 fibrocytes were also reduced in diabetic TS1P1KO mice
heart sections compared to diabetic littermate mice. However, our studies did not
elucidate specific subset of T lymphocytes role in myocardial fibrogenesis in long term
diabetes. Among the helper CD4+ and cytotoxic CD8+ T lymphocytes, CD4+ T
lymphocytes have been found to be responsible for cardiac fibrosis generation in various
cardiovascular diseases including hypertension, myocardial infarction and myocarditis.36
To date, four distinct CD4+ T lymphocyte subsets have been reported including TH1, TH2,
TH17 and regulatory T cells.68 All the CD4+ T cell subsets have been reported to be
involved in cardiac fibrosis.36 The expression of T helper type 1 (TH1) CD4+ T cells
increases collagen content and have been shown to increase procollagen synthesis in
cardiac fibroblasts.69 T helper type 2 (TH2) CD4+ T cells cytokines IL-4 and IL-13 have
been reported to be pro-fibrotic stimulators leading to synthesis of collagen in
fibroblasts.36,150 T helper type 17 (TH17) cells have been implicated in cardiac fibrosis in
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autoimmune inflammatory myocarditis.151 On the other hand, regulatory T cells attenuate
cardiac fibrosis in experimental models of hypertension, angiotensin-induced
cardiomyopathy and myocardial infarction.152,153,154 The attenuation of inflammation by
regulatory T cells has been implicated as a mechanism to reduce myocardial fibrosis
under pathological conditions.36 CD4+ T lymphocytes have also been reported to
facilitate fibrocytes development from blood derived monocytes and increase the
collagen deposition in murine kidney.155
Several epidemiological studies have reported the expansion of pro-inflammatory
CD4+ T lymphocytes in diabetic patients with increased systemic inflammation and
adverse cardiovascular outcomes including acute coronary events.78,79,110 The time course
analysis in rodent STZ-induced diabetic cardiomyopathy model has shown increased
CD3+ T lymphocytes into myocardium as early as 2-week after STZ induction.111 As both
mature CD4+ and CD8+ T lymphocytes express CD3+ on their cell surface,156 ambiguity
exists to precisely determine the cellular origin of infiltrating CD3+ T cells in the
myocardium under chronic diabetes.
TS1P1KO mice, due to genetic depletion of T cell specific S1P receptor 1, have
substantially reduced CD4+ and CD8+ T cells in blood and cardioprotection with less
myocardial fibrosis in long term diabetic cardiomyopathy model (Chapter 3). Because
CD4+ T cells have been shown to participate in cardiac fibrosis, we hypothesized that
adoptive transfer of CD4+ T cells from littermate mice to TS1P1KO mice reverses the
cardioprotective and antifibrotic effect in chronic diabetes. Evaluating the effects of
adoptive transfer of CD4+ T lymphocytes on myocardial fibrosis in chronic diabetes will
help to elucidate the role of CD4+ T cells more precisely, which in turn will facilitate
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future therapeutic strategy to ameliorate cardiac fibrosis in diabetes. In this study, we
isolated splenic CD4+ T cells from littermate mice and reconstituted purified CD4+ T
cells into TS1P1KO mice intravenously. CD4+ T cells recipient mice underwent long
term STZ-induced diabetes. At the end point of experimental period, we evaluated
cardiac contractility in an ex-vivo Langendorff’s heart perfusion system, we also studied
heart histology and fibrosis area. In addition, we assessed myocardium infiltrating CD3+
T cells number, profibrotic TGF-β1 and CD34 expressing fibrocyte expression in cardiac
tissue by immuohistological studies.
4.2. Materials and Methods

4.2.1. T cell specific S1P receptor 1 knock out mice
T cell specific S1P receptor 1 knock out (TS1P1KO) mice from S1P1loxP/loxP mice
and Lck-Cre mice breeding colony were genotyped and immunophenotyped as described
in chapter 3. We housed all mice in specific pathogen free room in Animal Research
Wing (ARW) facility at SDSU. Mice were given ad libitum rodent autoclaved food
(5010, LabDiet) and water. The animals were handled and cared in accordance with the
Guide for the Care and Use of Laboratory Animals by U.S. National Research Council
(Eighth Edition, 2011). All experimental procedures were approved by Institutional
Animal Care and Use Committee (IACUC) at SDSU.
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4.2.2. Isolation of CD4+ T cells and adoptive transfer
We isolated CD4+ T cells by positive selection from the littermate control mice
spleen by using microbeads conjugated with CD4+ antibody from Miltenyi Biotech
(Auburn, CA). Briefly, freshly excised spleen from anesthetized littermate control mice
was cut into 1 mm3 pieces and passed through 70 µm nylon cell strainer (352350,
Corning Inc. NY). The dissociated cells were collected in isolation buffer containing
0.5% w/v bovine serum albumin (A2153, Sigma-Aldrich, MO) and 2 mM EDTA in 0.01
M PBS (P3813, Sigma-Aldrich). The single-cell suspensions were centrifuged at 300 x g
for 10 minutes at room temperature (RT). Supernatants were discarded and red blood
cells were lysed by incubating at RT for 5 minutes with 5 mL of 1 x RBC lysis buffer
(00-4333, eBioscience) for each spleen. After incubation, the single-cell suspensions
were washed twice in isolation buffer by centrifugation at 500 x g for 10 minutes at RT.
The cell pellets were re-suspended in 10 ml isolation buffer and cell numbers were
counted in Cellometer Auto T4 (Nexcelom, MA) in prepared single-cell suspension of
splenocytes (Figure 4-1).
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Figure 4-1: Schematic diagram of preparation of single-cell suspensions from littermate
mouse spleen. The images used in the figure were taken from multiple web based sources
for schematic representation.
The prepared single-cell suspension of splenocytes was then incubated with 10 µL
of mouse CD4 antibody-microbeads (130-049-201, Miltenyi Biotech) per 107 cells at 4
ºC for 15 minutes. Cells were washed by centrifugation with isolation buffer at 300 x g
for 10 minutes at RT. The cell pellets were re-suspended with 500 µL of isolation buffer
per 108 cells and proceeded to magnetic separation. The magnetically labeled cells were
passed through MS column (130-042-201, Miltenyi Biotech) attached to a magnet (130042-102, Miltenyi Biotech) by washing with 500 µL isolation buffer for three times.
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Specific CD4 microbeads labeled cells were then collected by removing the MS column
from the magnet followed by immediate flushing of the column with a rubber plunger.
The collected CD4 positive T cells were counted, and viability was measured by trypan
blue exclusion assay. We also assessed the isolated CD4+ T cells purity by flow
cytometry using anti-mouse CD4 antibody (11-0041-82, eBioscience). The isolated CD4+
T cell viability and purity were ~90-95% in each case (Figure 4-2).

Figure 4-2: Schematic diagram of experimental procedure to isolate CD4+ T cells from
single-cell suspensions of splenocyte of littermate control mice. The images used in the
figure were taken from multiple web based sources for schematic presentation.
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One million (106) CD4+ T cells prepared by the above mentioned procedure in
0.01 M PBS was intravenously transferred through tail vein to littermate and TS1P1KO
mice. After CD4+ T cells transfer, littermate and TS1P1KO mice were observed for one
week. After one week, both strains were divided into vehicle and streptozotocin treated
group. The groups is represented as ‘CD4+mouse type & treatment name’. All mice
underwent similar 11-week long experimental protocol as described in chapter 3. The
experimental protocol is shown below (Figure 4-3).

One (01) week
observation

Five (05)
consecutive day
STZ or buffer only
intraperitoneal
injection

Eleven (11) week long experimental period

Following salient experiments were
done at the end of 11 weeks:


Day 1: One million of CD4+ T cells transfer
intravenously to littermate and TS1P1KO mice




Flow cytometry analysis
Heart contractile force
measurement in ex-vivo
Langendorff Heart
perfusion system
Histology study
Fibrosis area assessment
Immunohistochemistry
studies

Figure 4-3: Schematic diagram of experimental protocol of adoptive transfer of CD4+ T
cells in littermate and TS1P1KO mice followed by 11-week long streptozotocin (STZ)induced type 1 diabetes.
4.2.3. Flow cytometry analysis of CD4+ and CD8+ T cells in peripheral blood
We measured helper CD4+ and cytotoxic CD8+ T cells proportions in peripheral
blood of mice by two color flow cytometry analysis as described in chapter 2 in a BD
FACSCalibur flow cytometer (BD Biosciences, CA). Date was acquired and analyzed by
BD CellQuest Pro software (BD Biosciences, CA).
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4.2.4. Flow cytometry analysis of regulatory T cells
We measured relative percentage of CD4+Foxp3+ regulatory T cells (Treg cells) in
spleen and blood after 11-week study period in mice according to the procedures
described in chapter 3. Flow cytometry analysis was carried out in BD FACSCalibur flow
cytometer coupled to CellQuest Pro software (BD Biosciences).
4.2.5. Cardiac contractility assessment
We assessed cardiac contractile force (g) in the mice after 11-week experimental
period in a modified Langendorrf’s heart perfusion system ex-vivo, as described in
chapter 2. Cardiac contractile force was recorded and analyzed with Biopac MP 100 data
system (Goleta, CA, USA). The fold change in cardiac contractile force relative to
littermate vehicle mice was measured.
4.2.6. Heart histology and analysis of cardiac fibrosis
Paraffin-embedded 5 µm thick heart sections of littermate and TS1P1KO mouse
groups were prepared at the end of 11-weeks. Heart histology in Hematoxylin & Eosin
stained, and fibrosis area in Masson’s trichrome stained heart sections were studied at the
end of 11-weeks. H&E stained sections were examined under bright field illumination in
a upright microscope (Carl Zeiss, Germany), and score was given for each heart section
for (i) the presence of eosinophilic interstitial collagen fibers, (ii) extent of cellularity in
interstitial space of myocardium, (iii) myocardial cell necrosis/loss, (iv) myofiber
striation and myocytes organization on a five-point scale for each characteristics from 0
to 4.120,121 The cumulative scores were expressed from 0 to 16 for each group. Trichrome
stained whole heart sections image was acquired using a Leica EZ4 HD stereomicroscope
(Leica Microsystems, Buffalo Grove, IL, USA). The percentage of fibrosis area relative
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to the whole heart area was quantified by using NIH Image J (Bethesda, MA) software as
described by Zhao et al.117
4.2.7. Immunohistochemical analysis on littermate and TS1P1KO mice heart
sections
CD3+ T cells, TGF-β1 and CD34 bearing cell expression were analyzed in
myocardium by immunohistochemistry in paraffin embedded 5 µm tissue sections with
CD3 (10 µg/mL, sc-20047; Santa Cruz Biotechnology, Inc., CA), TGF-β1 (15 µg/mL,
MAB240; R&D Systems, Inc., Minneapolis, MN) and CD34 (10 µg/mL, MA5-17825;
Pierce Biotechnology, Rockford, IL, USA) primary antibodies. R&D systems mouse/rat
cell and tissue staining HRP-DAB kit (CTS002/CTS017; R&D Systems) were used to
amplify positive signals and visualize by using corresponding mouse/rat primary
antibodies. The detailed procedure is described in chapter 2. To count immunopositive
CD3+ cells, 30 fields of stained heart sections were pictured at bright-field under 400x
magnification in an upright microscope (Carl Zeiss, Germany). Myocardium infiltrating
cells number was calculated by counting the cells number in imaged 400x fields
(cells/field).75 TGF-β1 and CD34 positive staining percent area were quantified in 10
fields of 400x magnification images by using NIH ImageJ software (Bethesda, MD) and
the averaged percent of staining area is presented.119,139
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4.2.8. Data analyses
All the data was expressed as mean ± SEM. One-way ANOVA was used for
statistical analysis followed by Student-Newman-Keuls post hoc test for multiple
comparisons of group means to evaluate statistical significance. Two-tailed unpaired
Student’s t-test was done, where applicable. Data was analyzed in GraphPad Prism
software (v5.01, 2007). A P value of less than 0.05 was considered statistically
significant, and indicated with an asterisk (*) or a number (#) sign.

4.3. Results

4.3.1. Isolated CD4+ T cell number and purity by flow cytometry analysis

Total cell number was 7.03±0.45 million cells per milliliter (n=14) in single-cell
suspensions of splenocytes from littermate control mice. Isolated CD4+ T cell numbers
were 5.09±0.46 million cells per milliliter (n=14) from single-cell suspensions. The
purity of isolated CD4+ T cells was about 90-95% as analyzed by CD4+ antigen
expression in cells of CD4 positive and CD4 negative fraction from MS column effluent
by flow cytometry analysis (Figure 4-4).
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A

CD4+ T cells in total
splenocytes

+
B CD4 T cells in positive

fraction

C

CD4+ Staining
in negative fraction

M1

M1

17.07% in M1 gate

M1

95.99% in M1 gate

0.10% in M1 gate

Figure 4-4: Representative flow cytometry histogram represents CD4+ T cells staining
and number in total isolated splenocytes of littermate control mice (panel A). CD4+ T
cells staining in positive fraction after separation through MACS positive selection
method exhibited only CD4+ staining in positive fraction (panel B). CD4+ T cells staining
in negative fraction after separation, yielded negligible CD4+ staining (panel C).
4.3.2. Assessment of physiological parameters in chronic diabetes
We measured body weight (g) twice each week and blood glucose level (mg/dl) at
the beginning, after 4-week and after 11-week during experimental period. In our present
study, both littermate control and TS1P1KO mice were divided into vehicle treated and
streptozotocin (STZ) treated groups where all mice received one million CD4+ T cells
isolated from littermate mice spleen. Both littermate and TS1P1KO mice recipient of
streptozotocin (STZ) exhibited less body weight gain compared to vehicle treated mice
during 11-week study period. CD4+ T cells recipient littermate and TS1P1KO groups had
no significant difference in body weight at the beginning (Figure 4-5, Table 4-1). But
after STZ injection, CD4+ T cells recipient littermate STZ mice showed 39.68% reduced
body weight compared to littermate vehicle mice and TS1P1KO STZ mice had 35.83%
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reduced body weight compared to TS1P1KO vehicle mice at the end of 11-weeks (Figure
4-5, Table 4-1). This reduction was 2.59-fold less (39.68 % vs. 15.29 %) in body weight
for littermate STZ and 2.01-fold less (35.83 % vs. 17.75 %) in body weight for KO STZ
mice compared to respective STZ mice of both strain without CD4+ T cells transfer
(Figure 4-5, Table 4-1).

Body weight (g)

35
30
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20

*

CD4+Littermate Vehicle
CD4+TS1P 1KO Vehicle

15

CD4+Littermate STZ
CD4+TS1P 1KO STZ

10
0

20

40

60

80

Days post STZ administration

Figure 4-5: Body weight (g) change in CD4+ T cells recipient littermate and TS1P1KO
mice during 11-week study period. Both CD4+ T cells recipient littermate and TS1P1KO
STZ mice exhibited lower body weight gain trend throughout 11-week, and showed
significantly lower body weight (g) at the end of 11-week compared to littermate and
TS1P1KO vehicle mice. *P<0.05 vs. CD4+littermate vehicle and CD4+TS1P1KO vehicle
mice, respectively. Sample size n = 4-5 mice per each group. All data are expressed as
means ± SEM at each time point.

Table 4-1: Summary of physiological parameter in CD4+ T cells recipient littermate and TS1P1KO mice during 11-week experimental
period.
CD4+Littermate Vehicle

CD4+TS1P1KO Vehicle

CD4+Littermate STZ

CD4+TS1P1KO STZ

(n=5)

(n=5)

(n=4)

(n=4)

25.24±1.27

24.62±0.33

26.78±0.82

25.68±0.31

27.86±0.82

26.72±0.52

22.38±0.63*

21.75±1.14

32.1±1.45

30.4±1.07

22.98±0.82*

22.38±1.53*

At beginning
(before STZ
induction)
Body wt. (g)
After 4-week of STZ
induction
Body wt. (g)
After 11-week of
STZ induction
Body wt. (g)

The data is expressed as mean ± SEM. *P < 0.05 between vehicle and STZ groups of CD4+ T cells recipient littermate and TS1P1KO
mice. The values of ‘n’ represent number of mice in each group.
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At the beginning of the study, there was no significant difference in blood glucose
level (mg/dl) among CD4+ T cells recipient littermate and TS1P1KO mice (Figure 4-6,
Table 4-2). However, STZ induction exhibited significantly higher blood glucose level in
both littermate and TS1P1KO mice compared to respective vehicle only treated mice of
two strains after 4-weeks (Figure 4-6, Table 4-2). Hyperglycemia persisted significantly
after 11-week in both littermate and TS1P1KO STZ mice compared to vehicle treated
mice (Figure 4-6, Table 4-2). Notably, TS1P1KO STZ mice recipient of CD4+ T cells
showed 1.50-fold increased high blood glucose level compared to without CD4+ T cells
recipient TS1P1KO STZ mice (CD4+TS1P1KO STZ, [n=4], 527.75±41.16 mg/dl vs.
TS1P1KO STZ, [n=7], 350±32.98 mg/dl, #P<0.05) (Figure 4-7).
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Figure 4-6: Blood glucose level (mg/dl) during 11-week study period in CD4+ T cells
recipient littermate and TS1P1KO mice. Bar graphs show blood glucose level (mg/dl) at
the beginning, after 4-week and after 11-week of streptozotocin (STZ) administration in
all mice. Sample size, n = 5-4 mice per each group. **P < 0.01 between vehicle and STZ
groups of CD4+ T cells recipient littermate and TS1P1KO mice blood glucose level after
4-week and after 11-week of STZ induction. The data is expressed as mean ± SEM.
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Figure 4-7: Blood glucose level (mg/dl) at end of 11-week in diabetic TS1P1KO mice
without- and with- CD4+ T cells adoptive transfer. CD4+ T cells recipient TS1P1KO STZ
mice (n=4) exhibited significantly higher blood glucose level compared to TS1P1KO
STZ mice without CD4+ T cells transfer (n=4) at the end of 11 weeks, *P < 0.05. The
data is expressed as mean ± SEM.

Table 4-2: Summary of metabolic parameter in CD4+ T cells recipient littermate and TS1P1KO mice during 11-week experimental
period.

CD4+Littermate Vehicle

CD4+TS1P1KO Vehicle

CD4+Littermate STZ

CD4+TS1P1KO STZ

(n=5)

(n=5)

(n=4)

(n=4)

146±12.03

126.80±8.35

138.50±12.84

133.75±6.70

135.40±8.27

137.40±12.63

403±27.97**

466.75±56.76**

145.20±5.83

142.60±11.14

432.50±42.52**

527.75±41.16**

At the beginning
(before STZ
induction)
Blood glucose level
(mg/dl)
After 4-week of STZ
induction
Blood glucose level
(mg/dl)
After 11-week of
STZ induction
Blood glucose level
(mg/dl)

The data is expressed as mean ± SEM. **P < 0.01 between vehicle and STZ groups of CD4+ T cells recipient littermate and TS1P1KO mice.
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4.3.3. Flow cytometry analysis of T lymphocyte subsets
We measured dissected spleen wet weight (mg) and calculated spleen weight
(mg) to body weight (g) ratio in both without- and with- CD4+ T cells recipient mice to
detect gross splenic structural remodeling in long term diabetes. One-way ANOVA
followed by Tukey’s post hoc test yielded no significant difference between spleen
weight (mg) to body weight (g) ratio between littermate and TS1P1KO mice without- and
with-CD4+ T cells transfer (Table 4-3). Notably, splenocytes number (x106 cells/mL) was
significantly increased, as analyzed by student’s two-tailed t-test, in littermate and
TS1P1KO vehicle mice after CD4+ T cells transfer compared to littermate and TS1P1KO
vehicle mice without CD4+ T cells transfer. Although, littermate STZ mice had 12.84%
and TS1P1KO STZ mice had 21.34% increased splenocytes number (x106 cells/mL) after
CD4+ T cells transfer compared to littermate vehicle and TS1P1KO vehicle mice without
CD4+ T cells transfer, two-tailed t-test did not yield significant differences between these
two groups (Figure 4-8, Table 4-4).
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Table 4-3: Summary of spleen weight (mg) to body weight (g) ratio in littermate
and TS1P1KO mice without- and with- CD4+ T cells transfer.

Groups

Spleen wt. (mg)/body wt. (g)

Littermate Vehicle (n=4)

2.97±0.37

TS1P1KO Vehicle (n=5)

2.61±0.24

Littermate STZ (n=8)

2.82±0.23

TS1P1KO STZ (n=6)

2.72±0.27

CD4+Littermate Vehicle (n=5)

2.43±1.69

CD4+TS1P1KO Vehicle (n=5)

2.48±0.32

CD4+Littermate STZ (n=4)

2.79±0.29

CD4+TS1P1KO STZ (n=4)

2.15±0.23

The data is expressed as mean ± SEM. ‘n’ value represents number of mice in each
group.
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Figure 4-8: Effects in total splenocytes number (x106 cells/ml) in littermate and
TS1P1KO mice after CD4+ T cells transfer compared to littermate and TS1P1KO mice
without CD4+ T cells transfer. Both littermate and TS1P1KO vehicle mice had
significantly increased splenocytes number after CD4+ T cells transfer compared to
littermate and TS1P1KO vehicle mice, respectively, without CD4+ T cells transfer,
*P<0.05. Diabetic littermate (P = 0.72) and TS1P1KO mice (P = 0.47) had increased
splenocytes number after CD4+ T cells transfer compared to littermate and TS1P1KO
STZ mice, respectively, without CD4+ T cells transfer. The data is expressed as mean ±
SEM. ‘n’ value represents number of mice in each group.
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Table 4-4: Summary of splenocytes number (x106 cells/ml) in littermate and TS1P1KO
mice without- and with- CD4+ T cells transfer.
Groups

Splenocytes number
(x106 cells/ml)

Littermate Vehicle (n=3)

44.5±3.32

TS1P1KO Vehicle (n=4)

34.73±6.74

Littermate STZ (n=3)

50.1±10.89

TS1P1KO STZ (n=3)

33.73±9.65

CD4+Littermate Vehicle (n=5)

79.64±5.68*

CD4+TS1P1KO Vehicle (n=5)

65.35±5.80*

CD4+Littermate STZ (n=4)

57.48±14.69

CD4+TS1P1KO STZ (n=4)

42.88±6.83

The data is expressed as mean ± SEM. *P < 0.05 compared to littermate vehicle and
TS1P1KO vehicle without CD4+ T cells transfer. ‘n’ value represents number of mice in
each group.
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After CD4+ T cells adoptive transfer, although CD4+ and CD8+ T cell
numbers in TS1P1KO mouse groups blood remained significantly lower than littermate
mouse groups, CD4+ T cells number in TS1P1KO mice was increased by 1.58-fold in
vehicle and 1.95-fold in STZ mice compared to TS1P1KO vehicle and STZ groups,
respectively, without CD4+ T cells transfer at the end of 11-weeks (Figure 4-9A, 4-9B, 410 and Table 4-5). CD8+ T cell numbers did not show any significant difference between
these two categories of mouse. Similarly, CD4+Foxp3+ T cells number had increased in
spleen of both CD4+ T cells recipient TS1P1KO vehicle and STZ groups than TS1P1KO
mice without CD4+ T cells transfer (Figure 4-11A, 4-11B and Table 4-6). CD4+littermate
STZ mice had increased CD4+Foxp3+ T cells than CD4+littermate vehicle mice after 11weeks (Figure 4-11B). Both CD4+TS1P1KO vehicle and CD4+TS1P1KO STZ mice had
reduced CD4+Foxp3+ T cells than CD4+littermate vehicle and CD4+littermate STZ mice,
respectively, at the end of 11-weeks (Figure 4-11B). In blood, there was no significant
difference between CD4+Foxp3+ T cells numbers between groups after CD4+ T cells
transfer (Figure 4-11B). Although in CD4+TS1P1KO vehicle mice had 2.63-fold
increased CD4+Foxp3+ T cells in blood than TS1P1KO vehicle mice without CD4+ T cells
transfer (Table 4-6).
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Figure 4-9: Quantification data of CD4+ and CD8+ T cells number in blood of littermate
and TS1P1KO mice after CD4+ T cells transfer at the end of 11-weeks. (A)
Representative flow cytometry dot plot show increased CD4+ T cells in lower right
quadrant of TS1P1KO vehicle and STZ mice blood after CD4+ T cells transfer compared
to TS1P1KO vehicle and STZ mice, respectively, without CD4+ T cells transfer at the end
of 11-weeks. (B) Quantification of flow cytometry data of CD4+ and CD8+ T cells in
CD4+ T cells recipient mice blood after 11-weeks. *P<0.05 between CD4+littermate
vehicle and CD4+TS1P1KO vehicle mice, and CD4+littermate STZ and CD4+TS1P1KO
STZ mice, n = 3-4 mice per group. The data is expressed as mean ± SEM.
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Figure 4-10: Comparison of CD4+ T cells number in blood between CD4+ T cells
recipient TS1P1KO mouse groups and TS1P1KO mouse groups without CD4+ T cells
transfer at the end of 11-weeks. After CD4+ T cells transfer both TS1P1KO vehicle and
TS1P1KO STZ mice exhibited increased number of CD4+ T cells in blood at the end of
11 weeks compared to TS1P1KO vehicle and TS1P1KO STZ mice without CD4+ T cells
transfer. The data is expressed as mean ± SEM. P = 0.1894 between TS1P1KO vehicle
and CD4+TS1P1KO vehicle mice, and P = 0.098 between TS1P1KO STZ and
CD4+TS1P1KO STZ mice, n = 3-4 mice per group.
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Table 4-5: Summary of CD4+ T cells number in blood of TS1P1KO mouse groups
without- and with- CD4+ T cells transfer after 11-weeks.

Groups

CD4+ T cells in blood
(% of cell populations)

TS1P1KO Vehicle (n=3)

1.37±0.02

CD4+TS1P1KO Vehicle (n=3)

2.16±0.50 (36.57% increase, P =0.1894)

TS1P1KO STZ (n=3)

1.21±0.61

CD4+TS1P1KO STZ (n=4)

2.37±0.23 (48.95% increase, P =0.098)

The data is expressed as mean ± SEM. ‘n’ value represents number of mice in each
group. P = 0.1894 between TS1P1KO vehicle and CD4+TS1P1KO vehicle mice, and P =
0.098 between TS1P1KO STZ and CD4+TS1P1KO STZ mice, n = 3-4 mice per group.
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Figure 4-11: Quantification data of CD4+Foxp3+ T cells number in spleen and blood of
littermate and TS1P1KO mice after CD4+ T cells transfer at the end of 11-week
experimental period. (A) Representative flow cytometry dot plot show noticeable
increase in CD4+ T cells (lower right quadrant) and CD4+Foxp3+ T cells (upper right
quadrant) presence in TS1P1KO vehicle and STZ mice spleen after CD4+ T cells transfer
compared to TS1P1KO vehicle and STZ mice, respectively, without CD4+ T cells transfer
at the end of 11-weeks. (B) Quantification of flow cytometry data of CD4+Foxp3+ T cells
in CD4+ T cells recipient mice spleen and blood after 11-weeks. *P<0.05 between
CD4+littermate vehicle and CD4+littermate STZ mice, and #P < 0.05 between
CD4+liitermate vehicle and CD4+TS1P1KO vehicle, and CD4+littermate STZ and CD4+
TS1P1KO STZ mice , n = 4-5 mice per group. The data is expressed as mean ± SEM.
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Table 4-6: Summary of CD4+Foxp3+ T cells number in spleen and blood of TS1P1KO
mouse groups without- and with- CD4+ T cells transfer after 11-weeks.
CD4+Foxp3+ T cells

Groups

(% of cell populations)
Spleen
TS1P1KO Vehicle (n=3)

0.67±0.12

CD4+TS1P1KO Vehicle (n=5)

1.12±0.20 (40.18% increase, P=0.16)

TS1P1KO STZ (n=3)

1.38±0.37

CD4+TS1P1KO STZ (n=4)

1.68±0.08 (17.86% increase, P=0.40)
Blood

TS1P1KO Vehicle (n=3)

0.19±0.03

CD4+TS1P1KO Vehicle (n=4)

0.50±0.06 (62% increase, *P<0.05)

TS1P1KO STZ (n=3)

0.42±0.18

CD4+TS1P1KO STZ (n=4)

0.30±0.06

CD4+ T cells recipient TS1P1KO vehicle and TS1P1KO STZ mice showed increased
CD4+Foxp3+ T cells in spleen compared to TS1P1KO vehicle and TS1P1KO STZ mice,
respectively, without CD4+ T cells transfer. CD4+ T cells recipient TS1P1KO vehicle
mice showed increased CD4+Foxp3+ T cells in blood compared to TS1P1KO vehicle
without CD4+ T cells transfer. P values calculated through two-tailed student’s t-test. The
data is expressed as mean ± SEM. The value of ‘n’ represents number of mice in each
group.
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4.3.4. CD4+ T cells transfer exacerbates cardiac disorganization in TS1P1KO mice
under diabetes

We prepared Hematoxylin and Eosin (H&E) stained heart sections after 11-week
experimental period. H&E stained sections were examined microscopically and graded
based on cardiomyocyte morphology, organization, degree of cellularity in interstitial
space, myocyte loss, and presence of collagen fibers in interstitial space. CD4+ T cells
recipient TS1P1KO STZ mice (CD4+TS1P1KO STZ, n=4) hearts showed exacerbated
myocytes organization with discernible disarray compared to TS1P1KO STZ mice without
CD4+ T cells transfer (cumulative heart histology score: 9.25±0.95 vs. 3±0.58, *P < 0.05)
(Figure 4-12A, 4-12B and 4-13A, 4-13B). Noticeably, CD4+ T cells recipient TS1P1KO
vehicle mice (n=5) showed improved heart histology compared to TS1P1KO vehicle mice
without CD4+ T cells transfer (n=4) (3±0.76 vs. 9.5±0.87, *P < 0.05) (Figure 4-12A, 412B and 4-13A, 4-13B).
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Figure 4-12: Heart histology study in H&E stained sections of CD4+ T cells recipient
littermate and TS1P1KO mice after 11-week experimental period. (A) Diabetic
CD4+littermate STZ and CD4+TS1P1KO STZ mice heart sections showed discernible
disorganization of myocytes in myocardium after 11-week diabetes period. TS1P1KO
mice vehicle heart sections exhibited improved heart histology under diabetes after CD4+
T cells transfer. The magnification is 200x. (B) Bar graphs represents cumulative heart
histology score of littermate and TS1P1KO mice heart sections after CD4+ T cells transfer
at the end of 11-weeks. *P<0.05 between CD4+littermate vehicle and CD4+littermate
STZ mice, and between CD4+TS1P1KO vehicle and CD4+TS1P1KO STZ mice. The data
is expressed as mean ± SEM, n = 4-5 mice in each group.
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Figure 4-13: Comparison between TS1P1KO mouse groups heart histology in H&E
stained sections without- and with CD4+ T cells transfer. (A) Representative H&E stained
heart sections images (magnification is 200x). Diabetic CD4+ TS1P1KO STZ mice heart
sections showed discernible disorganization of myocytes in myocardium after 11-week
diabetes period compared to TS1P1KO STZ mice without CD4+ T cells transfer. In
contrast, TS1P1KO vehicle mice heart sections exhibited improved heart histology under
diabetes after CD4+ T cells transfer compared to TS1P1KO vehicle mice without CD4+ T
cells transfer. (B) Quantification of cumulative heart histology score of TS1P1KO mice
heart sections at the end of 11-weeks. *P<0.05 between CD4+ TS1P1KO vehicle and
TS1P1KO vehicle mice, and between CD4+TS1P1KO STZ and TS1P1KO STZ mice. The
data is expressed as mean ± SEM, n = 4-7 mice in each group.
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4.3.5. CD4+ T cells transfer increases fibrosis area in TS1P1KO diabetic mice
We assessed fibrosis area in Tri-chrome stained heart sections after 11-week
diabetic period. CD4+ T cells transfer to TS1P1KO mice exacerbated fibrotic area in
diabetic TS1P1KO STZ mice (n=4) compared to TS1P1KO STZ mice (n=7) without CD4+
T cells transfer (37.11±3.22 % vs. 11.86±4.34 %, *P < 0.05) (Figure 4-14A, 4-14B, 4-15A
and 4-15B). Notably, CD4+ T cell recipient TS1P1KO vehicle mice (n=4) heart sections
showed less fibrotic area compared to TS1P1KO vehicle mice (n=4) without CD4+ T cells
transfer (12.74±2.22 % vs. 46.03±7.60 %, *P < 0.05) (Figure 4-14A, 4-14B, 4-15A and 415B).

4.3.6. CD4+ T cells transfer attenuates cardiac contractility in TS1P1KO diabetic
mice
We determined cardiac contractility in ex-vivo Langendorff heart perfusion
system at the end of 11-weeks. The contractile force was expressed as fold change
compared to littermate control mice. After CD4+ T cells transfer, diabetic TS1P1KO mice
had shown 22% lower contractile force compared to CD4+littermate control mice
(P=0.57) (Figure 70). In contrast, TS1P1KO vehicle mice exhibited 47.09% higher
contractile force after CD4+ T cells transfer compared to CD4+littermate vehicle mice
(*P>0.05) (Figure 4-16).
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Figure 4-14: Fibrosis extent assessment in Trichrome stained heart sections of CD4+ T
cells recipient littermate and TS1P1KO mice after 11-weeks. (A) Upper panel represents
whole heart sections (magnification 16x) and lower panel represents magnified section
images (magnification 400x). CD4+ T cells transfer enhanced perivascular and interstitial
fibrosis area in diabetic TS1P1KO mice. Notably, CD4+ T cells transfer to TS1P1KO
vehicle mice, attenuates fibrosis area. (B) Quantification of percent fibrosis area. *P<0.05
in CD4+littermate STZ vs. CD4+littermate vehicle mice, *P<0.05 in CD4+TS1P1KO
STZ vs. CD4+TS1P1KO vehicle mice. The data is expressed as mean ± SEM. n = 4 mice
in each group.
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Figure 4-15: Comparison between TS1P1KO mouse groups fibrosis extent in Masson’s
Trichrome stained heart sections without- and with CD4+ T cells transfer. (A) Diabetic
CD4+ TS1P1KO STZ mice heart sections exhibited enhanced fibrosis after 11-week
diabetic period compared to TS1P1KO STZ mice without CD4+ T cells transfer. In
contrast, TS1P1KO vehicle mice heart sections exhibited attenuated fibrosis area after
CD4+ T cells transfer compared to TS1P1KO vehicle mice without CD4+ T cells transfer.
(B) Quantification of fibrosis area in TS1P1KO mice heart sections. *P<0.05 in CD4+
TS1P1KO vehicle and TS1P1KO vehicle mice, and in CD4+TS1P1KO STZ and
TS1P1KO STZ mice. The data is expressed as mean ± SEM, n = 4-7 mice in each group.
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Figure 4-16: Cardiac contractile force in CD4+ T cells recipient littermate and TS1P1KO
mice after 11-week study period. CD4+ T cells recipient TS1P1KO STZ mice showed
reduced cardiac contractile force compared to CD4+littermate vehicle mice (P=0.57). In
contrast, CD4+ T cells recipient TS1P1KO vehicle mice exhibited increased contractility
compared to CD4+littermate vehicle mice. The data is expressed as mean ± SEM.
Sample size, n=3 mice in each group.
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4.3.7. Increased infiltration of CD3 T cells in TS1P1KO mouse hearts after
reconstitution of CD4+ T cells

We detected CD3+ T cells in heart tissue by immunostaining with mouse
monoclonal CD3 antibody and counted the infiltrated CD3+ T cells in 30 high
magnification fields (400x) for each heart sections (Figure 4-17). After CD4+ T cells
transfer, in both vehicle and STZ group of TS1P1KO mice showed increased CD3+ T
cells in myocardium (vehicle: 1.56±0.06 cells/field vs. 0.97±0.08 cells/field,*P < 0.05,
and STZ: 1.84±0.05 cells/field vs. 0.84±0.09 cells/field, n=3 independent experiments, #P
< 0.05) than TS1P1KO vehicle and TS1P1KO STZ group, respectively, without CD4+ T
cells transfer (Figure 4-17, 4-18A and 4-18B).

4.3.8. CD4+ T cells recipient diabetic TS1P1KO mice heart show increased TGF beta
1 expression

Transforming growth factor beta 1 expression was assessed in immunostained
heart sections by computer assisted morphometric analysis. After CD4+ T cell transfer,
TS1P1KO STZ mice heart sections exhibited increased TGF-β1 expression (5.45±0.08 %
staining area vs. 3.54±0.10 % staining area, #P < 0.05, n= 3 experiments as compared to
TS1P1KO STZ without CD4+ T cells transfer (Figure 4-19, 4-20A and 4-20B). In
contrast, TGF-β1 expression was reduced in TS1P1KO vehicle mice after CD4+ T cells
transfer (2.78±0.15 % staining area vs. 6.78±0.71 % staining area, *P < 0.05, n= 3
experiments compared to TS1P1KO vehicle mice without CD4+ T cells transfer (Figure 419, 4-20A and 4-20B).
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Figure 4-17: Immunohistochemical detection of CD3+ T cells in CD4+ T cells recipient
littermate and TS1P1KO mice heart sections at the end of 11-weeks. CD4+ T cells
recipient TS1P1KO vehicle and TS1P1KO STZ mice heart sections have increased
infiltration of CD3+ T cells after 11-week of experimental period compared to littermate
vehicle mice. Images are representative of three independent experiments. The
magnification is 400x.
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Figure 4-18: Quantification of infiltrated CD3+ T cells in myocardium of CD4+ T cells
recipient littermate and TS1P1KO mice. (A) CD3+ T cells number (cells per 400x
magnification field) was significantly higher in TS1P1KO vehicle and TS1P1KO STZ
mice heart section compared to CD4+littermate vehicle mice. *P < 0.05 compared to
CD4+littermate vehicle mice. (B) Comparison of CD3+ T cells number in cardiac tissue
between TS1P1KO mice with CD4+ T cells transfer and TS1P1KO without CD4+ T cells
transfer. *P<0.05 compared to TS1P1KO vehicle mice, #P<0.05 compared to TS1P1KO
STZ mice. Results are from three independent experiments. The data is expressed as
mean ± SEM.
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Figure 4-19: Immunohistochemical assessment of TGF beta 1 (TGF-β1) expression in
CD4+ T cells recipient littermate and TS1P1KO mice heart sections at the end of 11weeks. CD4+ T cells recipient TS1P1KO vehicle and TS1P1KO STZ mice heart sections
have increased TGF-β1 expression after 11-week of experimental period as compared to
littermate vehicle mice. Images are representative of three independent experiments. The
magnification is 400x.
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Figure 4-20: Quantification of TGF-β1 expression in myocardium of CD4+ T cells
recipient littermate and TS1P1KO mice. (A) TGF-β1 expression was significantly higher
in littermate STZ (*P<0.05) and TS1P1KO STZ (#P<0.05) mice heart section compared
to CD4+littermate vehicle mice. TS1P1KO vehicle mice heart sections exhibited reduced
TGF-β1 expression after CD4+ T cell transfer. (B) Comparison of TGF-β1 expression in
cardiac tissue between TS1P1KO mice with CD4+ T cells transfer and TS1P1KO mice
without CD4+ T cells transfer. *P<0.05 compared to TS1P1KO vehicle mice, #P<0.05
compared to TS1P1KO STZ mice. Results are from three independent experiments. The
data is expressed as mean ± SEM.
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4.3.9. CD4+ T cells recipient diabetic TS1P1KO mice heart exhibited increased CD34
expression

We evaluated CD34 expression by immunostaining in heart sections through
computer assisted morphometric analysis. After CD4+ T cells transfer TS1P1KO diabetic
myocardium exhibited increased CD34 expression (5.53±0.33 % staining area vs.
2.97±0.17 % staining area, #P < 0.05, n= 3 experiments) than diabetic TS1P1KO mice
without CD4+ T cells transfer (Figure 4-21, 4-22A and 4-22B). Remarkably, CD4+ T cells
transfer reduced CD34 expression in TS1P1KO vehicle mice (2.77±0.43 % staining area
vs. 6.52±0.47 % staining area, #P < 0.05, n= 3 experiments) than TS1P1KO vehicle mice
without CD4+ T cells transfer (Figure 4-21, 4-22A and 4-22B).
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Figure 4-21: Immunohistochemical assessment of CD34 expression in CD4+ T cells
recipient littermate and TS1P1KO mice heart sections at the end of 11-weeks. (A) CD4+
T cells recipient TS1P1KO STZ mice heart sections have increased CD34 expression
after 11-week of experimental period. In contrast, CD4+ T cells recipient TS1P1KO
vehicle mice exhibited reduced CD34 expression in their myocardium. Images are
representative of three independent experiments. The magnification is 400x.

172

A
% area of positive
staining of CD34

8

*

6

#
CD4+Littermate Vehicle

4

CD4+TS1P1 KO Vehicle
CD4+Littermate STZ

2

CD4+TS1P1 KO STZ

0

B

% area of positive
staining of CD34

8

#

6
4
2

*

TS1P1 KO Vehicle
CD4+TS1P1 KO Vehicle
TS1P1 KO STZ
CD4+TS1P1 KO STZ

0

Figure 4-22: Quantification of CD34 expression in myocardium of CD4+ T cells
recipient littermate and TS1P1KO mice. (A) CD34 expression was significantly higher in
littermate STZ (*P<0.05) and TS1P1KO STZ (#P<0.05) mice heart section compared to
CD4+littermate vehicle mice. TS1P1KO vehicle mice heart sections exhibited reduced
CD34 expression after CD4+ T cells transfer. (B) Comparison of CD34 expression in
cardiac tissue between TS1P1KO mice with CD4+ T cells transfer and TS1P1KO mice
without CD4+ T cells transfer. *P<0.05 compared to TS1P1KO vehicle mice, #P<0.05
compared to TS1P1KO STZ mice. Results are from three independent experiments. The
data is expressed as mean ± SEM.
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4.4. Discussion
In this part of dissertation, we demonstrated that adoptive transfer of CD4+ T cells
from littermate mice to T cell specific S1P receptor 1 knockout (TS1P1KO) mice causes
exacerbation in cardiac histology and augmentation of fibrosis area in TS1P1KO mice
under long term diabetes. We found that CD4+ T cells transfer to TS1P1KO mice
increases infiltrating CD3+ T cells number into myocardium that is associated with
enhanced pro-fibrotic molecular (TGF-β1) and cellular (CD34) moieties expression in
myocardium of TS1P1KO mice under chronic hyperglycemia.
In chapter 3, we have shown that T cell specific S1P receptor 1 genetic depletion
results in profound deficiency of CD4+ helper T cells and CD8+ cytotoxic T cells in blood
of TS1P1KO mice compared to littermate mice. We have demonstrated that TS1P1KO
mice heart under long term streptozotocin (STZ)-induced type 1 diabetes exhibits
cardioprotection and shows attenuated collagen deposition in myocardium with improved
cardiac contractility compared to littermate diabetic mice. T lymphocytes under cardiac
injury and inflammation, such as, myocardial infarction, hypertension, myocarditis,
infiltrate in to the myocardium and participate in cardiac fibrotic remodeling and heart
failure.36,73 Thus, we evaluated the infiltrating CD3+ T cells number in myocardium of
diabetic littermate and TS1P1KO mice after 11-week experimental period. We have
found that TS1P1KO mice heart tissue exhibited significantly less CD3+ T cells invasion
under chronic diabetes compared to littermate diabetic mice. Cardiac fibrosis is a
complex, multifactorial, dynamic process in which diverse cellular and molecular
interactions are involved.49,157,158 We, therefore, evaluated the expression of transforming
growth factor beta 1 (TGF-β1) and CD34 expressing fibrocytes infiltration into the
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myocardium of littermate and TS1P1KO mice after 11-week experimental period. Our
immunohistochemical studies showed that TGF-β1 and CD34 expressing cells expression
were reduced markedly in diabetic TS1P1KO mice compared to diabetic littermate mice.
Enhanced myocardial fibrosis causes ventricular wall stiffening, which underlies diastolic
dysfunction with subsequent systolic dysfunction, if unresolved.46,159 Therefore, we also
evaluated the cardiac force of contraction in ex-vivo Langendorff’s heart perfusion
system in littermate and TS1P1KO mice after 11-weeks. We found that cardiac
contractility was improved in diabetic TS1P1KO mice compared to diabetic littermate
mice. Therefore, we demonstrated that genetic depletion of T cell S1P1 receptor in mice
results in circulatory T lymphocytes deficiency that is associated with cardioprotection
and improved cardiac function in chronic diabetes. To this end, in this part of dissertation
we further extended our investigation to evaluate the effects of naïve CD4+ T cells
transfer from littermate mice to TS1P1KO mice in context of cardioprotection and cardiac
fibrosis under chronic hyperglycemia.
Among the two main subsets of T lymphocytes, CD4+ helper T cells and CD8+
cytotoxic T cells, CD4+ helper T cells have been reported to be involved in fibrotic
remodeling in different organs, including heart, lungs, kidney and liver.36,150,160,161,162
CD4+ T cells participate in fibrosis generation through several distinct molecular
pathways, such as secretion of inflammatory cytokines that can stimulate collagen
producing fibroblasts, increasing collagen cross-linking enzymes activity, such as lysyl
oxidase (LOX) in heart tissue.70,163,164 Enhancement of T helper subset 1 (TH1) cells
increased total cardiac collagen content and cross-linked collagen in C57BL/6 mice heart,
whereas in a hypertensive disease model TH2 cytokine predominant BALB/c mice
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exhibited increased cardiac collagen content with augmented ventricular stiffness.69,70,72
TH1 cytokine IFN-γ and TH2 cytokine IL-4 have been shown to increase collagen crosslinking enzyme LOX activity in heart in normal physiological and inflammatory
conditions, respectively.69,70,72,73 In pressure overload transverse aortic constriction
(TAC) murine model, mature lymphocytes lacking Rag2 knock-out (KO) mice heart
tissue exhibited less LOX expression with attenuated fibrosis area after 6-week of TAC
induction.75 Splenic 2 X 107 CD3+ T cells from wild-type C57BL/6 mice to Rag2KO
mice increases LOX enzyme expression and fibrotic area in heart sections substantially
after TAC induction compared to only buffer recipient Rag2KO mice.75 In another recent
report, antibody induced neutralization of CD3 T cells activity showed cardioprotection
in TAC induced heart failure model of mice as manifested by reduced fibrosis area and
improved left ventricular function compared to only isotype treated mice after 4-weeks.76
In TAC induced cardiac injury model, recruitment of T lymphocytes has been implicated
with increased expression of adhesion molecules, such as ICAM-1, in cardiac endothelial
cells.76 Several approaches including T lymphocytes depletion and neutralization of T
cells activation have been tested experimentally to protect heart from T cell invasion
under chronic injury in order to reduce fibrosis.157 To this end, in chapter 3, we for the
first time showed that genetic depletion of T cell specific S1P1 receptor induced altered T
lymphocytes trafficking in systemic circulation associated with cardioprotection and
reduction in fibrosis area under chronic hyperglycemia. However, the type of T
lymphocytes important in cardiac fibrogenesis in diabetes associated hyperglycemia is
not known decisively, and our studies in chapter 3 also did not elucidate the role of
specific subset of T cells in diabetic myocardial fibrogenesis. To this end, in the present
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study we showed that CD4+ T cells reconstitution in TS1P1KO mice reverses the
observed cardioprotection and antifibrotic effect under chronic diabetes.
In TS1P1KO mice, T lymphocytes have depleted S1P1 expression due to T cell
specific lymphocyte tyrosine kinase (Lck) promoter driven Cre-mediated recombination
in coding region of S1P1 gene.83 S1P receptor 1 plays important role in T lymphocytes
egress from primary and secondary lymphoid organs to circulation.85 Genetic deficiency
of S1P1 in T cells inhibits T cells egress from lymphoid organs and sequesters them in
primary lymphoid organ thymus.83 Accordingly in chapter 3, we have shown that marked
reduction of CD3+ T cells in spleen and CD4+, CD8+ T cells in blood of TS1P1KO mice.
In the present chapter, we isolated CD4+ T cells from littermate mice spleen and
intravenously transferred to TS1P1KO mice. Our flow cytometry analysis showed 1.58fold and 1.95-fold increase of CD4+ T cells in blood of TS1P1KO vehicle and TS1P1KO
STZ mice, respectively, compared to TS1P1KO vehicle and TS1P1KO STZ mice without
CD4+ T cells transfer after 11-weeks. CD4+Foxp3+ T cells number also increased in
spleen of both TS1P1KO vehicle and TS1P1KO STZ mice as measured after 11-week
than without CD4+ T cells transfer TS1P1KO vehicle and TS1P1KO STZ mice. Together
the data indicate successful reconstitution of littermate CD4+ T cells in to TS1P1KO mice
in our present work. At the end of 11-week STZ-induced diabetic period, CD4+ T cells
recipient diabetic TS1P1KO STZ mice heart exhibited marked myocyte disorganization
with increased interstitial and perivascular fibrosis, and reduced cardiac contractility
compared to diabetic TS1P1KO mice without CD4+ T cells transfer. Notably, diabetic
TS1P1KO mice heart sections showed increased number of invading CD3+ T cells
number into myocardium compared to diabetic TS1P1KO mice without CD4+ T cells
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transfer at the end of 11-week diabetic period. Our immunohistolgical studies further
revealed enhanced profibrotic TGF-β1 and CD34 expressing cells expression in diabetic
TS1P1KO mice myocardium compared to diabetic TS1P1KO mice without CD4+ T cells
transfer. To this end, our findings revealed that CD4+ T cells are an essential component
in cardiac fibrogenesis under chronic hyperglycemia that provoke profibrotic molecular
and cellular milieu in myocardium to increase fibrosis area leading to cardiac
dysfunction.
Interestingly, administration of one million CD4+ T cells into TS1P1KO vehicle
mice increases CD4+ T cells in circulation with increased presence of CD3+ T cells in
myocardium than TS1P1KO vehicle mice without CD4+ T cells transfer. Strikingly, CD4+
T cells recipient TS1P1KO vehicle mice myocardium showed reduced expression of
TGF-β1 and CD34 expression with improved heart histology, reduced fibrosis area and
significant improvement in cardiac contractility. In chapter 3, normoglycemic TS1P1KO
vehicle mice myocardium showed exacerbated heart histology, increased fibrosis area
and attenuated cardiac contractility whereas hyperglycemic TS1P1KO STZ mice
myocardium showed cardioprotection with reduced fibrosis area and improved
contractility. In present chapter, adoptive transfer of CD4+ T cells to TS1P1KO mice
reverses the cardioprotection in hyperglycemic TS1P1KO STZ mice and ameliorates
fibrosis in normoglycmeic TS1P1KO vehicle mice. These contrary results imply T
lymphocytes have dual role in maintaining cardiac collagen homeostasis depending on
the physiological conditions. TS1P1KO mice have reduced T lymphocytes in blood that
increases circulatory B lymphocytes by two-fold as reported by Allende et al.83 Notably,
B lymphocytes generated auto-antibodies against heart derived antigens have been

178

implicated in cardiac dysfunction and fibrosis.146 In this regard, it is noteworthy that in
chapter 2 we found that diabetic Rag1 KO mice lacking both mature T and B
lymphocytes exhibited reduced fibrosis area and improved cardiac contractility compared
to diabetic wild-type C57BL/6 mice. Notably, normoglycemic Rag1 KO mice did not
show enhanced fibrosis unlike in normoglycemic TS1P1KO vehicle mice heart. Hence,
imbalance between T lymphocytes and B lymphocytes number in periphery could be a
possible reason of increased fibrosis area in normoglycemic TS1P1KO vehicle mice
heart. Increased presence of CD34 fibrocytes in normoglycemic TS1P1KO vehicle mice
heart indicate the presence of inflammation as CD34 fibrocytes recruited at the site of
tissue injury and inflammation. Notably, CD4+ T cells recipient TS1P1KO vehicle mice
spleen and blood showed 40.18% and 62% increase of regulatory CD4+Foxp3+ T cells
than TS1P1KO vehicle mice without CD4+ T cells recipient at the end of 11-week
experimental period.152 Adoptive transfer of regulatory T cells in aortic constriction
induced murine hypertension model reduced cardiac fibrosis area with reduced TGF-β1
expression in cardiac tissue.152 In our present work, after CD4+ T cells transfer to
TS1P1KO mice, normoglycemic TS1P1KO vehicle mice have increased CD4+Foxp3+ T
cells in periphery that couples with reduced TGF-β1 and CD34 expression in
myocardium with reduced fibrosis compared to TS1P1KO vehicle mice without CD4+ T
cells transfer. Regulatory CD4+Foxp3+ T cells maintain immune tolerance in periphery
by secreting immunosuppressive cytokines.68 Hence, increased regulatory CD4+Foxp3+ T
cells after CD4+ T cells transfer to TS1P1KO mice could be a possible reason for the
reduced fibrosis in TS1P1KO vehicle mice.
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Altogether, our findings indicate the dual role of CD4+ T lymphocytes depending
on normoglycemia and hyperglycemia. In normoglycemia, CD4+ T cells presence in
peripheral blood is necessary to maintain collagen homeostasis in heart, whereas in
chronic hyperglycemia CD4+ T cells potentiate collagen deposition by activating
profibrotic signaling and enhancing proinflammatory cells recruitment to cardiac tissue.
Thus, we demonstrated that CD4+ T lymphocytes as an upstream provocative cellular
component in myocardial fibrotic remodeling under chronic hyperglycemic conditions.
Our CD4+ T cells adoptive transfer experiment between littermate and TS1P1KO mice
further demonstrated the necessity of S1P1 mediated signaling in CD4+ T cells trafficking
in systemic circulation as well as in cardiac tissue to modulate cardiac fibrotic
remodeling both in normal and pathological conditions.
4.5. Conclusions
The important findings of our present investigation are: (1) supplement of CD4+ T
cells increases myocardial fibrosis in TS1P1KO mice under chronic hyperglycemia with
enhanced profibrotic milieu; (2) under normoglycemia CD4+ T cells transfer to TS1P1KO
mice protects cardiac histology and attenuates fibrosis area; (3) S1P receptor 1 is crucial
for CD4+ T lymphocytes trafficking that can be pharmacologically targeted to alter T
lymphocytes trafficking to protect heart under diabetes.
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CHAPTER 5: SUMMARY

T lymphocytes are reported to be involved in cardiac fibrogenesis under cardiac
inflammation and injury.73,77 T cells participate in fibrosis generation by secreting
cytokines, growth factors that facilitate profibrotic microenvironment development which
stimulate collagen producing fibroblasts.36,163 Activated fibroblasts, in turn, secrete
excessive collagen into myocardium that ensues in fibrosis.36,165,166 The activation and
recruitment of T cells into the myocardium have been observed in hypertension,
myocardial infarction, diabetes, pressure overload-induced cardiac injury.74,76,77,111,152 To
this end, enhanced T lymphocytes invasion has been detected in end stage heart failure
patient myocardium compared to non-heart failure cardiac tissues.76 Video microscopic
studies revealed T lymphocytes from heart failure patients adhered in significantly higher
numbers to activated vascular endothelial cells than T cells from non-heart failure
volunteers, indicating subsequent T cells infiltration into the inflamed cardiac tissue.76 To
this end, reduction of T cells infiltration into the myocardium is considered as a potential
translational target to protect the heart and reduce fibrosis in cardiovascular diseases.
To target T lymphocytes, the biology of these cells need to be taken in
consideration. The activation, proliferation and migration of T lymphocytes to inflamed
tissue are regulated through orchestrated innate immune cells i.e. antigen-presenting cells
and T lymphocytes interaction in respective tissue draining secondary lymphoid organs
i.e. lymph nodes.90 This paradigm of T cells trafficking has been observed in
experimental rodent heart failure and myocardial infarction model.77,157 After induction
of heart failure and myocardial infarction, increased numbers of antigen presenting cells
i.e. dendritic cells and T lymphocytes have been detected in heart draining lymph
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nodes.74,75,76 The increased T cells number in heart draining lymph nodes was coupled to
increased infiltration of T cells into the myocardium and increased cardiac fibrosis area.
In line with these observations, an increased number of recent investigations have
demonstrated that inhibition of T lymphocyte function reduces cardiac fibrosis and
improves cardiac performance in heart failure and ischemic-reperfusion injury.77,157
Several approaches, such as, antibody induced neutralization of T cells activation,
depletion of T cells in transgenic mice, have been shown to reduce myocardial fibrosis
with improved cardiac function.77,157 To this end, experimental data is scarce to
ameliorate cardiac fibrosis by modulating other aspects of T lymphocytes biology.
T lymphocytes trafficking from lymphoid organs to systemic circulation, i.e.
blood, is an important aspect in immune response mediation. Naïve T lymphocytes
continually recirculate between secondary lymphoid organs and systemic circulation.90
Activation and proliferation of T lymphocytes occur in secondary lymphoid organs under
appropriate microenvironment in response to inflammation, infection and injury. Upon
activation, T lymphocytes trafficking from secondary lymphoid organs to periphery and
the tissue leads to immune reaction in inflamed tissue. Epidemiological studies have
shown increased presence of pro-inflammatory T cells in periphery of diabetic
patient.78,79,110 In experimental rodent diabetic model, enhanced T lymphocytes
infiltration into the cardiac tissue has been observed with increased cardiac collagen
content and ventricular stiffness.111 Notably, the effects of T lymphocytes trafficking
modulation in diabetes-induced fibrosis is not yet established. In our studies, we aimed to
test our hypothesis that inhibition of T lymphocytes trafficking might protect diabetic
heart and reduce myocardial fibrosis in chronic diabetes as discussed below.
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In this dissertation, we have demonstrated that depletion of T lymphocytes in
systemic circulation through modulating sphingosine 1-phosphate receptor 1 (S1P1)
associated with reduced cardiac fibrosis and improved cardiac contractility in chronic
diabetes. The depletion of T cells was achieved with both pharmacological agent –
fingolimod (FTY70) and genetic approach – conditional knockout of T cell S1P1 receptor.
In chapter 2, we have shown that treatment with S1P1 receptor modulator drug FTY720
substantially reduced CD4+ and CD8+ T cells number in peripheral blood of wild-type
(WT) C57BL/6 mice compared to WT control and untreated diabetic mice. Chronic
FTY720 treatment reduced invading CD3+ T cells number into WT diabetic mice
myocardium at the end of 11-week experimental period than untreated WT diabetic mice.
In addition, FTY720 treated WT diabetic mice myocardium exhibited reduced expression
of profibrotic TGF-β1 and fibroblast progenitor CD34 cells compared to untreated WT
diabetic mice. The histology and morphometric analysis revealed that FTY720 improved
heart histology and reduced cardiac fibrosis area in diabetic WT mice myocardium
compared to untreated WT diabetic mice in chronic diabetes. Further, FTY720 treatment
increased cardiac contractility of diabetic WT mice heart compared to untreated WT
diabetic mice heart at the end of 11 weeks. We used recombination activating gene 1
knock-out (Rag1 KO) mice lacking mature B and T lymphocytes as a complementary
genetic mouse strain of WT C57BL/6 mice. Diabetic Rag1 KO mice exhibited improved
heart histology, less cardiac fibrosis and improved contractility compared to untreated
WT diabetic mice. Our findings, thus, indicate that T lymphocytes play an important role
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in fibrogenesis under diabetes. Paradoxically, we found that FTY720 treatment in Rag1
KO mice increased fibrosis area, deteriorated heart histology and attenuated cardiac
contractility under diabetes. These contrary results between WT C57BL/6 and Rag1 KO
mice after FTY720 treatment indicate that the drug might be enhancing other fibrotic
pathways in absence of T lymphocytes under diabetes. Although FTY720 has high
affinity towards binding with S1P1 receptor, it can also activate other S1P receptors.
FTY720 has been reported to bind on S1P3 receptor on fibroblasts that causes
transdifferentiation of these cells into collagen producing myofibroblasts. Therefore, the
paradoxical results of FTY720 treatment in Rag1 KO mice set the premise to study S1P1
mediated T cells trafficking effects in cardiac fibrogenesis by using a more precise
genetic approach.
To this end, in chapter 3, we utilized genetic approach to study specifically S1P1
loss-of-function effect on T lymphocytes trafficking to systemic circulation, and its
associated effects in myocardial fibrosis generation in chronic diabetes. We generated
conditional T cell specific S1P receptor 1 knock-out (TS1P1KO) mice through Cre-loxP
approach. TS1P1KO mice exhibited marked reduction of CD4+ and CD8+ T cells in blood
compared to littermate control mice. Under chronic diabetes, TS1P1KO mice heart
sections exhibited significantly reduced invaded CD3+ T cells with less fibrosis area
compared to littermate mice. We further investigated the effects of reduced CD3+ T cells
into myocardium on profibrotic molecular and cellular milieu by immunohistochemistry.
We demonstrated that diabetic TS1P1KO mice heart tissue had reduced expression of
TGF-β1 and CD34 fibrocytes expression compared to diabetic littermate mice. These
results indicate that T lymphocytes in diabetes is involved in myocardial fibrogenesis,
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and inhibition of S1P1 receptor associated altered T cells trafficking exerts
cardioprotection in chronic diabetes. Paradoxically, TS1P1KO vehicle treated mice at the
end of 11-week showed increased cardiac fibrosis area with deteriorated cardiac
contractility compared to littermate vehicle mice. Although TS1P1KO vehicle mice
myocardium had reduced CD3+ T cells infiltration into myocardium, TGF-β1 and CD34
expression were increased. Our observations is consistent with the literature notion that
fibrosis is a complex, multifactorial disease in which both systemic and cardiac resident
cells can affect cardiac collagen homeostasis. Notably, in TS1P1KO mice blood, two
times higher B lymphocytes number have been reported compared to littermate mice. To
this end, B lymphocytes have been implicated to secrete autoantibodies that can cause
myocytes apoptosis leading to fibrosis generation.146 Programmed cell death-1 (PD-1)
gene knock out mice developed severe form of cardiomyopathy with increased interstitial
fibrosis.145 PD-1 receptor is a negative immune regulator of lymphocytes proliferation,
thus, genetic depletion of PD-1 results in increased deposition of IgG antibodies in
myocardium. Notably, PD-1 KO mice generated in Rag2 KO mice background did not
develop fibrosis indicating important contributions of lymphocytes in maintaining cardiac
collagen homeostasis. In line with this finding, in chapter 2 we showed that diabetic Rag1
KO mice have reduced cardiac fibrosis area compared to diabetic WT mice. TS1P1KO
mice have increased B lymphocytes in circulation, while have substantially reduced T
lymphocytes in circulation compared to littermate mice. Imbalance between B and T
lymphocytes number might be one of the possible reasons for increased cardiac fibrosis
under normoglycemia in TS1P1KO mice. To this end, the results shown in chapter 4
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demonstrated the effects of reconstitution of splenic CD4+ T cells from littermate mice to
TS1P1KO mice on cardiac fibrogenesis and cardiac function.
In chapter 4, we demonstrated that adoptive transfer of naïve CD4+ T cells from
littermate mice spleen exacerbated cardiac fibrosis area and reduced cardiac contractility
in TS1P1KO mice in chronic diabetes. Infiltrating CD3+ T cells numbers increased in
myocardium of TS1P1KO mice after CD4+ T cells transfer. Further, the reconstitution of
CD4+ T cells increased TGF-β1 and CD34 cell expression in diabetic TS1P1KO mice
compared to diabetic TS1P1KO mice without CD4+ T cells transfer. Notably, adoptive
transfer of one million CD4+ T cells from littermate mice to TS1P1KO mice improved
heart histology, reduced cardiac fibrosis area and increased cardiac contractility under
normoglycemia compared to normoglycemic TS1P1KO mice without TS1P1KO mice.
We found that CD4+ T cells transfer increased CD4+ T cells number in blood and
CD4+Foxp3+ T cells number in spleen and blood of TS1P1KO vehicle mice compared to
TS1P1KO vehicle mice without CD4+ T cells transfer. TS1P1KO vehicle mice
myocardium exhibited increased CD3+ T cells presence in their myocardium compared to
TS1P1KO vehicle mice without CD4+ T cells transfer. Our immunohistochemistry studies
showed that TGF-β1 and CD34 cells expression were reduced in TS1P1KO vehicle mice
after CD4+ T cells transfer indicating attenuated profibrotic microenvironment compared
to TS1P1KO vehicle mice without CD4+ T cells transfer. Our results, thus, indicate that
CD4+ T cells can play dual role in cardiac fibrosis depending normoglycemic and
hyperglycemic conditions. Under normal physiological conditions CD4+ T cells presence
in periphery, i.e., blood, is necessary to maintain collagen homeostasis in cardiac tissue,
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while in chronic diabetes CD4+ T cells facilitate cardiac fibrosis generation by
potentiating profibrotic signaling in myocardium.
Overall, following are the key findings in this dissertation:
(1) T lymphocytes trafficking modulatory drug FTY720-induced CD4+ and CD8+ T
cells reduction in systemic circulation is associated with cardioprotection and
attenuated fibrosis area under chronic diabetes in WT C57BL/6 mice. Lack of T
lymphocytes associated cardioprotection in diabetes was confirmed in Rag1 KO
mice lacking mature lymphocytes. Contradictory results of FTY720 treatment in
Rag1 KO diabetic mice indicate FTY720 can target other fibrotic signaling
pathways in absence of T lymphocytes. (Chapter 2)
(2) Conditional T cell specific S1P receptor 1 (S1P1) genetic ablation ensued in
marked reduction of CD4+ and CD8+ T cells in blood and reduced infiltration of
CD3+ T cells in cardiac tissue under diabetes. Nonetheless, the presence of T
lymphocytes in periphery is necessary to maintain collagen homeostasis in
TS1P1KO mice as TS1P1KO mice under normoglycemic condition exhibited
exacerbation of fibrosis. (Chapter 3)
(3) Adoptive transfer of CD4+ T cells reversed cardioprotection and increased fibrosis
area in TS1P1KO mice under diabetes, while attenuated fibrosis and improved
contractility in TS1P1KO normoglycemic mice. Thus, CD4+ T cells might play
dual role depending on peripheral immune compartment composition and
pathological conditions in maintaining cardiac fibrosis. (Chapter 4)
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In summary, we have demonstrated through pharmacological and genetic approaches
that S1P1 receptor mediated T cells trafficking to periphery is directly responsible for
cardiac fibrosis development under chronic hyperglycemic conditions.
Alteration/depletion of T lymphocytes trafficking in periphery by modulating S1P1
receptor is a novel, promising translational approach to ameliorate myocardial fibrosis, to
protect the cardiac histology and improve cardiac contractility in chronic diabetes.
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CHAPTER 6: FUTURE PROSPECTS
Recent studies have shown T lymphocytes involvement in myocardial
fibrogenesis in different cardiovascular diseases. To this end, the present study provides
evidence that alteration/depletion of T lymphocytes trafficking to systemic circulation
through modulation of S1P1 receptor function is cardioprotective and attenuates cardiac
fibrosis under chronic diabetes. Our findings give rise to exciting new research directions
to ameliorate diabetic myocardial fibrogenesis as outlined below:
(1) Although FTY720 treatment has reduced cardiac fibrosis in diabetic WT
C57BL/6 mice, but increases fibrosis area in diabetic Rag1 KO mice (chapter 2).
Rag1 KO mice lacks mature lymphocytes due to genetic deficiency of Rag1 gene
necessary for mature lymphocytes development. FTY720 treatment increased
fibrosis area in diabetic Rag1 KO mice. These results indicate FTY720 targets
other fibrotic mechanisms which overrides cardioprotective effects of FTY720 in
the absence of lymphocytes. Thus, mechanisms of FTY720 induced cardiac
fibrosis in Rag1 KO mice under diabetes need to be studied further.
(2) Genetic depletion of T lymphocytic S1P receptor 1 (S1P1) reduces T lymphocytes
number substantially and exerts antifibrotic effect under chronic diabetes (chapter
3). The fate of T lymphocytic S1P1 under high glucose level has not been
investigated yet. The implications of S1P1 mediated signaling in T lymphocytes
infiltration to diabetic myocardium should be investigated further.
(3) We have shown that adoptive transfer of CD4+ T cells to TS1P1KO mice reverses
the observed cardioprotection and increases fibrosis in diabetes (chapter 4).
Notably, CD4+ T cells can further differentiate into TH1, TH2, Tregs and TH17
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cells.68 Thus, further studies on CD4+ T cells differentiation in chronic diabetic
mice and their effects in context of myocardial fibrosis is warranted.
(4) In our present study, we primarily focused on the extent of CD3+ T lymphocytes
infiltration to myocardium and levels of expression of TGF-β1 and fibrocytes
(CD34) invasion. We found that increased fibrosis area was coupled to increased
CD34 cells in interstitial space of myocardium. This indicates a direct correlation
between CD34 cells and the extent of myocardial fibrosis. Although our
immunohistochemical studies detected localization of CD34 cells in myocardium,
we did not elucidate the recruitment mechanism of these cells in diabetic
myocardium. CD34 cells recruitment to the site of inflammation/injury from the
blood occurs through chemokine-chemokine receptor interactions.61,62,63 Thus,
further studies are warranted to understand the chemokine receptor types
expressed by diabetic myocardium that facilitates CD34 cells recruitment under
inflammatory and profibrotic conditions, and how T lymphocytes modulate the
chemokine receptors expression in myocardium, if any.
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